0001164888 false Q2 --03-31 2022 0001164888 2021-04-01 2021-09-30 0001164888 2021-11-15 0001164888 2021-09-30 0001164888 2021-03-31 0001164888 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 us-gaap:SeriesBPreferredStockMember 2021-09-30 0001164888 us-gaap:SeriesBPreferredStockMember 2021-03-31 0001164888 2021-07-01 2021-09-30 0001164888 2020-07-01 2020-09-30 0001164888 2020-04-01 2020-09-30 0001164888 us-gaap:PreferredStockMember 2021-06-30 0001164888 KBPH:PreferredStockBMember 2021-06-30 0001164888 us-gaap:CommonStockMember 2021-06-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001164888 us-gaap:RetainedEarningsMember 2021-06-30 0001164888 2021-06-30 0001164888 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001164888 KBPH:PreferredStockBMember 2021-07-01 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001164888 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001164888 us-gaap:PreferredStockMember 2021-09-30 0001164888 KBPH:PreferredStockBMember 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001164888 us-gaap:RetainedEarningsMember 2021-09-30 0001164888 us-gaap:PreferredStockMember 2021-03-31 0001164888 KBPH:PreferredStockBMember 2021-03-31 0001164888 us-gaap:CommonStockMember 2021-03-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001164888 us-gaap:RetainedEarningsMember 2021-03-31 0001164888 us-gaap:PreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:PreferredStockBMember 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-09-30 0001164888 us-gaap:RetainedEarningsMember 2021-04-01 2021-09-30 0001164888 us-gaap:PreferredStockMember 2020-06-30 0001164888 KBPH:PreferredStockBMember 2020-06-30 0001164888 us-gaap:CommonStockMember 2020-06-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001164888 us-gaap:RetainedEarningsMember 2020-06-30 0001164888 2020-06-30 0001164888 us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0001164888 KBPH:PreferredStockBMember 2020-07-01 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001164888 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001164888 us-gaap:SeriesBPreferredStockMember 2020-09-30 0001164888 us-gaap:PreferredStockMember 2020-09-30 0001164888 KBPH:PreferredStockBMember 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001164888 us-gaap:RetainedEarningsMember 2020-09-30 0001164888 2020-09-30 0001164888 us-gaap:PreferredStockMember 2020-03-31 0001164888 KBPH:PreferredStockBMember 2020-03-31 0001164888 us-gaap:CommonStockMember 2020-03-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001164888 us-gaap:RetainedEarningsMember 2020-03-31 0001164888 2020-03-31 0001164888 us-gaap:PreferredStockMember 2020-04-01 2020-09-30 0001164888 KBPH:PreferredStockBMember 2020-04-01 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-04-01 2020-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-09-30 0001164888 us-gaap:RetainedEarningsMember 2020-04-01 2020-09-30 0001164888 KBPH:AbferoPharmaceuticalsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemeberTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:AbferoPharmaceuticalsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemeberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2021-04-01 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSidecarTwentyFivePercentageDiscountNoInterestMember 2021-09-30 0001164888 KBPH:AOADXIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFourPercentageDueMayTwoThousandTwentyFourMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AOADXIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteFourPercentageDueMayTwoThousandTwentyFourMember 2021-04-01 2021-09-30 0001164888 KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2021-04-01 2021-09-30 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CorinnovaIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2021-04-01 2021-09-30 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CorinnovaIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourOneMember 2021-04-01 2021-09-30 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteZeroPercentageOnDueDateMember 2021-09-30 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:EveryKeyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:EveryKeyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:IdenticalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:IdenticalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:IrisRAndDGroupIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMayTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:IrisRAndDGroupIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueMayTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:KianaAnalyticsMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:KianaAnalyticsMember KBPH:TechnologyMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-04-01 2021-09-30 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-04-01 2021-09-30 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2021-04-01 2021-09-30 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageNoDueDateMember 2021-09-30 0001164888 KBPH:MMTronIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFourPercentageDueAprilTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:MMTronIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteFourPercentageDueAprilTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:NavauxIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:NavauxIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2021-04-01 2021-09-30 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2021-09-30 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJulyTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJulyTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:RheosIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAugustTwoThousandTwentySixMember 2021-09-30 0001164888 KBPH:RheosIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAugustTwoThousandTwentySixMember 2021-04-01 2021-09-30 0001164888 KBPH:SaccharoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:SaccharoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SageMedicCorpMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SageMedicCorpMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedMember 2021-09-30 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedOneMember 2021-09-30 0001164888 KBPH:SinglePassIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyFourMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SinglePassIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyFourMember 2021-04-01 2021-09-30 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2021-04-01 2021-09-30 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-09-30 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:CorporateNoteSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:CorporateNoteSecuritiesMember KBPH:XpanIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:XpanIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:XpanIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2021-04-01 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:US 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:CA 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-09-30 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2021-09-30 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-09-30 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:HealionicsCorporationMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-09-30 0001164888 KBPH:HealionicsCorporationMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2021-09-30 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2021-04-01 2021-09-30 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-04-01 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember 2021-04-01 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-09-30 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:MakaniScienceIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:MakaniScienceIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-09-30 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-09-30 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-09-30 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredOneMember 2021-09-30 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredOneMember 2021-04-01 2021-09-30 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:PartheousIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:PartheousIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:PromaxolIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2021-04-01 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2021-04-01 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2021-09-30 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-09-30 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-09-30 0001164888 KBPH:VesteckIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001164888 KBPH:VesteckIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-09-30 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-04-01 2021-09-30 0001164888 KBPH:PreferredInvestmentsMember 2021-09-30 0001164888 KBPH:PreferredInvestmentsMember country:US 2021-09-30 0001164888 KBPH:PreferredInvestmentsMember country:CA 2021-09-30 0001164888 KBPH:PreferredInvestmentsMember KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-09-30 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-09-30 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-04-01 2021-09-30 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-09-30 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-09-30 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-04-01 2021-09-30 0001164888 KBPH:KuantsolIncMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-09-30 0001164888 KBPH:KuantsolIncMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SanabyHealthSponsorLLCMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-09-30 0001164888 KBPH:SanabyHealthSponsorLLCMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:CommonStockInvestmentMember 2021-09-30 0001164888 KBPH:CommonStockInvestmentsMember country:US 2021-09-30 0001164888 KBPH:CommonStockInvestmentsMember country:CA 2021-09-30 0001164888 KBPH:CommonStockInvestmentsMember KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:CommonStockInvestmentsMember 2021-09-30 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-09-30 0001164888 KBPH:MadorraIncMember KBPH:SafeInvestmentsMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-09-30 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:PolymertalIncMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:SafeInvestmentsMember 2021-09-30 0001164888 KBPH:SafeInvestmentsMember country:US 2021-09-30 0001164888 KBPH:SafeInvestmentsMember country:CA 2021-09-30 0001164888 KBPH:SafeInvestmentsMember KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-09-30 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-04-01 2021-09-30 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2021-09-30 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2021-04-01 2021-09-30 0001164888 KBPH:ExodosLifeSciencesLPMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-04-01 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2021-04-01 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2021-04-01 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsThreeMember 2021-09-30 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsThreeMember 2021-04-01 2021-09-30 0001164888 KBPH:RisoCapitalFundILPMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:OwnershipUnitsMember 2021-09-30 0001164888 KBPH:RisoCapitalFundILPMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:OwnershipUnitsOneMember 2021-09-30 0001164888 KBPH:OtherInvestmentMember 2021-09-30 0001164888 KBPH:OtherInvestmentMember country:US 2021-09-30 0001164888 KBPH:OtherInvestmentMember country:CA 2021-09-30 0001164888 KBPH:OtherInvestmentMember KBPH:RestOfWorldMember 2021-09-30 0001164888 country:US 2021-09-30 0001164888 country:CA 2021-09-30 0001164888 KBPH:RestOfWorldMember 2021-09-30 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2020-04-01 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2021-03-31 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2021-03-31 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2020-04-01 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteZeroPercentageOnDueDateMember 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:EveryKeyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:EveryKeyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:IdenticalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:IdenticalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:KianaAnalyticsMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:KianaAnalyticsMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2020-04-01 2021-03-31 0001164888 KBPH:NavauxIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:NavauxIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2020-04-01 2021-03-31 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedMember 2021-03-31 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedOneMember 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:CorporateNoteSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:CorporateNoteSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2020-04-01 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:US 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:CA 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-03-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2021-03-31 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:CoLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-03-31 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2020-04-01 2021-03-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2021-03-31 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2020-04-01 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember 2020-04-01 2021-03-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember 2021-03-31 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-03-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2020-04-01 2021-03-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-03-31 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-03-31 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:PromaxoMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:PromaxoMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2020-04-01 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2020-04-01 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2020-04-01 2021-03-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember country:US 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember country:CA 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2020-04-01 2021-03-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-03-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2020-04-01 2021-03-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-03-31 0001164888 KBPH:BoardwalkTechMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2020-04-01 2021-03-31 0001164888 KBPH:BoardwalkTechMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember country:US 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember country:CA 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-03-31 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-03-31 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:SafeInvestmentsMember 2021-03-31 0001164888 KBPH:SafeInvestmentsMember country:US 2021-03-31 0001164888 KBPH:SafeInvestmentsMember country:CA 2021-03-31 0001164888 KBPH:SafeInvestmentsMember KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2020-04-01 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2020-04-01 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2021-03-31 0001164888 KBPH:ExodosLifeSciencesLPMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2020-04-01 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2020-04-01 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2021-03-31 0001164888 KBPH:RisoCapitalFundILPMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:OwnershipUnitsMember 2021-03-31 0001164888 KBPH:OtherInvestmentMember 2021-03-31 0001164888 KBPH:OtherInvestmentMember country:US 2021-03-31 0001164888 KBPH:OtherInvestmentMember country:CA 2021-03-31 0001164888 KBPH:OtherInvestmentMember KBPH:RestOfWorldMember 2021-03-31 0001164888 country:US 2021-03-31 0001164888 country:CA 2021-03-31 0001164888 KBPH:RestOfWorldMember 2021-03-31 0001164888 2018-03-31 0001164888 srt:MaximumMember 2021-09-30 0001164888 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-01-02 0001164888 srt:ChiefExecutiveOfficerMember 2021-05-01 2021-05-31 0001164888 srt:ChiefExecutiveOfficerMember 2021-07-01 2021-09-30 0001164888 srt:ChiefExecutiveOfficerMember 2021-04-01 2021-09-30 0001164888 srt:ChiefExecutiveOfficerMember 2020-04-01 2020-09-30 0001164888 2021-10-01 0001164888 KBPH:ConsultantsAndAdvisorsMember 2021-07-01 2021-09-30 0001164888 KBPH:ConsultantsAndAdvisorsMember 2020-07-01 2020-09-30 0001164888 KBPH:ConsultantsAndAdvisorsMember 2021-04-01 2021-09-30 0001164888 KBPH:ConsultantsAndAdvisorsMember 2020-04-01 2020-09-30 0001164888 KBPH:CommonStockIssuedMember 2021-07-01 2021-09-30 0001164888 KBPH:CommonStockIssuedMember 2021-04-01 2021-09-30 0001164888 KBPH:CommonStockSubscribedNotIssuedMember 2021-07-01 2021-09-30 0001164888 KBPH:CommonStockSubscribedNotIssuedMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesAPreferredStocksMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesAPreferredStocksMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesBPreferredStocksMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesBPreferredStocksMember 2021-04-01 2021-09-30 0001164888 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001164888 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-09-30 0001164888 us-gaap:WarrantMember 2021-07-01 2021-09-30 0001164888 us-gaap:WarrantMember 2021-04-01 2021-09-30 0001164888 KBPH:CommonStockIssuedMember 2020-07-01 2020-09-30 0001164888 KBPH:CommonStockIssuedMember 2020-04-01 2020-09-30 0001164888 KBPH:SeriesAPreferredStocksMember 2020-07-01 2020-09-30 0001164888 KBPH:SeriesAPreferredStocksMember 2020-04-01 2020-09-30 0001164888 KBPH:SeriesBPreferredStocksMember 2020-07-01 2020-09-30 0001164888 KBPH:SeriesBPreferredStocksMember 2020-04-01 2020-09-30 0001164888 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001164888 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-09-30 0001164888 us-gaap:WarrantMember 2020-07-01 2020-09-30 0001164888 us-gaap:WarrantMember 2020-04-01 2020-09-30 0001164888 us-gaap:PreferredStockMember 2021-09-30 0001164888 us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:CommonStockMember 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-03-31 0001164888 KBPH:SafeMember 2021-09-30 0001164888 KBPH:SafeMember 2021-03-31 0001164888 KBPH:OtherOwnershipUnitsMember 2021-09-30 0001164888 KBPH:OtherOwnershipUnitsMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:PromaxoIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:PromaxoIncMember 2021-07-01 2021-09-30 0001164888 srt:WeightedAverageMember KBPH:PromaxoIncMember KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-07-01 2021-09-30 0001164888 srt:MinimumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-09-30 0001164888 srt:MaximumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:ShyftMovingIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:ShyftMovingIncMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:SealRockTherapeuticsIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:SealRockTherapeuticsIncMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-07-01 2021-09-30 0001164888 srt:MinimumMember KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-09-30 0001164888 srt:MaximumMember KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2021-07-01 2021-09-30 0001164888 KBPH:InvestmentFairValueMember 2021-09-30 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:KitotechMedicalIncMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:KitotechMedicalIncMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2020-04-01 2021-03-31 0001164888 srt:MinimumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-03-31 0001164888 srt:MaximumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:NeuroflowIncMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:NeuroflowIncMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:ConvertibleDebtSecuritiesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:PreferredStockMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:PreferredStockMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:PreferredStockMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 KBPH:CommonStockInPrivateCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:SafeMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:SafeMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:SafeMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 us-gaap:OtherInvestmentsMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:PrivatePortfolioCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:PrivatePortfolioCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:PrivatePortfolioCompaniesMember 2021-09-30 0001164888 KBPH:PrivatePortfolioCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPublicCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPublicCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPublicCompaniesMember 2021-09-30 0001164888 KBPH:CommonStockInPublicCompaniesMember 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001164888 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001164888 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:SafeMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:SafeMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:SafeMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001164888 country:US 2021-04-01 2021-09-30 0001164888 country:CA 2021-04-01 2021-09-30 0001164888 KBPH:RestOfWorldMember 2021-04-01 2021-09-30 0001164888 country:US 2020-03-31 0001164888 country:CA 2020-03-31 0001164888 KBPH:RestOfWorldMember 2020-03-31 0001164888 country:US 2020-04-01 2020-09-30 0001164888 country:CA 2020-04-01 2020-09-30 0001164888 KBPH:RestOfWorldMember 2020-04-01 2020-09-30 0001164888 country:US 2020-09-30 0001164888 country:CA 2020-09-30 0001164888 KBPH:RestOfWorldMember 2020-09-30 0001164888 KBPH:FintechMember 2021-03-31 0001164888 KBPH:TechnologyMember 2021-03-31 0001164888 KBPH:LifeScienceMember 2021-03-31 0001164888 KBPH:FintechMember 2021-04-01 2021-09-30 0001164888 KBPH:TechnologyMember 2021-04-01 2021-09-30 0001164888 KBPH:LifeScienceMember 2021-04-01 2021-09-30 0001164888 KBPH:FintechMember 2021-09-30 0001164888 KBPH:TechnologyMember 2021-09-30 0001164888 KBPH:LifeScienceMember 2021-09-30 0001164888 KBPH:FintechMember 2020-03-31 0001164888 KBPH:TechnologyMember 2020-03-31 0001164888 KBPH:LifeScienceMember 2020-03-31 0001164888 KBPH:FintechMember 2020-04-01 2020-09-30 0001164888 KBPH:TechnologyMember 2020-04-01 2020-09-30 0001164888 KBPH:LifeScienceMember 2020-04-01 2020-09-30 0001164888 KBPH:FintechMember 2020-09-30 0001164888 KBPH:TechnologyMember 2020-09-30 0001164888 KBPH:LifeScienceMember 2020-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2021-04-01 2021-09-30 0001164888 us-gaap:PreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SafeMember 2021-04-01 2021-09-30 0001164888 KBPH:OtherOwnershipUnitsMember 2021-04-01 2021-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2020-03-31 0001164888 us-gaap:PreferredStockMember 2020-03-31 0001164888 us-gaap:CommonStockMember 2020-03-31 0001164888 KBPH:SafeMember 2020-03-31 0001164888 KBPH:OtherOwnershipUnitsMember 2020-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2020-04-01 2020-09-30 0001164888 us-gaap:PreferredStockMember 2020-04-01 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-04-01 2020-09-30 0001164888 KBPH:SafeMember 2020-04-01 2020-09-30 0001164888 KBPH:OtherOwnershipUnitsMember 2020-04-01 2020-09-30 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2020-09-30 0001164888 us-gaap:PreferredStockMember 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-09-30 0001164888 KBPH:SafeMember 2020-09-30 0001164888 KBPH:OtherOwnershipUnitsMember 2020-09-30 0001164888 us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:SeriesAPreferredStockMember 2021-06-30 0001164888 KBPH:SeriesAOnePreferredStockMember 2021-09-30 0001164888 KBPH:SeriesAOnePreferredStockMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesAOneAndSeriesATwoPreferredStockMember us-gaap:IPOMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesAOnePreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesATwoPreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember us-gaap:SeriesBPreferredStockMember 2021-03-02 0001164888 KBPH:SeriesBOnePreferredStockMember 2021-02-28 2021-03-02 0001164888 KBPH:SeriesBOneAndSeriesBTwoPreferredStockMember us-gaap:IPOMember 2021-02-28 2021-03-02 0001164888 KBPH:SeriesBOnePreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesBTwoPreferredStockMember 2021-04-01 2021-09-30 0001164888 KBPH:SeriesBOnePreferredStockMember 2021-07-01 2021-09-30 0001164888 KBPH:SeriesBThreePreferredStockMember 2021-09-30 0001164888 KBPH:SeriesBThreePreferredStockMember 2021-09-29 2021-09-30 0001164888 us-gaap:CommonStockMember KBPH:AmendmentofPreferredStockMember 2021-07-01 2021-09-30 0001164888 us-gaap:CommonStockMember KBPH:AmendmentofPreferredStockMember 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember KBPH:AmendmentofPreferredStockMember 2021-03-31 0001164888 KBPH:TwoThousandAndEighteenStockOptionAndIncentivePlanMember 2018-04-28 2018-04-30 0001164888 KBPH:TwoThousandNineteenStockOptionAndIncentivePlanMember 2019-07-31 0001164888 KBPH:TwoThousandNineteenStockOptionAndIncentivePlanMember 2019-07-29 2019-07-31 0001164888 KBPH:TwoThousandAndTwentyStockOptionAndIncentivePlanMember 2020-12-31 0001164888 KBPH:NonQualifiedStockOptionsMember 2021-07-01 2021-09-30 0001164888 KBPH:NonQualifiedStockOptionsMember 2020-07-01 2020-09-30 0001164888 KBPH:NonQualifiedStockOptionsMember 2021-04-01 2021-09-30 0001164888 KBPH:NonQualifiedStockOptionsMember 2020-04-01 2020-09-30 0001164888 srt:MinimumMember 2021-03-31 0001164888 srt:MaximumMember 2021-03-31 0001164888 srt:MinimumMember 2021-04-01 2021-09-30 0001164888 srt:MaximumMember 2021-04-01 2021-09-30 0001164888 srt:MinimumMember 2020-04-01 2021-03-30 0001164888 srt:MaximumMember 2020-04-01 2021-03-30 0001164888 2020-04-01 2021-03-30 0001164888 us-gaap:WarrantMember 2020-03-31 0001164888 us-gaap:WarrantMember 2020-04-01 2020-09-30 0001164888 us-gaap:WarrantMember 2020-09-30 0001164888 us-gaap:WarrantMember 2019-04-01 2020-03-31 0001164888 us-gaap:WarrantMember 2021-03-31 0001164888 us-gaap:WarrantMember 2021-04-01 2021-09-30 0001164888 us-gaap:WarrantMember 2021-09-30 0001164888 us-gaap:WarrantMember 2020-04-01 2021-03-31 0001164888 2021-01-01 2021-09-30 0001164888 KBPH:SeriesBThreePreferredStockMember us-gaap:SubsequentEventMember 2021-10-05 0001164888 us-gaap:SubsequentEventMember KBPH:SeriesBThreePreferredStockMember 2021-11-12 2021-11-13 0001164888 us-gaap:SubsequentEventMember 2021-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure KBPH:Integer

0001164888 false --03-31 2022 Q3 0001164888 2021-04-01 2021-12-31 0001164888 2022-02-18 0001164888 2021-12-31 0001164888 2021-03-31 0001164888 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001164888 us-gaap:SeriesAPreferredStockMember 2021-03-31 0001164888 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001164888 us-gaap:SeriesBPreferredStockMember 2021-03-31 0001164888 2021-10-01 2021-12-31 0001164888 2020-10-01 2020-12-31 0001164888 2020-04-01 2020-12-31 0001164888 us-gaap:PreferredStockMember KBPH:PreferredAStockClassAOneATwoMember 2021-09-30 0001164888 us-gaap:PreferredStockMember KBPH:PreferredBStockBClassBOneBTwoBThreeMember 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001164888 us-gaap:RetainedEarningsMember 2021-09-30 0001164888 2021-09-30 0001164888 us-gaap:PreferredStockMember KBPH:PreferredAStockClassAOneATwoMember 2021-10-01 2021-12-31 0001164888 us-gaap:PreferredStockMember KBPH:PreferredBStockBClassBOneBTwoBThreeMember 2021-10-01 2021-12-31 0001164888 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001164888 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001164888 us-gaap:PreferredStockMember KBPH:PreferredAStockClassAOneATwoMember 2021-12-31 0001164888 us-gaap:PreferredStockMember KBPH:PreferredBStockBClassBOneBTwoBThreeMember 2021-12-31 0001164888 us-gaap:CommonStockMember 2021-12-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001164888 us-gaap:RetainedEarningsMember 2021-12-31 0001164888 us-gaap:PreferredStockMember KBPH:PreferredAStockClassAOneATwoMember 2021-03-31 0001164888 us-gaap:PreferredStockMember KBPH:PreferredBStockBClassBOneBTwoBThreeMember 2021-03-31 0001164888 us-gaap:CommonStockMember 2021-03-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001164888 us-gaap:RetainedEarningsMember 2021-03-31 0001164888 us-gaap:PreferredStockMember KBPH:PreferredAStockClassAOneATwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:PreferredStockMember KBPH:PreferredBStockBClassBOneBTwoBThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:CommonStockMember 2021-04-01 2021-12-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-12-31 0001164888 us-gaap:RetainedEarningsMember 2021-04-01 2021-12-31 0001164888 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-09-30 0001164888 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-09-30 0001164888 us-gaap:CommonStockMember 2020-09-30 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001164888 us-gaap:RetainedEarningsMember 2020-09-30 0001164888 2020-09-30 0001164888 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-10-01 2020-12-31 0001164888 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-10-01 2020-12-31 0001164888 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001164888 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001164888 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0001164888 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-12-31 0001164888 us-gaap:CommonStockMember 2020-12-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001164888 us-gaap:RetainedEarningsMember 2020-12-31 0001164888 2020-12-31 0001164888 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-03-31 0001164888 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-03-31 0001164888 us-gaap:CommonStockMember 2020-03-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001164888 us-gaap:RetainedEarningsMember 2020-03-31 0001164888 2020-03-31 0001164888 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-04-01 2020-12-31 0001164888 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-04-01 2020-12-31 0001164888 us-gaap:CommonStockMember 2020-04-01 2020-12-31 0001164888 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-12-31 0001164888 us-gaap:RetainedEarningsMember 2020-04-01 2020-12-31 0001164888 KBPH:PreferredBStockBClassBOneBTwoBThreeMember 2021-12-31 0001164888 KBPH:PreferredBStockClassBOneBThreeMember 2021-12-31 0001164888 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001164888 KBPH:AbferoPharmaceuticalsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemeberTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember 2021-12-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2021-12-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2021-12-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSidecarTwentyFivePercentageDiscountNoInterestMember 2021-12-31 0001164888 KBPH:AOADXIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFourPercentageDueMayTwoThousandTwentyFourMember 2021-12-31 0001164888 KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2021-12-31 0001164888 KBPH:BasepawsIncOneMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueOctoberTwoThousandThreeMember 2021-12-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2021-12-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:ColabsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-12-31 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2021-12-31 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourOneMember 2021-12-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-12-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteZeroPercentageOnDueDateMember 2021-12-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoOneMember 2021-12-31 0001164888 KBPH:EveryKeyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2021-12-31 0001164888 KBPH:FemtoDXIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:IdenticalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2021-12-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2021-12-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeMember 2021-12-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeOneMember 2021-12-31 0001164888 KBPH:IrisRAndDGroupIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMayTwoThousandTwentyThreeMember 2021-12-31 0001164888 KBPH:KianaAnalyticsMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-12-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-12-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2021-12-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOneMember 2021-12-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageNoDueDateMember 2021-12-31 0001164888 KBPH:MMTronIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFourPercentageDueAprilTwoThousandTwentyThreeMember 2021-12-31 0001164888 KBPH:NavauxIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2021-12-31 0001164888 KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2021-12-31 0001164888 KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueNovemberTwoThousandTwentyThreeMember 2021-12-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2021-12-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2021-12-31 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueMayTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeOnlyMember 2021-12-31 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJulyTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:RheosIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAugustTwoThousandTwentySixMember 2021-12-31 0001164888 KBPH:SaccharoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2021-12-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2021-12-31 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyThreeMember 2021-12-31 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedMember 2021-12-31 0001164888 KBPH:SensingElectromagneticPlusCorpMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFullyReservedOneMember 2021-12-31 0001164888 KBPH:ShyftMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyThreeMember 2021-12-31 0001164888 KBPH:SinglePassIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyFourMember 2021-12-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2021-12-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2021-12-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:US 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember country:CA 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:RestOfWorldMember 2021-12-31 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-12-31 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-12-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2021-12-31 0001164888 KBPH:ColabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-12-31 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-12-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001164888 KBPH:DistasenseIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesCPreferredStockMember 2021-12-31 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001164888 KBPH:HealionicsCorporationMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-12-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-12-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2021-12-31 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-12-31 0001164888 KBPH:KitotechMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredMember 2021-12-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-12-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-12-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-12-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-12-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember 2021-12-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-12-31 0001164888 KBPH:MakaniScienceIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-12-31 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2021-12-31 0001164888 KBPH:NanochonIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredPlusWarrantsMember 2021-12-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-12-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-12-31 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-12-31 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredOneMember 2021-12-31 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2021-12-31 0001164888 KBPH:PartheousIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2021-12-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredMember 2021-12-31 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-12-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-12-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2021-12-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2021-12-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2021-12-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2021-12-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2021-12-31 0001164888 KBPH:TrioLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-12-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-12-31 0001164888 KBPH:VesteckIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2021-12-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-12-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-12-31 0001164888 KBPH:PreferredInvestmentsMember 2021-12-31 0001164888 KBPH:PreferredInvestmentsMember country:US 2021-12-31 0001164888 KBPH:PreferredInvestmentsMember country:CA 2021-12-31 0001164888 KBPH:PreferredInvestmentsMember KBPH:RestOfWorldMember 2021-12-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-12-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-12-31 0001164888 KBPH:KuantsolIncMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-12-31 0001164888 KBPH:CommonStockInvestmentMember 2021-12-31 0001164888 KBPH:CommonStockInvestmentsMember country:US 2021-12-31 0001164888 KBPH:CommonStockInvestmentsMember country:CA 2021-12-31 0001164888 KBPH:CommonStockInvestmentsMember KBPH:RestOfWorldMember 2021-12-31 0001164888 KBPH:CommonStockInvestmentsMember 2021-12-31 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:PublicCommonStockInvestmentsMember us-gaap:CommonStockMember 2021-12-31 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:PublicCommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-12-31 0001164888 KBPH:SanabyHealthAcquisitionCorpOneMember KBPH:LifeScienceMember KBPH:PublicCommonStockInvestmentsMember us-gaap:CommonStockMember 2021-12-31 0001164888 KBPH:PublicCommonStockInvestmentMember 2021-12-31 0001164888 KBPH:PublicCommonStockInvestmentsMember country:US 2021-12-31 0001164888 KBPH:PublicCommonStockInvestmentsMember country:CA 2021-12-31 0001164888 KBPH:PublicCommonStockInvestmentsMember KBPH:RestOfWorldMember 2021-12-31 0001164888 KBPH:PublicCommonStockInvestmentsMember 2021-12-31 0001164888 KBPH:AOADXIncMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-12-31 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-12-31 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-12-31 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeTwoMember 2021-12-31 0001164888 KBPH:MadorraIncMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-12-31 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-12-31 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-12-31 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-12-31 0001164888 KBPH:PolymertalIncMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-12-31 0001164888 KBPH:SafeInvestmentsMember 2021-12-31 0001164888 KBPH:SafeInvestmentsMember country:US 2021-12-31 0001164888 KBPH:SafeInvestmentsMember country:CA 2021-12-31 0001164888 KBPH:SafeInvestmentsMember KBPH:RestOfWorldMember 2021-12-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-12-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2021-12-31 0001164888 KBPH:ExodosLifeSciencesLPMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-12-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-12-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2021-12-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2021-12-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsThreeMember 2021-12-31 0001164888 KBPH:RisoCapitalFundILPMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:OwnershipUnitsMember 2021-12-31 0001164888 KBPH:RisoCapitalFundILPMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:OwnershipUnitsOneMember 2021-12-31 0001164888 KBPH:OtherInvestmentMember 2021-12-31 0001164888 KBPH:OtherInvestmentMember country:US 2021-12-31 0001164888 KBPH:OtherInvestmentMember country:CA 2021-12-31 0001164888 KBPH:OtherInvestmentMember KBPH:RestOfWorldMember 2021-12-31 0001164888 country:US 2021-12-31 0001164888 country:CA 2021-12-31 0001164888 KBPH:RestOfWorldMember 2021-12-31 0001164888 KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:AcheliosTherapeuticsIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:AcheliosTherapeuticsIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:AcheliosTherapeuticsIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:AvisiTechnologiesIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:CorinnovaIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteZeroPercentageOnDueDateMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:DeepBlueMedicalAdvancesIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:EveryKeyIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:IdenticalIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:KianaAnalyticsMember 2021-03-31 0001164888 KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:KiotechMedicalIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:KiotechMedicalIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:NavauxIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:NeuroFoutyTwoIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:OctagonTherapeuticsIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:OctagonTherapeuticsIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:PerikineticsIncMember 2021-03-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:SageMedicCorpMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:SageMedicCorpMember 2021-03-31 0001164888 KBPH:ConvertibleNoteFullyReservedMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:SensingElectromagneticPlusCorpMember 2021-03-31 0001164888 KBPH:ConvertibleNoteFullyReservedOneMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:SensingElectromagneticPlusCorpMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ValfixMedicalIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember KBPH:LifeScienceMember us-gaap:CorporateNoteSecuritiesMember KBPH:XpanIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:XpanIncMember 2021-03-31 0001164888 KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:XpanIncMember 2021-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 country:US us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 country:CA us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 KBPH:RestOfWorldMember us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember KBPH:AltisBiosystemsMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember KBPH:AstrocytePharmaceuticalsIncMember 2021-03-31 0001164888 KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember KBPH:CnoteGroupIncMember 2021-03-31 0001164888 KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember KBPH:CnoteGroupIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember KBPH:ColabsIncMember 2021-03-31 0001164888 KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember KBPH:ConnectusServicesLtdMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember KBPH:DeepBlueMedicalAdvancesIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember KBPH:EumentisThereapeuticsIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember KBPH:FemtoDXIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember KBPH:ILumenScientificIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember KBPH:ILumenScientificIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember KBPH:InhalonBiopharmaIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember KBPH:LightLineMedicalIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember KBPH:LightLineMedicalIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember KBPH:LightLineMedicalIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember KBPH:LightLineMedicalIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember KBPH:LowellTherapeuticsIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember KBPH:LowellTherapeuticsIncMember 2021-03-31 0001164888 KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember KBPH:MicronicTechnologiesIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember KBPH:NeuroflowIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember KBPH:NeuroflowIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember KBPH:NewViewSurgicalIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember KBPH:OtomagneticsIncMember 2021-03-31 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember KBPH:SealRockTherapeuticsIncMember 2021-03-31 0001164888 KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember KBPH:ShyftFKACraterGroupIncMember 2021-03-31 0001164888 KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember KBPH:ShyftFKACraterGroupIncMember 2021-03-31 0001164888 KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember KBPH:ShyftFKACraterGroupIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember KBPH:TrellisBioscienceLLCMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember KBPH:TrellisBioscienceLLCMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember KBPH:TrellisBioscienceLLCMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember KBPH:ValfixMedicalIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember KBPH:VisgenxIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember KBPH:VisgenxIncMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember KBPH:VisgenxIncMember 2021-03-31 0001164888 KBPH:PreferredInvestmentsMember 2021-03-31 0001164888 country:US KBPH:PreferredInvestmentsMember 2021-03-31 0001164888 country:CA KBPH:PreferredInvestmentsMember 2021-03-31 0001164888 KBPH:RestOfWorldMember KBPH:PreferredInvestmentsMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember KBPH:BendaRXCorpMember 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember KBPH:BendaRXCorpMember 2021-03-31 0001164888 KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember KBPH:BoardwalkTechMember 2021-03-31 0001164888 KBPH:CommonStockInvestmentsMember 2021-03-31 0001164888 country:US KBPH:CommonStockInvestmentsMember 2021-03-31 0001164888 country:CA KBPH:CommonStockInvestmentsMember 2021-03-31 0001164888 KBPH:RestOfWorldMember KBPH:CommonStockInvestmentsMember 2021-03-31 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:InfinidomeLtdMember KBPH:TechnologyMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-03-31 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:MitreMedicalCorpMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeOneMember 2021-03-31 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:SafeInvestmentsMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:SafeInvestmentsMember 2021-03-31 0001164888 country:US KBPH:SafeInvestmentsMember 2021-03-31 0001164888 country:CA KBPH:SafeInvestmentsMember 2021-03-31 0001164888 KBPH:RestOfWorldMember KBPH:SafeInvestmentsMember 2021-03-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-03-31 0001164888 KBPH:SeriesAOneOwnershipUnitsOneMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:EnduralockLLCMember 2021-03-31 0001164888 KBPH:ExodosLifeSciencesLPMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-03-31 0001164888 KBPH:ClassAOnePreferredOwnershipUnitsMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:GreenSunMedicalLLCMember 2021-03-31 0001164888 KBPH:ClassAOnePreferredOwnershipUnitsOneMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:GreenSunMedicalLLCMember 2021-03-31 0001164888 KBPH:ClassAOnePreferredOwnershipUnitsTwoMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:GreenSunMedicalLLCMember 2021-03-31 0001164888 KBPH:OwnershipUnitsMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:RisoCapitalFundILPMember 2021-03-31 0001164888 KBPH:OtherInvestmentMember 2021-03-31 0001164888 country:US KBPH:OtherInvestmentMember 2021-03-31 0001164888 country:CA KBPH:OtherInvestmentMember 2021-03-31 0001164888 KBPH:RestOfWorldMember KBPH:OtherInvestmentMember 2021-03-31 0001164888 country:US 2021-03-31 0001164888 country:CA 2021-03-31 0001164888 KBPH:RestOfWorldMember 2021-03-31 0001164888 KBPH:AbferoPharmaceuticalsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemeberTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember 2021-04-01 2021-12-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2021-04-01 2021-12-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AOADXIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteFourPercentageDueMayTwoThousandTwentyFourMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2021-04-01 2021-12-31 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueOctoberTwoThousandThreeMember 2021-12-31 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueOctoberTwoThousandThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:ColabsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CorinnovaIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CorinnovaIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourOneMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoOneMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:EveryKeyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:FemtoDXIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:IdenticalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeOneMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:IrisRAndDGroupIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteEightPercentageDueMayTwoThousandTwentyThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:KianaAnalyticsMember KBPH:TechnologyMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOneMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:MMTronIncMember KBPH:TechnologyMember KBPH:ConvertibleNoteFourPercentageDueAprilTwoThousandTwentyThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:NavauxIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueNovemberTwoThousandTwentyThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2021-04-01 2021-12-31 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueMayTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2021-12-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2021-04-01 2021-12-31 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJulyTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 KBPH:RheosIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAugustTwoThousandTwentySixMember 2021-04-01 2021-12-31 0001164888 KBPH:SaccharoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueSeptemberTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SageMedicCorpMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SageMedicCorpMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:ShyftMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyThreeMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:SinglePassIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyFourMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2021-04-01 2021-12-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:CorporateNoteSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-12-31 0001164888 us-gaap:CorporateNoteSecuritiesMember KBPH:XpanIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:XpanIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2021-04-01 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember KBPH:XpanIncMember KBPH:LifeScienceMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2021-04-01 2021-12-31 0001164888 KBPH:AltisBiosystemsMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:AstrocytePharmaceuticalsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:CnoteGroupIncMember KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:ColabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:ConnectusServicesLtdMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:DistasenseIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:EumentisThereapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:FemtoDXIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:HealionicsCorporationMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-04-01 2021-12-31 0001164888 KBPH:ILumenScientificIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember 2021-04-01 2021-12-31 0001164888 KBPH:InhalonBiopharmaIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:KitotechMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-12-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-04-01 2021-12-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:LightLineMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember 2021-04-01 2021-12-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember 2021-04-01 2021-12-31 0001164888 KBPH:LowellTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:MakaniScienceIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember 2021-04-01 2021-12-31 0001164888 KBPH:MicronicTechnologiesIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredPlusWarrantsMember 2021-04-01 2021-12-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:NeuroflowIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:NewViewSurgicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredOneMember 2021-04-01 2021-12-31 0001164888 KBPH:OrionBiotechnologyIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:OtomagneticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember 2021-04-01 2021-12-31 0001164888 KBPH:PartheousIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2021-04-01 2021-12-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-12-31 0001164888 KBPH:SealRockTherapeuticsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-12-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2021-04-01 2021-12-31 0001164888 KBPH:ShyftFKACraterGroupIncMember KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember 2021-04-01 2021-12-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember 2021-04-01 2021-12-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember 2021-04-01 2021-12-31 0001164888 KBPH:TrellisBioscienceLLCMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember 2021-04-01 2021-12-31 0001164888 KBPH:TrioLabsIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember 2021-04-01 2021-12-31 0001164888 KBPH:VesteckIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember 2021-04-01 2021-12-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember 2021-04-01 2021-12-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember 2021-04-01 2021-12-31 0001164888 KBPH:VisgenxIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember 2021-04-01 2021-12-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-12-31 0001164888 KBPH:BendaRXCorpMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-04-01 2021-12-31 0001164888 KBPH:KuantsolIncMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-12-31 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:PublicCommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-12-31 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:PublicCommonStockInvestmentsMember KBPH:CommonStockOneMember 2021-04-01 2021-12-31 0001164888 KBPH:SanabyHealthAcquisitionCorpOneMember KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2021-04-01 2021-12-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsMember 2021-04-01 2021-12-31 0001164888 KBPH:EnduralockLLCMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:SeriesAOneOwnershipUnitsOneMember 2021-04-01 2021-12-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsMember 2021-04-01 2021-12-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsOneMember 2021-04-01 2021-12-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsTwoMember 2021-04-01 2021-12-31 0001164888 KBPH:GreenSunMedicalLLCMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:ClassAOnePreferredOwnershipUnitsThreeMember 2021-04-01 2021-12-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember 2020-04-01 2021-03-31 0001164888 KBPH:AcheliosTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:AvisiTechnologiesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:BasepawsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:BeamSemiConductorIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:CorinnovaIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember 2020-04-01 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:CyberdonticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:DeepBlueMedicalAdvancesIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:EveryKeyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:IdenticalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:INBayTechnonlogyIncMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:KianaAnalyticsMember KBPH:TechnologyMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:KiotechMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember 2020-04-01 2021-03-31 0001164888 KBPH:LifewaveBiomedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember 2020-04-01 2021-03-31 0001164888 KBPH:NavauxIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:NeuroFoutyTwoIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:OctagonTherapeuticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember 2020-04-01 2021-03-31 0001164888 KBPH:PerikineticsIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:PreviewMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember 2020-04-01 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:SageMedicCorpMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember 2020-04-01 2021-03-31 0001164888 KBPH:ValfixMedicalIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember 2020-04-01 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:CorporateNoteSecuritiesMember KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember 2020-04-01 2021-03-31 0001164888 KBPH:XpanIncMember KBPH:LifeScienceMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember KBPH:AltisBiosystemsMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember KBPH:AstrocytePharmaceuticalsIncMember 2020-04-01 2021-03-31 0001164888 KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember KBPH:CnoteGroupIncMember 2020-04-01 2021-03-31 0001164888 KBPH:FintechMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedThreePreferredMember KBPH:CnoteGroupIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember KBPH:ColabsIncMember 2020-04-01 2021-03-31 0001164888 KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember KBPH:ConnectusServicesLtdMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember KBPH:DeepBlueMedicalAdvancesIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember KBPH:EumentisThereapeuticsIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember KBPH:FemtoDXIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember KBPH:ILumenScientificIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsOneMember KBPH:ILumenScientificIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember KBPH:InhalonBiopharmaIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember KBPH:LightLineMedicalIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember KBPH:LightLineMedicalIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember KBPH:LightLineMedicalIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredPlusWarrantsMember KBPH:LightLineMedicalIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesAPreferredStockMember KBPH:LowellTherapeuticsIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredStockOneMember KBPH:LowellTherapeuticsIncMember 2020-04-01 2021-03-31 0001164888 KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredPlusWarrantsMember KBPH:MicronicTechnologiesIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedTwoPreferredMember KBPH:NeuroflowIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember us-gaap:SeriesBPreferredStockMember KBPH:NeuroflowIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember KBPH:NewViewSurgicalIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredPlusWarrantsMember KBPH:OtomagneticsIncMember 2020-04-01 2021-03-31 0001164888 KBPH:PromaxoIncMember KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBOnePreferredConvertedNoteMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember KBPH:SealRockTherapeuticsIncMember 2020-04-01 2021-03-31 0001164888 KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredMember KBPH:ShyftFKACraterGroupIncMember 2020-04-01 2021-03-31 0001164888 KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAPreferredConvertedNoteMember KBPH:ShyftFKACraterGroupIncMember 2020-04-01 2021-03-31 0001164888 KBPH:TechnologyMember KBPH:PreferredInvestmentsMember KBPH:SeriesAOnePreferredConvertedNoteMember KBPH:ShyftFKACraterGroupIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsMember KBPH:TrellisBioscienceLLCMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsOneMember KBPH:TrellisBioscienceLLCMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesBPreferredPlusWarrantsTwoMember KBPH:TrellisBioscienceLLCMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredMember KBPH:ValfixMedicalIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedOnePreferredConvertedNoteMember KBPH:VisgenxIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteMember KBPH:VisgenxIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:PreferredInvestmentsMember KBPH:SeriesSeedPreferredConvertedNoteOneMember KBPH:VisgenxIncMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember KBPH:BendaRXCorpMember 2020-04-01 2021-03-31 0001164888 KBPH:LifeScienceMember KBPH:CommonStockInvestmentsMember KBPH:CommonStockOneMember KBPH:BendaRXCorpMember 2020-04-01 2021-03-31 0001164888 KBPH:BoardwalkTechMember KBPH:TechnologyMember KBPH:CommonStockInvestmentsMember us-gaap:CommonStockMember 2020-04-01 2021-03-31 0001164888 KBPH:SeriesAOneOwnershipUnitsMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:EnduralockLLCMember 2020-04-01 2021-03-31 0001164888 KBPH:SeriesAOneOwnershipUnitsOneMember KBPH:TechnologyMember KBPH:OtherInvestmentMember KBPH:EnduralockLLCMember 2020-04-01 2021-03-31 0001164888 KBPH:ClassAOnePreferredOwnershipUnitsMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:GreenSunMedicalLLCMember 2020-04-01 2021-03-31 0001164888 KBPH:ClassAOnePreferredOwnershipUnitsOneMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:GreenSunMedicalLLCMember 2020-04-01 2021-03-31 0001164888 KBPH:ClassAOnePreferredOwnershipUnitsTwoMember KBPH:LifeScienceMember KBPH:OtherInvestmentMember KBPH:GreenSunMedicalLLCMember 2020-04-01 2021-03-31 0001164888 2018-03-31 0001164888 srt:MaximumMember 2021-12-31 0001164888 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-01-02 0001164888 srt:ChiefExecutiveOfficerMember 2021-10-01 2021-12-31 0001164888 srt:ChiefExecutiveOfficerMember 2021-04-01 2021-12-31 0001164888 srt:ChiefExecutiveOfficerMember 2021-12-31 0001164888 srt:ChiefExecutiveOfficerMember 2020-10-01 2020-12-31 0001164888 srt:ChiefExecutiveOfficerMember 2020-04-01 2020-12-31 0001164888 srt:RestatementAdjustmentMember 2021-07-01 2021-09-30 0001164888 srt:RestatementAdjustmentMember 2021-04-01 2021-09-30 0001164888 srt:RestatementAdjustmentMember 2021-04-01 2021-06-30 0001164888 KBPH:ConsultantsAndAdvisorsMember 2021-10-01 2021-12-31 0001164888 KBPH:ConsultantsAndAdvisorsMember 2020-10-01 2020-12-31 0001164888 KBPH:ConsultantsAndAdvisorsMember 2021-04-01 2021-12-31 0001164888 KBPH:ConsultantsAndAdvisorsMember 2020-04-01 2020-12-31 0001164888 srt:ScenarioPreviouslyReportedMember 2021-07-01 2021-09-30 0001164888 srt:ScenarioPreviouslyReportedMember 2021-04-01 2021-06-30 0001164888 srt:ScenarioPreviouslyReportedMember 2021-04-01 2021-09-30 0001164888 2021-07-01 2021-09-30 0001164888 2021-04-01 2021-06-30 0001164888 2021-04-01 2021-09-30 0001164888 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001164888 us-gaap:CommonStockMember 2021-04-01 2021-12-31 0001164888 us-gaap:SeriesAPreferredStockMember 2021-10-01 2021-12-31 0001164888 us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-12-31 0001164888 us-gaap:SeriesBPreferredStockMember 2021-10-01 2021-12-31 0001164888 us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-12-31 0001164888 us-gaap:EmployeeStockOptionMember 2021-10-01 2021-12-31 0001164888 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-12-31 0001164888 us-gaap:WarrantMember 2021-10-01 2021-12-31 0001164888 us-gaap:WarrantMember 2021-04-01 2021-12-31 0001164888 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001164888 us-gaap:CommonStockMember 2020-04-01 2020-12-31 0001164888 us-gaap:SeriesAPreferredStockMember 2020-10-01 2020-12-31 0001164888 us-gaap:SeriesAPreferredStockMember 2020-04-01 2020-12-31 0001164888 us-gaap:SeriesBPreferredStockMember 2020-10-01 2020-12-31 0001164888 us-gaap:SeriesBPreferredStockMember 2020-04-01 2020-12-31 0001164888 us-gaap:EmployeeStockOptionMember 2020-10-01 2020-12-31 0001164888 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-12-31 0001164888 us-gaap:WarrantMember 2020-10-01 2020-12-31 0001164888 us-gaap:WarrantMember 2020-04-01 2020-12-31 0001164888 KBPH:ConvertibleNotesMember 2021-12-31 0001164888 KBPH:ConvertibleNotesMember 2021-03-31 0001164888 KBPH:PreferredStockFairValueMember 2021-12-31 0001164888 KBPH:PreferredStockFairValueMember 2021-03-31 0001164888 us-gaap:PreferredStockMember 2021-03-31 0001164888 us-gaap:CommonStockMember 2021-12-31 0001164888 us-gaap:CommonStockMember 2021-03-31 0001164888 KBPH:SafeMember 2021-12-31 0001164888 KBPH:SafeMember 2021-03-31 0001164888 KBPH:OtherOwnershipUnitsMember 2021-12-31 0001164888 KBPH:OtherOwnershipUnitsMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:BasepawsIncMember 2021-04-01 2021-12-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:CyberdonticsIncMember 2021-04-01 2021-12-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:PromaxoIncMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:PromaxoIncMember 2021-04-01 2021-12-31 0001164888 srt:WeightedAverageMember KBPH:PromaxoIncMember KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-04-01 2021-12-31 0001164888 srt:MinimumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-12-31 0001164888 srt:MaximumMember KBPH:InvestmentFairValueMember KBPH:ConvertibleDebtSecuritiesOtherMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:InhalonIncMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:InhalonIncMember 2021-04-01 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:NeuroflowIncMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:NeuroflowIncMember 2021-04-01 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:ValfixIncMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:ValfixIncMember 2021-04-01 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:ShyftMovingIncMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:ShyftMovingIncMember 2021-04-01 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:SealRockTherapeuticsIncMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:SealRockTherapeuticsIncMember 2021-04-01 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2021-04-01 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-04-01 2021-12-31 0001164888 srt:MinimumMember KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-12-31 0001164888 srt:MaximumMember KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:PromaxoIncMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2021-04-01 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2021-04-01 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2021-04-01 2021-12-31 0001164888 KBPH:InvestmentFairValueMember 2021-12-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:KitotechMedicalIncMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember KBPH:KitotechMedicalIncMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2020-04-01 2021-03-31 0001164888 srt:MinimumMember KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 srt:MaximumMember KBPH:InvestmentFairValueMember us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:FemtoDXIncMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:NeuroflowIncMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesMember KBPH:NeuroflowIncMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:PreferredStockInPrivateCompaniesOtherMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:CommonStockInPrivateCompaniesMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember KBPH:SafeMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 KBPH:InvestmentFairValueMember us-gaap:OtherInvestmentsMember 2020-04-01 2021-03-31 0001164888 KBPH:InvestmentFairValueMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:ConvertibleDebtSecuritiesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtSecuritiesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:ConvertibleDebtSecuritiesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:PreferredStockInPrivateCompaniesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:PreferredStockInPrivateCompaniesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:PreferredStockInPrivateCompaniesMember 2021-12-31 0001164888 KBPH:PreferredStockInPrivateCompaniesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPrivateCompaniesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPrivateCompaniesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPrivateCompaniesMember 2021-12-31 0001164888 KBPH:CommonStockInPrivateCompaniesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:SafeMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:SafeMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:SafeMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:PrivatePortfolioCompaniesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:PrivatePortfolioCompaniesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:PrivatePortfolioCompaniesMember 2021-12-31 0001164888 KBPH:PrivatePortfolioCompaniesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPublicCompaniesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPublicCompaniesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPublicCompaniesMember 2021-12-31 0001164888 KBPH:CommonStockInPublicCompaniesMember 2021-12-31 0001164888 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001164888 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001164888 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:ConvertibleDebtSecuritiesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:PreferredStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:PreferredStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:PreferredStockInPrivateCompaniesMember 2021-03-31 0001164888 KBPH:PreferredStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 KBPH:CommonStockInPrivateCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:SafeMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:SafeMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:SafeMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:OtherInvestmentsMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 KBPH:PrivatePortfolioCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 KBPH:CommonStockInPublicCompaniesMember 2021-03-31 0001164888 us-gaap:FairValueInputsLevel1Member 2021-03-31 0001164888 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001164888 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001164888 country:US 2021-04-01 2021-12-31 0001164888 country:CA 2021-04-01 2021-12-31 0001164888 KBPH:RestOfWorldMember 2021-04-01 2021-12-31 0001164888 country:US 2020-03-31 0001164888 country:CA 2020-03-31 0001164888 KBPH:RestOfWorldMember 2020-03-31 0001164888 country:US 2020-04-01 2020-12-31 0001164888 country:CA 2020-04-01 2020-12-31 0001164888 KBPH:RestOfWorldMember 2020-04-01 2020-12-31 0001164888 country:US 2020-12-31 0001164888 country:CA 2020-12-31 0001164888 KBPH:RestOfWorldMember 2020-12-31 0001164888 KBPH:FintechMember 2021-03-31 0001164888 KBPH:TechnologyMember 2021-03-31 0001164888 KBPH:LifeScienceMember 2021-03-31 0001164888 KBPH:FintechMember 2021-04-01 2021-12-31 0001164888 KBPH:TechnologyMember 2021-04-01 2021-12-31 0001164888 KBPH:LifeScienceMember 2021-04-01 2021-12-31 0001164888 KBPH:FintechMember 2021-12-31 0001164888 KBPH:TechnologyMember 2021-12-31 0001164888 KBPH:LifeScienceMember 2021-12-31 0001164888 KBPH:FintechMember 2020-03-31 0001164888 KBPH:TechnologyMember 2020-03-31 0001164888 KBPH:LifeScienceMember 2020-03-31 0001164888 KBPH:FintechMember 2020-04-01 2020-12-31 0001164888 KBPH:TechnologyMember 2020-04-01 2020-12-31 0001164888 KBPH:LifeScienceMember 2020-04-01 2020-12-31 0001164888 KBPH:FintechMember 2020-12-31 0001164888 KBPH:TechnologyMember 2020-12-31 0001164888 KBPH:LifeScienceMember 2020-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2021-04-01 2021-12-31 0001164888 us-gaap:PreferredStockMember 2021-04-01 2021-12-31 0001164888 us-gaap:CommonStockMember 2021-04-01 2021-12-31 0001164888 KBPH:SafeMember 2021-04-01 2021-12-31 0001164888 KBPH:OtherOwnershipUnitsMember 2021-04-01 2021-12-31 0001164888 us-gaap:PreferredStockMember 2021-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2020-03-31 0001164888 us-gaap:PreferredStockMember 2020-03-31 0001164888 us-gaap:CommonStockMember 2020-03-31 0001164888 KBPH:SafeMember 2020-03-31 0001164888 KBPH:OtherOwnershipUnitsMember 2020-03-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2020-04-01 2020-12-31 0001164888 us-gaap:PreferredStockMember 2020-04-01 2020-12-31 0001164888 us-gaap:CommonStockMember 2020-04-01 2020-12-31 0001164888 KBPH:SafeMember 2020-04-01 2020-12-31 0001164888 KBPH:OtherOwnershipUnitsMember 2020-04-01 2020-12-31 0001164888 us-gaap:ConvertibleDebtSecuritiesMember 2020-12-31 0001164888 us-gaap:PreferredStockMember 2020-12-31 0001164888 us-gaap:CommonStockMember 2020-12-31 0001164888 KBPH:SafeMember 2020-12-31 0001164888 KBPH:OtherOwnershipUnitsMember 2020-12-31 0001164888 us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:SeriesAOnePreferredStockMember 2021-03-02 0001164888 KBPH:SeriesAOnePreferredStockMember 2021-02-28 2021-03-02 0001164888 KBPH:SeriesAOneAndSeriesATwoPreferredStockMember us-gaap:IPOMember 2021-04-01 2021-12-31 0001164888 KBPH:SeriesAOnePreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:SeriesATwoPreferredStockMember 2021-04-01 2021-12-31 0001164888 us-gaap:CommonStockMember us-gaap:SeriesBPreferredStockMember 2021-03-02 0001164888 KBPH:SeriesBOnePreferredStockMember 2021-02-28 2021-03-02 0001164888 KBPH:SeriesBOneAndSeriesBTwoPreferredStockMember us-gaap:IPOMember 2021-02-28 2021-03-02 0001164888 KBPH:SeriesBOnePreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:SeriesBTwoPreferredStockMember 2021-04-01 2021-12-31 0001164888 KBPH:SeriesBOnePreferredStockMember 2021-10-01 2021-12-31 0001164888 KBPH:SeriesBThreePreferredStockMember 2021-04-01 2021-12-31 0001164888 us-gaap:CommonStockMember KBPH:AmendmentofPreferredStockMember 2021-10-01 2021-12-31 0001164888 us-gaap:CommonStockMember KBPH:AmendmentofPreferredStockMember 2021-04-01 2021-12-31 0001164888 us-gaap:CommonStockMember KBPH:AmendmentofPreferredStockMember 2021-03-31 0001164888 KBPH:TwoThousandAndEighteenStockOptionAndIncentivePlanMember 2018-04-01 2018-04-30 0001164888 KBPH:TwoThousandNineteenStockOptionAndIncentivePlanMember 2019-07-31 0001164888 KBPH:TwoThousandAndTwentyStockOptionAndIncentivePlanMember 2020-12-31 0001164888 KBPH:TwoThousandAndTwentyOneStockOptionAndIncentivePlanMember 2021-12-20 0001164888 KBPH:NonQualifiedStockOptionsMember 2021-10-01 2021-12-31 0001164888 KBPH:NonQualifiedStockOptionsMember 2020-10-01 2020-12-31 0001164888 KBPH:NonQualifiedStockOptionsMember 2021-04-01 2021-12-31 0001164888 KBPH:NonQualifiedStockOptionsMember 2020-04-01 2020-12-31 0001164888 us-gaap:WarrantMember 2021-04-01 2021-12-31 0001164888 srt:MinimumMember 2021-03-31 0001164888 srt:MaximumMember 2021-03-31 0001164888 srt:MinimumMember 2021-04-01 2021-12-31 0001164888 srt:MaximumMember 2021-04-01 2021-12-31 0001164888 srt:MinimumMember 2020-04-01 2021-03-31 0001164888 srt:MaximumMember 2020-04-01 2021-03-31 0001164888 2020-04-01 2021-03-31 0001164888 us-gaap:WarrantMember 2021-12-31 0001164888 us-gaap:WarrantMember 2020-03-31 0001164888 us-gaap:WarrantMember 2020-04-01 2020-12-31 0001164888 us-gaap:WarrantMember 2020-12-31 0001164888 us-gaap:WarrantMember 2019-04-01 2020-03-31 0001164888 us-gaap:WarrantMember 2021-03-31 0001164888 us-gaap:WarrantMember 2020-04-01 2021-03-31 0001164888 us-gaap:SubsequentEventMember 2022-01-01 2022-02-22 0001164888 us-gaap:SubsequentEventMember 2022-02-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure KBPH:Integer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~December 3031, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from: _____________ to _____________

KYTO TECHNOLOGY AND LIFE SCIENCE, INC.

(Exact name of registrant as specified in its charter)

delaware	000-50390	65-1086538
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

13050 Paloma Road, Los Altos Hills, CA 94022

(Address of Principal Executive Office) (Zip Code)

(650) 204 7896

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Title of each class		Trading Symbol		Exchange
Common stock		KBPH		OTC QB

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (ss. 232.405 of this chapter) during the preceding 12 (or for such shorter period that the registrant was required to submit such files). ☒ Yes No ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Yes ☒ No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

13,287,621 Common Shares - $0.01 Par Value - as of ~~November~~February 1518, ~~2021~~ 2022

~~KYTO~~Kyto Technology and Life Science, Inc.

For the quarterly period ended ~~September~~December 3031, 2021

INDEX

	PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements	3
	Condensed Statements of Asset and Liabilities as of September 30, 2021 (Unaudited) and March 31, 2021	3
	Condensed Statements of Assets and Liabilities as of December 31, 2021 (Unaudited) and March 31, 2021	3
	Unaudited Condensed Statements of Operations for the Three Months and Six Months Ended September 30, 2021 and 2020	4
	Unaudited Condensed Statements of Operations for the Three Months and Nine Months Ended December 31, 2021 and 2020	4
	Unaudited Condensed Statements of Changes in Net Assets for the Three Months and Six Months Ended September 30, 2021 and 2020	5
	Unaudited Condensed Statements of Changes in Net Assets for the Three Months and Nine Months Ended December 31, 2021 and 2020	5
	Unaudited Condensed Statements of Cash Flows for the Six Months Ended September 30, 2021 and 2020	7
	Unaudited Condensed Statements of Cash Flows for the Nine Months Ended December 31, 2021 and 2020	7
	Condensed Schedule of Investments as of September 30, 2021 (Unaudited) and March 31, 2021	9
	Condensed Schedule of Investments as of December 31, 2021 (Unaudited) and March 31, 2021	8
	Notes to Unaudited Interim Condensed Financial Statements	1413
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	2829
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	3233
Item 4.	Controls and Procedures.	3233
	PART II. OTHER INFORMATION
Item 1.	Legal Proceedings.	3335
Item 1A.	Risk Factors.	3335
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	3335
Item 3.	Defaults Upon Senior Securities.	3335
Item 4.	Mine Safety Disclosures	3335
Item 5.	Other Information	3335
Item 6.	Exhibits	3335
	Signatures	3537

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Kyto Technology and Life Science, Inc.

Condensed ~~Statements~~Statement of Assets and Liabilities

	September 30,			March 31,
	December 31,			March 31,
	2021			2021
	(Unaudited)
ASSETS
Investments at fair value (cost of $7,904,636 and $5,686,545, respectively)	$	10,442,813		$	6,821,407
Investments at fair value (cost of $8,926,469 and $5,686,545, respectively)	$	12,156,511		$	6,821,407
Cash		~~316~~608,~~124~~223			1,437,868
Other current assets		230,434			169,891
Other assets		293,564			169,891
Total Assets	$	1013,~~989~~058,~~371~~298		$	8,429,166
LIABILITIES
Liabilities
Accounts payable and accrued liabilities	$	8463,~~477~~675		$	193,141
Accrued liabilities - related parties		8783,000			51,420
Common stock subscription liability		-			1,191,442
Total Liabilities		~~171~~146,~~477~~675			1,436,003
Commitments and Contingencies (Note 3)		-			-
Net Assets
Preferred stock authorized but not designated, $.01 par value 19,800,000 shares, none issued and outstanding as of September 30, 2021 and March 31, 2021, respectively		-			-
Preferred stock authorized but not designated, $0.01 par value 16,800,000 shares, none issued or outstanding as of December 31, 2021 and March 31, 2021, respectively		-			-
Series A (including Series A-1 and A-2) preferred convertible stock, $0.01 par value, 4,200,000 shares designated, 4,200,000 issued and outstanding as of September 30, 2021 and March 31, 2021, respectively, aggregate liquidation preference of $6,720,000 at September 30, 2021 and March 31, 2021, respectively		42,001			42,001
Class A (including Class A-1 and A-2) preferred convertible stock, $0.01 par value, 4,200,000 shares designated, 4,200,000 issued and outstanding as of December 31, 2021 and March 31, 2021, respectively; aggregate liquidation preference of $6,720,000 at December 31, 2021 and March 31, 2021, respectively		42,001			42,001
Series B (including Series B-1 and B-2) preferred convertible stock, $0.01 par value, 6,000,000 shares designated, 5,911,406 and 3,628,906 issued and outstanding as of September 30, 2021 and March 31, 2021, respectively, aggregate liquidation preference of $9,458,250 at September 30, 2021 and $5,806,250 at March 31, 2021, respectively		59,114			36,289
Class B (including Class B-1, B-2 and B-3) preferred convertible stock, $0.01 par value, 9,000,000 shares designated, 8,087,656 and 3,628,906 issued and outstanding as of December 31, 2021 and March 31, 2021, respectively, aggregate liquidation preference of $6,951,945 at December 31, 2021 and $2,903,125 at March 31, 2021, respectively		80,877			36,289
Preferred stock, value		-			-
Common stock, $.01 par value, 40,000,000 shares authorized, 13,287,621 and 9,983,082 issued and outstanding as of September 30, 2021 and March 31 2021, respectively		132,876			99,831
Common stock, $0.01 par value, 40,000,000 shares authorized, 13,287,621 and 9,983,082 issued and outstanding as of December 31, 2021 and March 31 2021, respectively		132,876			99,831
Additional paid-in capital		4244,~~878~~630,~~748~~564			39,772,228
Accumulated deficit		(3231,~~294~~974,~~845~~695	)		(32,957,186	)
Total Net Assets		1012,~~817~~911,~~894~~623			6,993,163
Total Liabilities and Net Assets	$	1013,~~989~~058,~~371~~298		$	8,429,166

The accompanying notes are an integral part of these condensed interim financial statements.

Kyto Technology and Life Science, Inc.

Condensed ~~Statements~~Statement of Operations

(Unaudited)

	2021			2020			2021			2020
	For the Three months ended September 30,						For the Six months ended September 30,
	For the Three months ended December 31,						For the Nine months ended December 31,
	2021			2020			2021			2020
INVESTMENT INCOME
Interest and other income	$	-		$	-5		$	-		$	~~500~~505
Total investment income		-			-5			-			~~500~~505
EXPENSES
Professional fees		~~107~~98,~~201~~241			6391,~~605~~669			~~273~~371,~~359~~600			76168,~~543~~212
Other operating expenses		~~245~~273,~~519~~473			96241,~~506~~047			~~466~~741,~~027~~089			~~122~~363,~~936~~983
Interest and non operating expenses		1,596			-			1,588			-
Total expenses		371,714			332,716			1,112,689			532,195
Total expenses		354,316			160,111			740,974			199,479
Net investment loss		(371,714	)		(332,711	)		(1,112,689	)		(531,690	)
Net investment loss		(354,316	)		(160,111	)		(740,974	)		(198,979	)
Net change in unrealized gain on investments		691,864			328,694			2,095,180			806,942
Net change in unrealized gain from investments		1,350,449			478,248			1,403,315			478,248
Net increase (decrease) in net assets resulting from operations		320,150			(4,017	)		982,491			275,252
Net increase in net assets resulting from operations	$	996,133		$	318,137		$	662,341		$	279,269
Less: dividends attributable to Class B-1, B-2 and B-3		(131,999 )			-			(482,693)			-
Less: dividends attributable to Class B-1, B-2 and B-3 Preferred Stock (see Note 2 (I))		(131,999	)		-			(482,693	)		-
Net increase (decrease) in net assets resulting from operations attributable to Common Shareholders	$	188,151		$	(4,017	)	$	499,798		$	275,252
Basic earnings per Common Share,
Net increase in net assets resulting from operations per common share	$	0.0801		$	~~0.05~~-		$	0.0504		$	0.0504
Weighted average common shares outstanding		13,~~271~~287,~~996~~621			58,~~836~~528,~~832~~007			13,~~269~~273,~~764~~038			56,~~836~~737,~~832~~152
Fully-diluted earnings per Common Share,
Net increase in net assets resulting from operations per common share	$	0.0401		$	~~0.02~~-		$	0.0302		$	0.02
Weighted average common shares outstanding		2723,~~338~~516,~~695~~038			1719,~~987~~272,~~040~~128			2622,~~263~~400,~~218~~260			17,~~058~~142,~~856~~683

The accompanying notes are an integral part of these condensed interim financial statements.

Kyto Technology and Life Science, Inc.

Condensed ~~Statements~~Statement of Changes in Net Assets for the Three and ~~Six~~Nine months ended ~~September~~December 3031, 2021

( Unaudited)

			Preferred A				Preferred B				Common		Additional
	Preferred A (Including Class A-1, A-2)		Preferred A Stock (Including Class A-1, A-2)		Preferred B (Including Class B-1, B-2, B-3)		Preferred B Stock (Including Class B-1, B-2, B-3)		Common		Common Stock		Additional Paid-in		Accumulated
	Preferred A (Including Series A-1, A-2)		Preferred A Stock (Including Series A-1, A-2)		Preferred B (Including Series B-1, B-2)		Preferred B (Including Series B-1, B-2) Stock		Common		Common Stock		Additional Paid-in		Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Total
Three months ended September 30, 2021
Three months ended December 31, 2021
Balance, June 30, 2021		4,200,000	$	42,001		4,320,156	$	43,202		13,268,871	$	132,689	$	41,610,332	$	(33,290,978	)	$	8,537,246
Net increase in net assets resulting from operations																996,133			996,133
Sale of Series B-1 Preferred stock at $0.80 per share		-		-		1,591,250		15,912						1,257,088					1,273,000
Sale of common stock at $0.40 per share
Sale of common stock at $0.40 per share, shares
Exercise of stock options										18,750		187		431					618
Compensation expense from stock options														10,897					10,897
Balance, September 30, 2021		4,200,000	$	42,001		5,911,406	$	59,114		13,287,621	$	132,876	$	42,878,748	$	(32,294,845	)	$	10,817,894
Six months ended September 30, 2021
Net increase in net assets resulting from operations		-		-		-		-		-		-		-		320,150			320,150
Sale of Class B-3 Preferred stock at $0.80 per share		-		-		2,176,250		21,763		-		-		1,719,237		-			1,741,000
Sale of Common stock
Sale of common stock $0.40 per share, shares
Exercise of stock options
Exercise of stock options, shares
Common stock issued for warrants and options exercise
Common stock issued for warrants and options exercise, shares
Compensation expense from stock options		-		-		-		-		-		-		32,579		-			32,579
Balance, December 31, 2021		4,200,000	$	42,001		8,087,656	$	80,877		13,287,621	$	132,876	$	44,630,564	$	(31,974,695	)	$	12,911,623
Nine months ended December 31, 2021
Balance, March 31, 2021		4,200,000	$	42,001		3,628,906	$	36,289		9,983,082	$	99,831	$	39,772,228	$	(32,957,186	)	$	6,993,163
Net increase in net assets resulting from operations		-		-		-		-		-		-		-		~~662~~982,~~341~~491			~~662~~982,~~341~~491
Sale of Series B-1 Preferred stock at $0.80 per share		-		-		2,282,500		22,825						1,803,176					1,826,001
Sale of Class B-1 and B-3 Preferred stock at $0.80 per share		-		-		4,458,750		44,588		-		-		3,522,413		-			3,567,001
Sale of common stock at $0.40 per share										3,285,789		32,858		1,281,459					1,314,317
Sale of Common stock at $0.40 per share		-		-		-		-		3,285,789		32,858		1,281,459		-			1,314,317
Exerrcise of stock options										18,750		187		431					618
Exercise of stock options		-		-		-		-		18,750		187		431		-			618
Compensation expense from stock options		-		-		-		-		-		-		2154,~~454~~033		-			2154,~~454~~033
Balance, September 30, 2021		4,200,000	$	42,001		5,911,406	$	59,114		13,287,621	$	132,876	$	42,878,748	$	(32,294,845	)	$	10,817,894
Balance, December 31, 2021		4,200,000	$	42,001		8,087,656	$	80,877		13,287,621	$	132,876	$	44,630,564	$	(31,974,695	)	$	12,911,623

The accompanying notes are an integral part of these condensed interim financial statements.

Kyto Technology and Life Science, Inc.

Condensed ~~Statements~~Statement of Changes in Net Assets for the Three and ~~Six~~Nine months ended ~~September~~December 3031, 2020

( Unaudited)

	Preferred A		Preferred A ~~Stock~~Shares		Preferred B		Preferred B ~~Stock~~Shares		Common		Common Stock		Additional Paid-in		Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Total
Three months ended September 30, 2020
Three months ended December 31, 2020
Balance, June 30, 2020		42,000,000	$	42,001		1,281,250	$	12,188		5,836,832	$	58,368	$	36,315,354	$	(33,423,120	)	$	3,004,791
Balance, September 30, 2020		4,200,000	$	42,001		2,337,500	$	23,375		5,836,832	$	58,368	$	37,211,970	$	(33,104,983	)	$	4,230,731
Net increase in net assets resulting from operations		-		-		-		-		-		-		-		318,137			318,137
Net decrease in net assets resulting from operations		-		-		-		-		-		-		-		(4,017	)		(4,017	)
Sale of Series B Preferred stock at $0.80 per share		-		-		1,056,250		11,187		-		-		883,813		-			895,000
Sale of Class B Preferred stock at $0.80 per share		-		-		753,906		7,539		-		-		595,586		-			603,125
Compensation expense from stock options		-		-		-		-		-		-		12,803		-			12,803
Common stock issued for warrants and options exercise		-		-		-		-		3,965,000		39,650		1,526,580		-			1,566,230
Balance, September 30, 2020		42,000,000	$	42,001		2,337,500	$	23,375		5,836,832	$	58,368	$	37,211,970	$	(33,104,983	)	$	4,230,731
Compensation expense from stock options		-		-		-		-		-		-		3,474		-			3,474
Six months ended September 30, 2020
Balance, December 31, 2020		4,200,000	$	42,001		3,091,406	$	30,914		9,801,832	$	98,018	$	39,337,610	$	(33,109,000	)	$	6,399,543
Balance, March 31, 2020		42,000,000	$	42,001		812,500	$	8,125		5,836,832	$	58,368	$	35,943,369	$	(33,384,252	)	$	2,667,611
Nine months ended December 31, 2020
Balance		42,000,000	$	42,001		812,500	$	8,125		5,836,832	$	58,368	$	35,943,369	$	(33,384,252	)	$	2,667,611
Balance, March 31, 2020		4,200,000	$	42,001		812,500	$	8,125		5,836,832	$	58,368	$	35,943,369	$	(33,384,252	)	$	2,667,611
Net increase in net assets resulting from operations		-		-		-		-		-		-		-		~~279~~275,~~269~~252			~~279~~275,~~269~~252
Sale of Series B Preferred stock at $0.80 per share		-		-		1,525,000		15,250		-		-		1,254,750		-			1,270,000
Net increase (decrease) in net assets resulting from operations		-		-		-		-		-		-		-		275,252			275,252
Compensation expense from stock options		-		-		-		-		-		-		13,851		-			13,851
Sale of Class B Preferred stock at $0.80 per share		-		-		2,278,906		22,789		-		-		1,850,336		-			1,873,125
Balance, September 30, 2020		42,000,000	$	42,001		2,337,500	$	23,375		5,836,832	$	58,368	$	37,211,970	$	(33,104,983	)	$	4,230,731
Sale of Class B, B-1 and B-3 Preferred stock		-		-		2,278,906		22,789		-		-		1,850,336		-			1,873,125
Balance		42,000,000	$	42,001		2,337,500	$	23,375		5,836,832	$	58,368	$	37,211,970	$	(33,104,983	)	$	4,230,731
Common stock issued for warrants and options exercise		-		-		-		-		3,965,000		39,650		1,526,579		-			1,566,229
Compensation expense from stock options		-		-		-		-		-		-		17,326		-			17,326
Balance, December 31, 2020		4,200,000	$	42,001		3,091,406	$	30,914		9,801,832	$	98,018	$	39,337,610	$	(33,109,000	)	$	6,399,543

The accompanying notes are an integral part of these condensed interim financial statements.

Kyto Technology and Life Science, Inc.

Condensed ~~Statements~~Statement of Cash Flows

(Unaudited)

	2021			2020
	Six months months ended September 30,
	Nine months months ended
	December 31,
	2021			2020
Operating activities:
Net increase in net assets resulting from operations	$	~~662~~982,~~341~~491		$	~~279~~275,~~269~~252
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash used in operating activities
Adjustments to reconcile net increase in net assets resulting from operations to net cash used in operating activities
Net change in unrealized gain on investments		(12,~~403~~095,~~315~~180	)		(~~478~~806,~~248~~942	)
Stock option compensation expense		2154,~~454~~033			1317,~~851~~326
Change in operating assets and liabilities
Other current assets		(60,543	)		500
Other assets		(123,673	)		500
Accounts payable and accrued liabilities		(~~108~~129,~~664~~466	)		1547,~~064~~708
Accrued liabilities to related parties		3531,580			-
Purchase of investments		(2,218,091	)		(740,000	)
Purchases of investments		(3,328,478	)		(2,410,000	)
Net cash used in operating activities		(3,071,238	)		(909,564	)
Proceeds from sale of investments		88,554			-
Net cash used in operating activities		(4,520,139	)		(2,876,156	)
Cash flows from financing activities:
Sale of Common stock in connection with preference rights (see Note 6)		122,875			-
Sale of Common stock from exercise of options stock		618			-
Sale of Common stock from exercise of warrants and stock options		618			1,566,229
Sale of Series B-1 Preferred stock		1,826,001			1,270,000
Sale of Class B-1 Preferred stock		1,626,000			1,873,125
Sale of Class B-3 Preferred stock		1,941,001			-
Deferred fundraising expenses		-			(36,409	)
Receipt of SBA loan		-			1,000
Advances from related party		-			2,250
Net cash provided by financing activities		13,~~949~~690,494			13,~~273~~406,~~250~~195
Net increase/(decrease) in cash		(1829,~~121,744~~645	)		~~363~~530,~~686~~039
Cash, beginning of period		1,437,868			33,756
Cash, end of period	$	~~316~~608,~~124~~223		$	~~397~~563,~~442~~795
Supplemental cash flow information
Interest paid	$	1,588		$	-
Taxes paid	$	800		$	800
Supplemental schedule of noncash financing activities:
Conversion of common stock subscription liability to common stock	$	1,191,442		$	-

The accompanying notes are an integral part of these condensed interim financial statements.

Kyto Technology and Life Science, Inc.

~~Condensed~~ Schedule of Investments as of ~~September~~December 3031, 2021

(Unaudited)

	Portfolio Company		Industry	Investment	Cost		Fair value		% of net assets (a)
Convertible loan investments
	Abfero Pharmaceuticals Inc		Life science	Convertible Note, 6% due, December 2022	$	~~100~~11,~~000~~447	$	~~102~~15,~~630~~589		0.91	%
( i )	Achelios Therapeutics Inc.		Life science	Convertible Note, 8% due, December 2021		100,000		~~125~~127,~~184~~200		1.20	%
( i )	Achelios Therapeutics Inc.		Life science	Convertible Note, 8% due December 2021		25,000		30,~~036~~540		0.32	%
( i )	Achelios Therapeutics Inc.		Life science	Convertible Note, 8% due December 2021		50,000		5657,~~586~~595		0.54	%
( i )	Achelios Therapeutics Inc.		Life science	Convertible Note Sidecar, 25% discount. No interest		50,000		50,000		0.54	%
	AOA DX Inc		Life science	Convertible Note, 4%, due May 2024		100,000		~~101~~102,~~567~~575		0.98	%
	Avisi Technologies Inc		Life science	Convertible Note, 8% due July 2022		50,000		5455,~~679~~688		0.54	%
	Basepaws Inc		Life science	Convertible Note, 1% due April 2020		50,000		~~201~~244,~~663~~980		1.9	%
( i )	Beam Semiconductor Inc	*	Technology	Convertible Note, 8% due April 2022		150,000		177,058		1.6	%
	Basepaws Inc		Life science	Convertible Note, 6% due October 2023		150,000		150,000		1.2	%
( i )	Beam Semiconductor Inc	*	Technology	Convertible Note, 8% due ~~March~~April ~~2021~~2022		50150,000		56180,~~290~~082		01.54	%
( i )	Beam Semiconductor Inc	*	Technology	Convertible Note, 8% due March ~~2022~~2021		~~100~~50,000		~~103~~57,~~704~~299		1.0.4	%
	CoLabs Inc		Life science	Convertible Note, 6% due February 2023		50,000		50,304		0.5	%
( i )	Beam Semiconductor Inc	*	Technology	Convertible Note, 8% due March 2022		100,000		105,721		0.8	%
	Corinnova Inc		Life science	Convertible Note, 6% due December 2024		100,000		105,211		1.0	%
	CoLabs Inc		Life science	Convertible Note, 6% due February 2023		50,000		51,060		0.4	%
	Corinnova Inc		Life science	Convertible Note, 6% due December 2024		50100,000		50106,~~164~~723		0.58	%
*	Cyberdontics Inc	*	Life science	Convertible Note, 8% due September 2022		30,000		34,971		0.3	%
	Corinnova Inc		Life science	Convertible Note, 6% due December 2024		50,000		50,921		0.4	%
*	Cyberdontics Inc	*	Life science	Convertible Note, 8% due ~~February~~September ~~2023~~2022		3530,000		3971,~~457~~733		0.46	%
*	Cyberdontics Inc	*	Life science	Convertible Note, 08% no due ~~date~~February 2023		35,000		3783,~~700~~689		0.36	%
	Deep Blue Medical Advances Inc		Life science	Convertible Note, 6% due June 2022		50,000		52,351		0.5	%
*	Cyberdontics Inc	*	Life science	Convertible Note, 0% no due date		35,000		35,000		0.3	%
	Every Key Inc		Technology	Convertible Note, 5% due December 2023		100,000		109,027		1.0	%
	Deep Blue Medical Advances Inc		Life science	Convertible Note, 6% due June 2022		50,000		53,107		0.4	%
	Identical Inc		Life science	Convertible Note, 2% due May 2022		100,000		101,775		0.9	%
	Deep Blue Medical Advances Inc		Life science	Convertible Note, 6% due June 2022		50,000		50,181		0.4	%
*	INBay Technology Inc		Technology	Convertible Note, 12% due October 2020		50,000		67,589		0.6	%
	Every Key Inc		Technology	Convertible Note, 5% due December 2023		100,000		110,288		0.9	%
*	INBay Technology Inc		Technology	Convertible Note, 12% due July 2021		30,000		38,028		0.4	%
	Femto DX Inc.		Life science	Convertible Note, 12% due December 2022		100,000		100,526		0.8	%
*	INBay Technology Inc		Technology	Convertible Note, 12% due February 2022		50,000		59,649		0.6	%
	Identical Inc		Life science	Convertible Note, 2% due May 2022		100,000		102,279		0.8	%
*	INBay Technology Inc		Technology	Convertible Note, 12% due December 2022		40,000		43,958		0.4	%
( i )*	INBay Technology Inc	*	Technology	Convertible Note, 12% due October 2020		50,000		69,101		0.5	%
*	INBay Technology Inc		Technology	Convertible Note, 12% due December 2023		50,000		52,926		0.5	%
( i )*	INBay Technology Inc	*	Technology	Convertible Note, 12% due July 2021		30,000		38,936		0.3	%
*	Iris R&D Group Inc		Technology	Convertible Note, 8% May 2023		50,000		51,447		0.5	%
( i )*	INBay Technology Inc	*	Technology	Convertible Note, 12% due February 2022		50,000		61,162		0.5	%
	Kiana Analytics Inc		Technology	Convertible Note, 3% December 2022		100,000		102,326		0.9	%
( i )*	INBay Technology Inc	*	Technology	Convertible Note, 12% due December 2022		40,000		45,168		0.3	%
	Kitotech Medical Inc		Life science	Convertible Note, 6% due December 2020		100,000		246,141		2.3	%
( i )*	INBay Technology Inc	*	Technology	Convertible Note, 12% due December 2023		50,000		54,437		0.4	%
	Kitotech Medical Inc		Life science	Convertible Note, 6% due November 2022		75,000		85,896		0.8	%
( i )*	INBay Technology Inc	*	Technology	Convertible Note, 12% due December 2023		25,000		25,001		0.2	%
	Lifewave Biomedical Inc		Life science	Convertible Note, 6% due December 2020		30,000		33,733		0.3	%
*	Iris R&D Group Inc	*	Technology	Convertible Note, 8% May 2023		50,000		52,455		0.4	%
	Lifewave Biomedical Inc		Life science	Convertible Note, 6% due December 2020		70,000		76,916		0.7	%
	Kiana Analytics Inc		Technology	Convertible Note, 3% December 2022		100,000		103,082		0.8	%
	Lifewave Biomedical Inc		Life science	Convertible Note, 6% due December 2021		50,000		51,159		0.5	%
	Kitotech Medical Inc		Life science	Convertible Note, 6% due December 2020		100,000		247,654		1.9	%
	Lowell Therapeutics Inc		Life science	Convertible Note, 8% no due date		27,491		27,955		0.3	%
	Kitotech Medical Inc		Life science	Convertible Note, 6% due November 2022		75,000		87,030		0.7	%
	mmTron Inc		Technology	Convertible Note, 4% due April 2023		100,000		101,030		0.9	%
	Lifewave Biomedical Inc		Life science	Convertible Note, 6% due December 2020		30,000		34,187		0.3	%
	Navaux Inc		Life science	Convertible Note, 6% due December 2023		60,000		62,841		0.6	%
	Lifewave Biomedical Inc		Life science	Convertible Note, 6% due December 2020		70,000		77,974		0.6	%
	Neuro42 Inc.		Life science	Convertible Note, 8% due December 2023		50,000		52,564		0.5	%
	Lifewave Biomedical Inc		Life science	Convertible Note, 6% due December 2021		50,000		51,915		0.4	%
	Octagon Therapeutics Inc		Life science	Convertible Note, 5% due June 2021		50,000		52,349		0.5	%
	Lowell Therapeutics Inc		Life science	Convertible Note, 8% no due date		27,491		28,509		0.2	%
	Octagon Therapeutics Inc		Life science	Convertible Note, 5% due June 2021		50,000		52,219		0.5	%
	mmTron Inc		Technology	Convertible Note, 4% due April 2023		100,000		102,038		0.8	%
	Perikinetics Inc		Life science	Convertible Note, 6% due May 2022		100,000		105,326		1.0	%
	Navaux Inc		Life science	Convertible Note, 6% due December 2023		60,000		63,748		0.5	%
	Preview Medical Inc		Life science	Convertible Note, 7% due January 2023		100,000		104,948		1.0	%
	Neuro42 Inc.		Life science	Convertible Note, 8% due December 2023		50,000		53,573		0.4	%
	Promaxo Inc		Life science	Convertible note, 5% due July 2022		100,000		183,876		1.7	%
	Neuro42 Inc.		Life science	Convertible Note, 5% due November 2023		150,000		150,801		1.2	%
	Rheos Inc		Life science	Convertible note, 8% due August 2026		100,000		101,074		0.9	%
	Octagon Therapeutics Inc		Life science	Convertible Note, 5% due June 2021		50,000		52,979		0.4	%
	Saccharo Inc		Life science	Convertible note, 7% due September 2022		50,000		50,815		0.5	%
	Octagon Therapeutics Inc		Life science	Convertible Note, 5% due June 2021		50,000		52,849		0.4	%
	SageMedic Corp		Life science	Convertible Note, 8% April 2021 plus warrants		50,000		59,885		0.6	%
	Perikinetics Inc		Life science	Convertible Note, 6% due May 2022		100,000		106,838		0.8	%
	SageMedic Corp		Life science	Convertible Note, 8% December 2022 plus warrants		75,000		79,948		0.7	%
	Preview Medical Inc		Life science	Convertible Note, 7% due May 2022		50,000		50,278		0.4	%
	Preview Medical Inc		Life science	Convertible Note, 7% due January 2023		100,000		106,712		0.8	%
	Promaxo Inc		Life science	Convertible note, 5% due July 2022		100,000		185,136		1.4	%
	Rheos Inc		Life science	Convertible note, 8% due August 2026		100,000		103,090		0.8	%
	Saccharo Inc		Life science	Convertible note, 7% due September 2022		50,000		51,697		0.4	%
	SageMedic Corp		Life science	Convertible Note, 8% April 2021 plus warrants		50,000		60,893		0.5	%
	SageMedic Corp		Life science	Convertible Note, 8% December 2022 plus warrants		75,000		81,460		0.6	%
	Seal Rock Therapeutics Inc		Life science	Convertible Note , 6% due June 2023		100,000		100,000		0.8	%
	Sensing Electromagnetic Plus Corp		Technology	Convertible Note, Fully reserved		50,000		1		0.0	%
	Sensing Electromagnetic Plus Corp		Technology	Convertible Note, Fully reserved		11,048		1		0.0	%
	Single Pass Inc		Life science	Convertible Note, 6% April 2024		50,000		50,970		0.5	%
	Shyft (FKA Crater Group Inc)		Technology	Convertible Note, 6% due April 2023		100,000		100,000		0.8	%
*	Valfix Medical Inc	*	Life science	Convertible Note, 8% December 2021		50,000		54,515		0.5	%
	Single Pass Inc		Life science	Convertible Note, 6% April 2024		50,000		51,726		0.4	%
*	~~Xpan~~Valfix Medical Inc	*	Life science	Convertible Note, 8% ~~due~~December ~~March 2022~~2021		50,000		56123,~~301~~160		01.50	%
*	Xpan Inc	*	Life science	Convertible Note, 8% due ~~June~~March 2022		2550,000		2757,~~548~~310		0.34	%
*	Xpan Inc	*	Life science	Convertible Note, 8% due June 2022		25,000		2728,~~542~~052		0.32	%
Total convertible loan investments					$	3,243,539	$	3,801,833		35.1	%
*	Xpan Inc	*	Life science	Convertible Note, 8% due June 2022		25,000		28,047		0.2	%
	United States				$	2,423,539	$	2,873,150		26.6	%
Total Convertible loan investments					$	3,879,986	$	4,679,776		36.2	%
	Canada					470,000		537,116		5.0	%
	United States				$	3,034,986	$	3,563,423		27.6	%
	Rest of World					350,000		391,567		3.6	%
	Canada					495,000		650,091		5.0	%
Total convertible loan investments					$	3,243,539	$	3,801,833		35.1	%
	Rest of World					350,000		466,262		3.6	%
Total Convertible loan investments					$	3,879,986	$	4,679,776		36.2	%

Continued onto next page

The accompanying notes are an integral part of these condensed interim financial statements.

Continued from previous page

Kyto Technology and Life Science, Inc.

~~Condensed~~ Schedule of Investments as of ~~September~~December 3031, 2021

(Unaudited)

	Portfolio Company		Industry	Investment	Cost		Fair value		~~% of net assets (a)~~	% of net assets (a)
Preferred stock investments
	Altis Biosystems		Life science	22,028 shares of Series Seed Preferred	$	50,000	$	50,000	~~0.5~~	%0.4	%
	Astrocyte Pharmaceuticals Inc		Life science	260,756 shares of Series A Preferred		100,000		100,000	~~0.9~~	%0.8	%
	Cnote Group, Inc		Fintech	84,655 shares of series Seed-2 Preferred (converted SAFE)		51,500		59,783	~~0.6~~	%0.5	%
	Cnote Group, Inc		Fintech	93,807 shares of Series Seed-3 Preferred (converted note)		50,000		66,247	~~0.6~~	%0.5	%
	Colabs Inc		Life science	147,058 shares of Series A-1 Preferred		50,000		50,000	~~0.5~~	%0.4	%
*	Connectus Services Ltd	*	Technology	31,348 shares of Series Seed Preferred		100,000		100,000	~~0.9~~	%0.8	%
	Deep Blue Medical Advances Inc		Life science	10,474 shares of Series A Preferred		49,996		49,997	~~0.5~~	%0.4	%
	Eumentis Thereapeutics Inc		Life science	85,009 shares of Series A Preferred		100,000		100,000	0.9	%
	Distasense Inc (FKA Life Detection Technologies Inc		Life science	117,813 shares of Series C Preferred		50,000		50,000		0.4	%
	FemtoDX Inc		Life science	42,436 shares of Series A Preferred		100,000		290,046	2.7	%
	Eumentis Thereapeutics Inc		Life science	85,009 shares of Series A Preferred		100,000		100,000		0.8	%
	Healionics Corporation		Life science	35,075 of Series A-1 Preferred		100,000		100,000	0.9	%
	FemtoDX Inc		Life science	42,436 shares of Series A Preferred		100,000		290,046		2.2	%
	i-Lumen Scientific Inc.		Life science	50,000 shares of Series A Preferred plus warrants		50,000		50,000	0.5	%
	Healionics Corporation		Life science	35,075 of Series A-1 Preferred		100,000		100,000		0.8	%
	i-Lumen Scientific Inc.		Life science	50,000 shares of Series A Preferred plus warrants		50,000		50,000	~~0.5~~	%0.4	%
	Inhalon Biopharma Inc		Life science	18,843 shares of Series Seed Preferred		99,997		99,997	0.9	%
	i-Lumen Scientific Inc.		Life science	50,000 shares of Series A Preferred plus warrants		50,000		50,000		0.4	%
	Light Line Medical Inc		Life science	62,849 shares of Series Seed Preferred (converted note)		30,000		38,031	0.4	%
	Inhalon Biopharma Inc		Life science	18,843 shares of Series Seed Preferred		99,997		256,198		2.0	%
	Light Line Medical Inc		Life science	141,871 shares of Series Seed Preferred (converted note)		70,000		106,049	1.0	%
	Kitotech Medical Inc		Life science	49,027shares of Series B Preferred		74,998		74,998		0.6	%
	Light Line Medical Inc		Life science	4062,~~323~~849 shares of Series Seed ~~preferred~~Preferred (converted note)		2530,000		2538,~~000~~031	~~0.2~~	%0.3	%
	Light Line Medical Inc		Life science	72141,~~464~~871 shares of Series ASeed Preferred ~~plus~~(converted ~~warrants~~note)		5070,000		50106,~~000~~049	~~0.5~~	%0.8	%
	Lowell Therapeutics Inc		Life science	20,000 shares of Series A Preferred		50,000		50,000	0.5	%
	Light Line Medical Inc		Life science	40,323 shares of Series Seed preferred		25,000		25,000		0.2	%
	Lowell Therapeutics Inc		Life science	20,000 shares of Series A Preferred		50,000		50,000	0.5	%
	Light Line Medical Inc		Life science	72,464 shares of Series A Preferred plus warrants		50,000		50,000		0.4	%
	Lowell Therapeutics Inc		Life science	2520,000 shares of Series BA Preferred		~~100~~50,000		~~100~~50,000	~~0.9~~	%0.4	%
	Makani Science Inc		Life science	172,413 shares of Series Seed Preferred		50,000		50,000	0.5	%
	Lowell Therapeutics Inc		Life science	20,000 shares of Series A Preferred		50,000		50,000		0.4	%
	Micronic Technologies Inc		Technology	51,929 shares of Series Seed-1 Preferred plus warrants		100,000		100,000	0.9	%
	Lowell Therapeutics Inc		Life science	25,000 shares of Series B Preferred		100,000		100,001		0.8	%
	Neuroflow Inc		Life science	98,684 shares of Series Seed -2 Preferred		150,000		224,998	2.1	%
	Makani Science Inc		Life science	172,413 shares of Series Seed Preferred		50,000		50,000		0.4	%
	Neuroflow Inc		Life science	20,429 shares of Series B Preferred		100,000		212,497	2.0	%
	Micronic Technologies Inc		Technology	51,929 shares of Series Seed-1 Preferred plus warrants		100,000		100,000		0.8	%
	New View Surgical, Inc.		Life science	53,825 shares of Series A-1 Preferred		75,000		75,000	0.7	%
	Nanochon Inc		Life science	200,401 shares of Series Seed Preferred		50,000		50,000		0.4	%
	New View Surgical, Inc.		Life science	58,220 shares of Series A-1 Preferred		100,000		100,000	0.9	%
	Neuroflow Inc		Life science	98,684 shares of Series Seed -2 Preferred		150,000		540,053		4.2	%
*	Orion Biotechnology Inc	*	Life science	5,824 shares of Series A Preferred		100,000		100,000	0.9	%
	Neuroflow Inc		Life science	20,429 shares of Series B Preferred		100,000		136,829		1.1	%
	Otomagnetics Inc		Life science	16,538 shares of Series A-1 Preferred		100,000		100,000	0.9	%
	New View Surgical, Inc.		Life science	53,825 shares of Series A-1 Preferred		75,000		75,000		0.6	%
	Partheous Inc		Life science	50,000 shares of Series A Preferred		50,000		50,000	0.5	%
	New View Surgical, Inc.		Life science	58,220 shares of Series A-1 Preferred		100,000		100,000		0.8	%
	Promaxo		Life science	104,248 shares of Series B-1 Preferred, (converted note)		250,000		1,034,684	9.6	%
*	Orion Biotechnology Inc	*	Life science	5,824 shares of Series A Preferred		100,000		100,000		0.8	%
	Seal Rock Therapeutics, Inc.		Life science	68,075 shares of Series Seed Preferred, (converted note)		78,000		199,112	1.8	%
	Otomagnetics Inc		Life science	16,538 shares of Series A-1 Preferred		100,000		100,000		0.8	%
	Shyft (FKA Crater Group Inc)		Technology	42,657 shares of Series A-1 Preferred (converted note)		51,500		107,059	1.0	%
	Partheous Inc		Life science	50,000 shares of Series A Preferred		50,000		50,000		0.4	%
	Shyft (FKA Crater Group Inc)		Technology	28,147 shares of Series A Preferred (converted note)		50,000		91,771	0.8	%
	Promaxo		Life science	104,248 shares of Series B-1 Preferred, (converted note)		250,000		1,034,684		8.0	%
	Shyft (FKA Crater Group Inc)		Technology	21,774 shares of Series A-1 Preferred (plus warrants)		50,000		70,990	0.7	%
	SageMedic Corp		Life science	12,717 shares of Series A Preferred		10,389		10,389		0.1	%
( i )	Trellis Bioscience LLC		Life science	50,000 shares of Series B Preferred plus warrants		50,000		50,000	0.5	%
	Seal Rock Therapeutics, Inc.		Life science	68,075 shares of Series Seed Preferred, (converted note)		78,000		199,375		1.5	%
( i )	Trellis Bioscience LLC		Life science	50,000 shares of Series B Preferred plus warrants		50,000		50,000	0.5	%
	Shyft (FKA Crater Group Inc)		Technology	42,657 shares of Series A-1 Preferred (converted note)		51,500		107,059		0.8	%
( i )	Trellis Bioscience LLC		Life science	100,000 shares of Series B Preferred plus warrants		100,000		100,000	0.9	%
	Shyft (FKA Crater Group Inc)		Technology	28,147 shares of Series A Preferred (converted note)		50,000		91,771		0.7	%
*	Valfix Medical Inc	*	Life science	27,217 shares of Series Seed Preferred		50,000		50,000	0.5	%
	Shyft (FKA Crater Group Inc)		Technology	21,774 shares of Series A-1 Preferred plus warrants		50,000		70,990		0.5	%
	Vesteck Inc		Life science	34,783 shares of Series A preferred		100,000		100,000	0.9	%
( i )	Trellis Bioscience LLC		Life science	50,000 shares of Series B Preferred plus warrants		50,000		50,000		0.4	%
	Visgenx Inc		Life science	7,833 shares of Series Seed-1 Preferred (converted note)		30,000		46,352	0.4	%
( i )	Trellis Bioscience LLC		Life science	50,000 shares of Series B Preferred plus warrants		50,000		50,000		0.4	%
	Visgenx Inc		Life science	4,132 shares of Series Seed Preferred (converted note)		25,000		25,648	0.2	%
( i )	Trellis Bioscience LLC		Life science	100,000 shares of Series B Preferred plus warrants		100,000		100,000		0.8	%
	Visgenx Inc		Life science	2,480 shares of Series Seed Preferred (converted note)		15,003		15,392	0.1	%
	Trio Labs Inc		Life science	29,809 shares of Series Seed Preferred		50,000		50,000		0.4	%
Total Preferred stock investments					$	3,050,997	$	4,538,653	42.0	%
*	Valfix Medical Inc	*	Life science	27,217 shares of Series Seed Preferred		50,000		105,607		0.8	%
	United States				$	2,800,997	$	4,288,653	39.6	%
	Vesteck Inc		Life science	34,783 shares of Series A preferred		100,000		100,000		0.8	%
	Canada					200,000		200,000	1.8	%
	Visgenx Inc		Life science	7,833 shares of Series Seed-1 Preferred (converted note)		30,000		46,352		0.4	%
	Rest of World					50,000		50,000	0.5	%
	Visgenx Inc		Life science	4,132 shares of Series Seed Preferred (converted note)		25,000		25,648		0.2	%
Total Preferred stock investments					$	3,050,997	$	4,538,653	42.0	%
	Visgenx Inc		Life science	2,480 shares of Series Seed Preferred (converted note)		15,003		15,391		0.1	%
Common stock investments
Total Preferred stock investments					$	3,286,383	$	5,225,498		40.5	%
*	BendaRX Corp	*	Life science	12,500 Common shares	$	100,000	$	150,000	1.4	%
	United States				$	3,036,383	$	4,919,891		38.2	%
*	BendaRX Corp	*	Life science	12,500 Common shares		100,000		150,000	1.4	%
	Canada					200,000		200,000		1.5	%
	Boardwalk Tech		Technology	75,000 Common shares		65,600		65,600	0.6	%
	Rest of World					50,000		105,607		0.8	%
	Boardwalk Tech		Technology	150,000 Common shares		73,500		91,995	0.9	%
Total Preferred stock investments					$	3,286,383	$	5,225,498		40.5	%
	Kuantsol Inc		Technology	133.333 Common shares		25,000		25,000	0.2	%
Common stock investments
	Sanaby Health Sponsor LLC		Life science	50,000 Common shares		100,000		473,732	4.4	%
*	BendaRX Corp	*	Life science	12,500 Common shares	$	100,000	$	150,000		1.2	%
Total Common stock investments					$	464,100	$	956,327	4.2	%
*	BendaRX Corp	*	Life science	12,500 Common shares		100,000		150,000		1.2	%
	United States				$	264,100	$	656,327	6.1	%
	Kuantsol Inc		Technology	133.333 Common shares		25,000		25,000		0.2	%
	Canada					200,000		300,000	2.8	%
Total Common stock investments					$	225,000	$	325,000		2.5	%
	Rest of World					-		-
	United States				$	25,000	$	25,000		0.2	%
Total Common stock investments					$	464,100	$	956,327	8.8	%
	Canada					200,000		300,000		2.3	%
		*
	Rest of World					-		-		0.0	%
SAFE investments
Total Common stock investments					$	225,000	$	325,000		2.5	%
*	Infinidome Ltd	*	Technology	SAFE	$	50,000	$	50,000	0.5	%
*	Infinidome Ltd	*	Technology	SAFE		50,000		50,000	0.5	%
*	Madorra Inc	*	Life science	SAFE		100,000		100,000	0.9	%
	Mitre Medical Corp		Life science	SAFE		75,000		75,000	0.7	%
	Mitre Medical Corp		Life science	SAFE		50,000		50,000	0.5	%
*	Orion Biotechnology Inc.	*	Life science	SAFE		100,000		100,000	0.9	%
*	Polymertal Ltd	*	Technology	SAFE		150,000		150,000	1.4	%
Total SAFE investments					$	575,000	$	575,000	5.3	%
	United States					125,000		125,000	1.2	%
	Canada					100,000		100,000	0.9	%
	Rest of World					350,000		350,000	3.2	%
Total SAFE investments					$	575,000	$	575,000	5.3	%

Continued onto next page

The accompanying notes are an integral part of these condensed interim financial statements.

Continued from previous page

Kyto Technology and Life Science, Inc.

~~Condensed~~ Schedule of Investments as of ~~September~~December 3031, 2021

(Unaudited)

	Portfolio Company		~~Industry~~	Industry	~~Investment~~	Investment	~~Cost~~	Cost		~~Fair value~~	Fair value		~~% of net assets (a)~~		% of net assets (a)
Other investments
Public common stock investments
	Enduralock LLC		Technology		34.1 Series A-1 Ownership Units		$	30,000		$	30,000			0.3	%
	Boardwalk Tech			Technology		75,000 Common shares		$	65,600		$	70,000			0.5	%
	Enduralock LLC		Technology		39.7 Series A-1 Ownership Units			35,000			35,000			0.3	%
	Boardwalk Tech			Technology		150,000 Common shares			73,500			86,505			0.7	%
( i )	Exodos Life Sciences LP		Life science		Class A-1 Preferred Ownership Units			206,000			206,000			1.9	%
	Sanaby Health Acquisition Corp 1			Life science		50,000 Common shares			100,000			473,732			3.7	%
	Green Sun Medical LLC		Life science		2,193 Class A-1 Ownership units			50,000			50,000			0.5	%
Total Public common stock investments								$	239,100		$	630,237			4.9	%
	Green Sun Medical LLC		Life science		1,096 Class A-1 Ownership units			25,000			25,000			0.2	%
	United States							$	239,100		$	630,237			4.9	%
	Green Sun Medical LLC		Life science		1,096 Class A-1 Ownership units			25,000			25,000			0.2	%
	Canada								-			-			0.0	%
	Green Sun Medical LLC		Life science		4,386 Class A-1 Ownership units			100,000			100,000			0.9	%
	Rest of World								-			-			0.0	%
	Riso Capital Fund I, LP		Technology		Ownership units			50,000			50,000			0.5	%
Total Public common stock investments								$	239,100		$	630,237			4.9	%
	Riso Capital Fund I, LP		Technology		Ownership units			50,000			50,000			0.5	%
SAFE investments
Total other investments							$	571,000		$	571,000			5.3	%
	AOA DX inc			Life science		SAFE		$	50,000		$	50,000			0.4	%
	United States						$	571,000		$	571,000			5.3	%
*	Infinidome Ltd	*		Technology		SAFE			50,000			50,000			0.4	%
	Canada							-			-
*	Infinidome Ltd	*		Technology		SAFE			50,000			50,000			0.4	%
	Rest of World							-			-
*	Infinidome Ltd	*		Technology		SAFE			100,000			100,000			0.8	%
Total other investments							$	571,000		$	571,000			5.3	%
*	Madorra Inc	*		Life science		SAFE			100,000			100,000			0.8	%
Total investments							$	7,904,636		$	10,442,813			96.5	%
	Mitre Medical Corp			Life science		SAFE			75,000			75,000			0.6	%
	United States						$	6,184,636		$	8,514,130			78.7	%
	Mitre Medical Corp			Life science		SAFE			50,000			50,000			0.4	%
	Canada							970,000			1,137,116			10.5	%
*	Orion Biotechnology Inc.	*		Life science		SAFE			100,000			100,000			0.8	%
	Rest of World							750,000			791,567			7.3	%
*	Polymertal Ltd	*		Technology		SAFE			150,000			150,000			1.2	%
Total investments							$	7,904,636		$	10,442,813			96.5	%
Total SAFE investments								$	725,000		$	725,000			5.6	%
	(a) based on total net assets of	$	10,817,894
	United States								175,000			175,000			1.3	%
	Canada								100,000			100,000			0.8	%
	Rest of World								450,000			450,000			3.5	%
Total SAFE investments								$	725,000		$	725,000			5.6	%
Other investments
	Enduralock LLC			Technology		34.1 Series A-1 Ownership Units		$	30,000		$	30,000			0.2	%
	Enduralock LLC			Technology		39.7 Series A-1 Ownership Units			35,000			35,000			0.3	%
	Exodos Life Sciences LP			Life science		Class A-1 Preferred Ownership Units			206,000			206,000			1.6	%
	Green Sun Medical LLC			Life science		2,193 Class A-1 Ownership units			50,000			50,000			0.4	%
	Green Sun Medical LLC			Life science		1,096 Class A-1 Ownership units			25,000			25,000			0.2	%
	Green Sun Medical LLC			Life science		1,096 Class A-1 Ownership units			25,000			25,000			0.2	%
	Green Sun Medical LLC			Life science		4,386 Class A-1 Ownership units			100,000			100,000			0.8	%
	Riso Capital Fund I, LP			Technology		Ownership units			50,000			50,000			0.4	%
	Riso Capital Fund I, LP			Technology		Ownership units			50,000			50,000			0.4	%
Total Other investments								$	571,000		$	571,000			4.4	%
	United States							$	521,000		$	571,000			4.4	%
	Canada								-			-			0.0	%
	Rest of World								50,000			-			0.0	%
Total Other investments								$	571,000		$	571,000			4.4	%
Total investments								$	8,926,469		$	12,156,511			94.2	%
	United States							$	7,031,469		$	9,884,551			76.6	%
	Canada								995,000			1,250,091			9.7	%
	Rest of World								900,000			1,021,869			7.9	%
Total investments								$	8,926,469		$	12,156,511			94.2	%
	(a) based on total net assets of $ 12,911,623
( i )	Kyto management sit on the Board of these companies.
*	These companies are headquartered outside of the US.

( i ) Kyto representatives sit on the Board of Directors of these companies.

* These companies are headquartered outside of the US.

The accompanying notes are an integral part of these condensed interim financial statements.

Kyto Technology and Life Science, Inc.

~~Condensed~~ Schedule of Investments as of March 31, 2021

(Unaudited)

	Portfolio Company	~~Portfolio Company~~	Industry		Investment	~~Industry~~Cost		~~Investment~~		Fair value		~~Cost~~		% of net assets (a)		~~Fair value~~		~~% of net assets (a)~~
Convertible loan investments
(i)		Achelios Therapeutics Inc.				Life science			Convertible Note, 8% due, December 2021			$	100,000			$	121,173	1.7	%
( i )	Achelios Therapeutics Inc.		Life science		Convertible Note, 8% due, December 2021	$	100,000			$	121,173				1.7	%
(i)		Achelios Therapeutics Inc.				Life science			Convertible Note, 8% due December 2021				25,000				29,033	0.4	%
( i )	Achelios Therapeutics Inc.		Life science		Convertible Note, 8% due December 2021		25,000				29,033				0.4	%
(i)		Achelios Therapeutics Inc.				Life science			Convertible Note, 8% due December 2021				50,000				54,581	0.8	%
( i )	Achelios Therapeutics Inc.		Life science		Convertible Note, 8% due December 2021		50,000				54,581				0.8	%
	Avisi Technologies Inc	~~Avisi Technologies Inc~~	Life science		Convertible Note, 8% due July 2022	~~Life science~~	50,000		~~Convertible Note, 8% due July 2022~~		52,674		~~50,000~~		0.8	%	~~52,674~~	~~0.8~~	%
	Basepaws Inc	~~Basepaws Inc~~	Life science		Convertible Note, 1% due April 2020	~~Life science~~	50,000		~~Convertible Note, 1% due April 2020~~		162,319		~~50,000~~		2.3	%	~~162,319~~	~~2.3~~	%
(i)		Beam Semiconductor Inc		*		Technology			Convertible Note, 8% due April 2022				150,000				171,041	2.4	%
( i )	Beam Semiconductor Inc	*	Technology		Convertible Note, 8% due April 2022		150,000				171,041				2.4	%
(i)		Beam Semiconductor Inc		*		Technology			Convertible Note, 8% due March 2021				50,000				54,285	0.8	%
( i )	Beam Semiconductor Inc	*	Technology		Convertible Note, 8% due March 2021		50,000				54,285				0.8	%
	Corinnova Inc	~~Corinnova Inc~~	Life science		Convertible Note, 6% due December 2024	~~Life science~~	100,000		~~Convertible Note, 6% due December 2024~~		102,318		~~100,000~~		1.5	%	~~102,318~~	~~1.5~~	%
	Cyberdontics Inc	~~Cyberdontics Inc~~*	Life science	*	Convertible Note, 8% due September 2022	~~Life science~~	30,000		~~Convertible Note, 8% due September 2022~~		33,768		~~30,000~~		0.5	%	~~33,768~~	~~0.5~~	%
	Cyberdontics Inc	~~Cyberdontics Inc~~*	Life science	*	Convertible Note, 8% due February 2023	~~Life science~~	35,000		~~Convertible Note, 8% due February 2023~~		38,053		~~35,000~~		0.5	%	~~38,053~~	~~0.5~~	%
	Cyberdontics Inc	~~Cyberdontics Inc~~*	Life science	*	Convertible Note, 0% no due date	~~Life science~~	35,000		~~Convertible Note, 0% no due date~~		36,296		~~35,000~~		0.5	%	~~36,296~~	~~0.5~~	%
	Deep Blue Medical Advances Inc	~~Deep Blue Medical Advances Inc~~	Life science		Convertible Note, 6% due June 2022	~~Life science~~	50,000		~~Convertible Note, 6% due June 2022~~		50,863		~~50,000~~		0.7	%	~~50,863~~	~~0.7~~	%
	Every Key Inc	~~Every Key Inc~~	Technology		Convertible Note, 5% due December 2023	~~Technology~~	100,000		~~Convertible Note, 5% due December 2023~~		106,521		~~100,000~~		1.5	%	~~106,521~~	~~1.5~~	%
	Identical Inc	~~Identical Inc~~	Life science		Convertible Note, 2% due May 2022	~~Life science~~	100,000		~~Convertible Note, 2% due May 2022~~		100,844		~~100,000~~		1.4	%	~~100,844~~	~~1.4~~	%
	INBay Technology Inc	~~INBay Technology Inc~~*	Technology	*	Convertible Note, 12% due October 2020	~~Technology~~	50,000		~~Convertible Note, 12% due October 2020~~		59,721		~~50,000~~		0.9	%	~~59,721~~	~~0.9~~	%
	INBay Technology Inc	~~INBay Technology Inc~~*	Technology	*	Convertible Note, 12% due July 2021	~~Technology~~	30,000		~~Convertible Note, 12% due July 2021~~		34,149		~~30,000~~		0.5	%	~~34,149~~	~~0.5~~	%
	INBay Technology Inc	~~INBay Technology Inc~~*	Technology	*	Convertible Note, 12% due February 2022	~~Technology~~	50,000		~~Convertible Note, 12% due February 2022~~		56,640		~~50,000~~		0.8	%	~~56,641~~	~~0.8~~	%
	INBay Technology Inc	~~INBay Technology Inc~~*	Technology	*	Convertible Note, 12% due December 2022	~~Technology~~	40,000		~~Convertible Note, 12% due December 2022~~		41,552		~~40,000~~		0.6	%	~~41,552~~	~~0.6~~	%
	Kiana Analytics Inc	~~Kiana Analytics Inc~~	Technology		Convertible Note, 3% December 2022	~~Technology~~	100,000		~~Convertible Note, 3% December 2022~~		100,847		~~100,000~~		1.4	%	~~100,847~~	~~1.4~~	%
	Kitotech Medical Inc	~~Kitotech Medical Inc~~	Life science		Convertible Note, 6% due December 2020	~~Life science~~	100,000		~~Convertible Note, 6% due December 2020~~		243,133		~~100,000~~		3.5	%	~~243,133~~	~~3.5~~	%
	Kitotech Medical Inc	~~Kitotech Medical Inc~~	Life science		Convertible Note, 6% due November 2022	~~Life science~~	75,000		~~Convertible Note, 6% due November 2022~~		83,738		~~75,000~~		1.2	%	~~83,738~~	~~1.2~~	%
	Lifewave Biomedical Inc	~~Lifewave Biomedical Inc~~	Life science		Convertible Note, 6% due December 2020	~~Life science~~	30,000		~~Convertible Note, 6% due December 2020~~		32,830		~~30,000~~		0.5	%	~~32,831~~	~~0.5~~	%
	Lifewave Biomedical Inc	~~Lifewave Biomedical Inc~~	Life science		Convertible Note, 6% due December 2020	~~Life science~~	70,000		~~Convertible Note, 6% due December 2020~~		74,810		~~70,000~~		1.1	%	~~74,810~~	~~1.1~~	%
	Navaux Inc	~~Navaux Inc~~	Life science		Convertible Note, 6% due December 2023	~~Life science~~	60,000		~~Convertible Note, 6% due December 2023~~		61,036		~~60,000~~		0.9	%	~~61,036~~	~~0.9~~	%
	Neuro42 Inc.	~~Neuro42 Inc.~~	Life science		Convertible Note, 8% due December 2023	~~Life science~~	50,000		~~Convertible Note, 8% due December 2023~~		50,559		~~50,000~~		0.7	%	~~50,559~~	~~0.7~~	%
	Octagon Therapeutics Inc	~~Octagon Therapeutics Inc~~	Life science		Convertible Note, 5% due June 2021	~~Life science~~	50,000		~~Convertible Note, 5% due June 2021~~		51,110		~~50,000~~		0.7	%	~~51,110~~	~~0.7~~	%
	Octagon Therapeutics Inc	~~Octagon Therapeutics Inc~~	Life science		Convertible Note, 5% due June 2021	~~Life science~~	50,000		~~Convertible Note, 5% due June 2021~~		50,966		~~50,000~~		0.7	%	~~50,966~~	~~0.7~~	%
	Perikinetics Inc	~~Perikinetics Inc~~	Life science		Convertible Note, 6% due May 2022	~~Life science~~	100,000		~~Convertible Note, 6% due May 2022~~		102,318		~~100,000~~		1.5	%	~~102,318~~	~~1.5~~	%
	Preview Medical Inc	~~Preview Medical Inc~~	Life science		Convertible Note, 7% due January 2023	~~Life science~~	100,000		~~Convertible Note, 7% due January 2023~~		101,918		~~100,000~~		1.5	%	~~101,918~~	~~1.5~~	%
	SageMedic Corp	~~SageMedic Corp~~	Life science		Convertible Note, 8% April 2021 plus warrants	~~Life science~~	50,000		~~Convertible Note, 8% April 2021 plus warrants~~		57,879		~~50,000~~		0.8	%	~~57,879~~	~~0.8~~	%
	SageMedic Corp	~~SageMedic Corp~~	Life science		Convertible Note, 8% December 2022 plus warrants	~~Life science~~	75,000		~~Convertible Note, 8% December 2022 plus warrants~~		77,086		~~75,000~~		1.1	%	~~77,088~~	~~1.1~~	%
	Sensing Electromagnetic Plus Corp	~~Sensing Electromagnetic Plus Corp~~	Technology		Convertible Note, Fully reserved	~~Technology~~	50,000		~~Convertible Note, Fully reserved~~		1		~~50,000~~		0.0	%	1	~~0.0~~	%
	Sensing Electromagnetic Plus Corp	~~Sensing Electromagnetic Plus Corp~~	Technology		Convertible Note, Fully reserved	~~Technology~~	11,048		~~Convertible Note, Fully reserved~~		1		~~11,048~~		0.0	%	1	~~0.0~~	%
	Valfix Medical Inc	~~Valfix Medical Inc~~*	Life science	*	Convertible Note, 8% December 2021	~~Life science~~	50,000		~~Convertible Note, 8% December 2021~~		52,510		~~50,000~~		0.8	%	~~52,510~~	~~0.8~~	%
	Xpan Inc	~~Xpan Inc~~*	Life science	*	Convertible Note, 8% due March 2022	~~Life science~~	50,000		~~Convertible Note, 8% due March 2022~~		54,296		~~50,000~~		0.8	%	~~54,296~~	~~0.8~~	%
	Xpan Inc	~~Xpan Inc~~*	Life science	*	Convertible Note, 8% due June 2022	~~Life science~~	25,000		~~Convertible Note, 8% due June 2022~~		26,545		~~25,000~~		0.4	%	~~26,545~~	~~0.4~~	%
	Xpan Inc	~~Xpan Inc~~*	Life science	*	Convertible Note, 8% due June 2022	~~Life science~~	25,000		~~Convertible Note, 8% due June 2022~~		26,540		~~25,000~~		0.4	%	~~26,540~~	~~0.4~~	%
Total Convertible loan investments						$	2,216,048			$	2,553,954	$	~~2,216,048~~		36.5	$%	~~2,553,954~~	~~36.5~~	%
	United States	~~United States~~				$	1,596,048			$	1,868,557	$	~~1,596,048~~		26.7	$%	~~1,868,557~~	~~26.7~~	%
	Canada	~~Canada~~					370,000				407,561		~~370,000~~		5.8	%	~~407,561~~	~~5.8~~	%
	Rest of World	~~Rest of World~~					250,000				277,836		~~250,000~~		4.0	%	~~277,836~~	~~4.0~~	%
Total Convertible loan investments						$	2,216,048			$	2,553,954	$	~~2,216,048~~		36.5	$%	~~2,553,954~~	~~36.5~~	%
Preferred stock investments
	Altis Biosystems		Life science		22,028 shares of Series Seed Preferred	$	50,000			$	50,000				0.7	%
	Astrocyte Pharmaceuticals Inc		Life science		260,756 shares of Series A Preferred		100,000				100,000				1.4	%
	Cnote Group, Inc		Fintech		84,655 shares of series Seed-2 Preferred (converted SAFE)		51,500				59,783				0.9	%
	Cnote Group, Inc		Fintech		93,807 shares of Series Seed-3 Preferred (converted note)		50,000				66,247				0.9	%
	Colabs Inc		Life science		147,058 shares of Series A-1 Preferred		50,000				50,000				0.7	%
	Connectus Services Ltd	*	Technology		31,348 shares of Series Seed Preferred		100,000				100,000				1.4	%
	Deep Blue Medical Advances Inc		Life science		10,474 shares of Series A Preferred		49,997				49,997				0.7	%
	Eumentis Thereapeutics Inc		Life science		85,009 shares of Series A Preferred		100,000				100,000				1.4	%
	FemtoDX Inc		Life science		42,436 shares of Series A Preferred		100,000				159,835				2.3	%
	i-Lumen Scientific Inc.		Life science		50,000 shares of Series A Preferred plus warrants		50,000				50,000				0.7	%
	i-Lumen Scientific Inc.		Life science		50,000 shares of Series A Preferred plus warrants		50,000				50,000				0.7	%
	Inhalon Biopharma Inc		Life science		18,843 shares of Series Seed Preferred		99,997				99,997				1.4	%
	Light Line Medical Inc		Life science		62,849 shares of Series Seed Preferred (converted note)		30,000				38,031				0.5	%
	Light Line Medical Inc		Life science		141,871 shares of Series Seed Preferred (converted note)		70,000				106,049				1.5	%
	Light Line Medical Inc		Life science		40,323 shares of Series Seed preferred		25,000				25,000				0.4	%
	Light Line Medical Inc		Life science		72,464 shares of Series A Preferred plus warrants		50,000				50,000				0.7	%
	Lowell Therapeutics Inc		Life science		20,000 shares of Series A Preferred		50,000				50,000				0.7	%
	Lowell Therapeutics Inc		Life science		20,000 shares of Series A Preferred		50,000				50,000				0.7	%
	Micronic Technologies Inc		Technology		51,929 shares of Series Seed-1 Preferred plus warrants		100,000				100,000				1.4	%
	Neuroflow Inc		Life science		98,684 shares of Series Seed -2 Preferred		150,000				224,998				3.2	%
	Neuroflow Inc		Life science		20,429 shares of Series B Preferred		100,000				212,497				3.0	%
	New View Surgical, Inc.		Life science		53,825 shares of Series A-1 Preferred		75,000				75,000				1.1	%

Continued onto next page

The accompanying notes are an integral part of these condensed interim financial statements.

Continued from previous page

Kyto Technology and Life Science, Inc.

~~Condensed~~ Schedule of Investments as of March 31, 2021 ~~- continued~~

(Unaudited)

Preferred stock investments
	Portfolio Company		Industry	Investment	Cost		Fair value			% of net assets (a)
	Altis Biosystems		Life science	22,028 shares of Series Seed Preferred	$	50,000	$	50,000	0.7	%
Preferred stock investments (continued)
	Astrocyte Pharmaceuticals Inc		Life science	260,756 shares of Series A Preferred		100,000		100,000	1.4	%
	Otomagnetics Inc		Life science	16,538 shares of Series A-1 Preferred plus warrants	$	100,000	$	100,000		1.4	%
	Cnote Group, Inc		Fintech	84,655 shares of series Seed-2 Preferred (converted SAFE)		51,500		59,783	0.9	%
	Promaxo		Life science	104,248 shares of Series B-1 Preferred, (converted note)		250,000		531,738		7.6	%
	Cnote Group, Inc		Fintech	93,807 shares of Series Seed-3 Preferred (converted note)		50,000		66,247	0.9	%
	Seal Rock Therapeutics, Inc.		Life science	68,075 shares of Series Seed Preferred, (converted note)		78,000		80,329		1.1	%
	Colabs Inc		Life science	147,058 shares of Series A-1 Preferred		50,000		50,000	0.7	%
	Shyft (FKA Crater Group Inc)		Technology	42,657 shares of Series A-1 Preferred		51,500		97,940		1.4	%
	Connectus Services Ltd	*	Technology	31,348 shares of Series Seed Preferred		100,000		100,000	1.4	%
	Shyft (FKA Crater Group Inc)		Technology	28,147 shares of Series A Preferred (converted note)		50,000		64,626		0.9	%
	Deep Blue Medical Advances Inc		Life science	10,474 shares of Series A Preferred		49,997		49,997	0.7	%
	Shyft (FKA Crater Group Inc)		Technology	21,774 shares of Series A-1 Preferred (converted note)		50,000		50,000		0.7	%
	Eumentis Thereapeutics Inc		Life science	85,009 shares of Series A Preferred		100,000		100,000	1.4	%
( i )	Trellis Bioscience LLC		Life science	50,000 shares of Series B Preferred plus warrants		50,000		50,000		0.7	%
	FemtoDX Inc		Life science	42,436 shares of Series A Preferred		100,000		159,835	2.3	%
( i )	Trellis Bioscience LLC		Life science	50,000 shares of Series B Preferred plus warrants		50,000		50,000		0.7	%
	i-Lumen Scientific Inc.		Life science	50,000 shares of Series A Preferred plus warrants		50,000		50,000	0.7	%
( i )	Trellis Bioscience LLC		Life science	100,000 shares of Series B Preferred plus warrants		100,000		100,000		1.4	%
	i-Lumen Scientific Inc.		Life science	50,000 shares of Series A Preferred plus warrants		50,000		50,000	0.7	%
	Valfix Medical Inc	*	Life science	27,217 shares of Series Seed Preferred		50,000		50,000		0.7	%
	Inhalon Biopharma Inc		Life science	18,843 shares of Series Seed Preferred		99,997		99,997	1.4	%
	Visgenx Inc		Life science	7,833 shares of Series Seed-1 Preferred (converted note)		30,000		46,352		0.7	%
	Light Line Medical Inc		Life science	62,849 shares of Series Seed Preferred (converted note)		30,000		38,031	0.5	%
	Visgenx Inc		Life science	4,132 shares of Series Seed Preferred (converted note)		25,000		25,648		0.4	%
	Light Line Medical Inc		Life science	141,871 shares of Series Seed Preferred (converted note)		70,000		106,049	1.5	%
	Visgenx Inc		Life science	2,480 shares of Series Seed Preferred (converted note)		15,003		15,391		0.2	%
	Light Line Medical Inc		Life science	40,323 shares of Series Seed preferred		25,000		25,000	0.4	%
Total Preferred stock investments					$	2,450,997	$	3,129,458		44.8	%
	Light Line Medical Inc		Life science	72,464 shares of Series A Preferred plus warants		50,000		50,000	0.7	%
	United States				$	2,300,997	$	2,979,458		42.6	%
	Lowell Therapeutics Inc		Life science	20,000 shares of Series A Preferred		50,000		50,000	0.7	%
	Canada					100,000		100,000		1.4	%
	Lowell Therapeutics Inc		Life science	20,000 shares of Series A Preferred		50,000		50,000	0.7	%
	Rest of World					50,000		50,000		0.7	%
	Micronic Technologies Inc		Technology	51,929 shares of Series Seed-1 Preferred plus warrants		100,000		100,000	1.4	%
Total Preferred stock investments					$	2,450,997	$	3,129,458		44.8	%
	Neuroflow Inc		Life science	98,684 shares of Series Seed -2 Preferred		150,000		224,998	3.2	%
Common stock investments
	Neuroflow Inc		Life science	20,429 shares of Series B Preferred		100,000		212,497	3.0	%
	BendaRX Corp	*	Life science	12,500 Common shares	$	100,000	$	150,000		2.1	%
	New View Surgical, Inc.		Life science	53,825 shares of Series A-1 Preferred		75,000		75,000	1.1	%
	BendaRX Corp	*	Life science	12,500 Common shares		100,000		150,000		2.1	%
	Otomagnetics Inc		Life science	16,538 shares of Series A-1 Preferred plus warrants		100,000		100,000	1.4	%
	Boardwalk Tech		Technology	150,000 Common shares		73,500		91,995		1.3	%
	Promaxo		Life science	104,248 shares of Series B-1 Preferred, (converted note)		250,000		531,738	7.6	%
Total Common stock investments					$	273,500	$	391,995		5.6	%
	Seal Rock Therapeutics, Inc.		Life science	68,075 shares of Series Seed Preferred, (converted note)		78,000		80,329	1.1	%
	United States				$	73,500	$	91,995		1.3	%
	Shyft (FKA Crater Group Inc)		Technology	42,657 shares of Series A-1 Preferred		51,500		97,940	1.4	%
	Canada					200,000		300,000		4.3	%
	Shyft (FKA Crater Group Inc)		Technology	28,147 shares of Series A Preferred (converted note)		50,000		64,626	0.9	%
	Rest of World					-		-		0.0	%
	Shyft (FKA Crater Group Inc)		Technology	21,774 shares of Series A-1 Preferred (converted note)		50,000		50,000	0.7	%
Total Common stock investments					$	273,500	$	391,995		5.6	%
(i)	Trellis Bioscience LLC		Life science	50,000 shares of Series B Preferred plus warrants		50,000		50,000	0.7	%
SAFE investments
(i)	Trellis Bioscience LLC		Life science	50,000 shares of Series B Preferred plus warrants		50,000		50,000	0.7	%
	Infinidome Ltd	*	Technology	SAFE	$	50,000	$	50,000		0.7	%
(i)	Trellis Bioscience LLC		Life science	100,000 shares of Series B Preferred plus warrants		100,000		100,000	1.4	%
	Infinidome Ltd	*	Technology	SAFE		50,000		50,000		0.7	%
	Valfix Medical Inc	*	Life science	27,217 shares of Series Seed Preferred		50,000		50,000	0.7	%
	Mitre Medical Corp		Life science	SAFE		75,000		75,000		1.1	%
	Visgenx Inc		Life science	7,833 shares of Series Seed-1 Preferred (converted note)		30,000		46,352	0.7	%
	Mitre Medical Corp		Life science	SAFE		50,000		50,000		0.7	%
	Visgenx Inc		Life science	4,132 shares of Series Seed Preferred (converted note)		25,000		25,648	0.4	%
	Orion Biotechnology Inc.	*	Life science	SAFE		100,000		100,000		1.4	%
	Visgenx Inc		Life science	2,480 shares of Series Seed Preferred (converted note)		15,003		15,392	0.2	%
Total SAFE investments					$	325,000	$	325,000		4.6	%
Total Preferred stock investments					$	2,450,998	$	3,129,458	44.8	%
	United States				$	125,000	$	125,000		1.8	%
	United States				$	2,300,998	$	2,979,458	42.6	%
	Canada					100,000		100,000		1.4	%
	Canada					100,000		100,000	1.4	%
	Rest of World					100,000		100,000		1.4	%
	Rest of World					50,000		50,000	0.7	%
Total SAFE investments					$	325,000	$	325,000		4.6	%
Total Preferred stock investments					$	2,450,998	$	3,129,458	44.8	%
Other investments
Common stock investments
	Enduralock LLC		Technology	34.1 Series A-1 Ownership Units	$	30,000	$	30,000		0.4	%
	BendaRX Corp	*	Life science	12,500 Common shares	$	100,000	$	150,000	2.1	%
	Enduralock LLC		Technology	39.7 Series A-1 Ownership Units		35,000		35,000		0.5	%
	BendaRX Corp	*	Life science	12,500 Common shares		100,000		150,000	2.1	%
( i )	Exodos Life Sciences LP		Life science	Class A-1 Preferred Ownership Units		206,000		206,000		2.9	%
	Boardwalk Tech		Technology	150,000 Common shares		73,500		91,995	1.3	%
	Green Sun Medical LLC		Life science	2,193 Class A-1 Ownership units		50,000		50,000		0.7	%
Total common stock investments					$	273,500	$	391,995	5.6	%
	Green Sun Medical LLC		Life science	1,096 Class A-1 Ownership units		25,000		25,000		0.4	%
	United States				$	73,500	$	91,995	1.3	%
	Green Sun Medical LLC		Life science	1,096 Class A-1 Ownership units		25,000		25,000		0.4	%
	Canada					200,000		300,000	4.3	%
	Riso Capital Fund I, LP		Technology	Ownership units		50,000		50,000		0.7	%
	Rest of World					-		-
Total Other investments					$	421,000	$	421,000		6.0	%
Total common stock investments					$	273,500	$	391,995	5.6	%
	United States				$	421,000	$	421,000		6.0	%
SAFE investments
	Canada					-		-		0.0	%
	Infinidome Ltd	*	Technology	SAFE	$	50,000	$	50,000	0.7	%
	Rest of World					-		-		0.0	%
	Infinidome Ltd	*	Technology	SAFE		50,000		50,000	0.7	%
Total Other investments					$	421,000	$	421,000		6.0	%
	Mitre Medical Corp		Life science	SAFE		75,000		75,000	1.1	%
Total investments					$	5,686,545	$	6,821,407		97.5	%
	Mitre Medical Corp		Life science	SAFE		50,000		50,000	0.7	%
	United States				$	4,516,545	$	5,486,010		78.4	%
	Orion Biotechnology Inc.	*	Life science	SAFE		100,000		100,000	1.4	%
	Canada					770,000		907,561		13.0	%
Total SAFE investments					$	325,000	$	325,000	4.6	%
	Rest of World					400,000		427,836		6.1	%
	United States				$	125,000	$	125,000	1.8	%
Total investments					$	5,686,545	$	6,821,407		97.5	%
	Canada					100,000		100,000	1.4	%
	(a) based on total net assets of $ 6,993,163
	Rest of World					100,000		100,000	1.4	%
( i )	Kyto management sit on the Board of these companies.
Total SAFE investments					$	325,000	$	325,000	4.6	%
*	These companies are headquartered outside of the US.

Continued on next page

The accompanying notes are an integral part of these condensed interim financial statements.

Continued from previous page

Kyto Technology and Life Science, Inc.

~~Condensed~~Notes ~~Schedule~~to ofUnaudited ~~Investments~~Condensed asFinancial ofStatements ~~March 31, 2021 - continued~~

~~(Unaudited)~~December 31, 2021

Preferred stock investments
Other investments
	Enduralock LLC		Technology	34.1 Series A-1 Ownership Units	$	30,000	$	30,000	0.4	%
	Enduralock LLC		Technology	39.7 Series A-1 Ownership Units		35,000		35,000	0.5	%
(i)	Exodos Life Sciences LP		Life science	Class A-1 Preferred Ownership Units		206,000		206,000	2.9	%
	Green Sun Medical LLC		Life science	2,193 Class A-1 Ownership units		50,000		50,000	0.7	%
	Green Sun Medical LLC		Life science	1,096 Class A-1 Ownership units		25,000		25,000	0.4	%
	Green Sun Medical LLC		Life science	1,096 Class A-1 Ownership units		25,000		25,000	0.4	%
	Riso Capital Fund I, LP		Technology	Ownership units		50,000		50,000	0.7	%
Total other investments					$	421,000	$	421,000	6.0	%
	United States				$	421,000	$	421,000	6.0	%
	Canada					-		-
	Rest of World					-		-
Total Other investments					$	421,000	$	421,000	6.0	%
Total investments					$	5,686,545	$	6,821,407	97.5	%
	United States				$	4,516,546	$	5,486,011	78.4	%
	Canada					770,000		907,560	13.0	%
	Rest of World					400,000		427,836	6.1	%
Total investments					$	5,686,545	$	6,821,407	97.5	%
	(a) based on total net assets of	$	6,993,163

( i ) Kyto representatives sit on the Board of Directors of these companies. * These companies are headquartered outside of the US. The accompanying notes are an integral part of these condensed interim financial statements.

KYTO TECHNOLOGY AND LIFE SCIENCE INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2021

NOTE 1 – DESCRIPTION OF BUSINESS

Kyto Technology and Life Science, Inc. (the “Company”) was formed as a Florida corporation on March 5, 1999 under the name of B Twelve, Inc. In August, 2002, the Company changed its name from B Twelve, Inc. to Kyto BioPharma Inc. and in May 2018, the name was changed again to Kyto Technology and Life Science, Inc. In July 2019, the Company was re-incorporated as a Delaware company. The Company operates virtually, from public locations or the homes of its officers, and does not currently lease any office space.

The Company was originally formed to acquire and develop proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases and had been evaluating a number of strategies. As of March 31, 2018, the Company had accumulated a deficit of $32,380,746 from all prior operations. In April 2018, the Board adopted a new business plan focused on the development of early-stage technology and life science businesses through early-stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, sophisticated early-stage investors and successful entrepreneurs with experience across a number of technology and life science products and markets, and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment groups and other sophisticated investors and participates only after these groups have completed due diligence and committed to invest, in effect becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors. The Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally, it is expected that investments will be realized from an exit within a period of four to five years following initial investment. Such exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions or an initial public offering (“IPO”) which may result in cash or equity proceeds. Other than making its initial and, potentially, follow-on investments in its portfolio companies, the Company does not provide any financial support to any of its investees.

The Company has one regular employee – the CEO, Mr,. Paul Russo. Prior to December 31, 2020, ~~Mr.~~he ~~Russo~~ was acting as a consultant to the Company and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged as an employee of the Company at a salary of $400,000 per annum of which ~~60% was paid monthly from January to April 2021~~$100,000 ~~then 75% from May 2021, with the balance being deferred to be paid once the Company lists~~ and ~~starts trading on the Nasdaq exchange. The full terms of Mr. Russo’s employment are described in a Form 8-K filed on February 1~~$300,000 ~~2021, which~~ was ~~approved~~earned byin the ~~Compensation committee of the Board of Directors on that date. During the~~ three months and ~~six~~nine months ended ~~September~~December 3031, 2021, ~~Mr.~~respectively, ~~Russo~~of ~~received~~which ~~gross~~a ~~pay~~ balance of $9080,000 ~~and~~ ~~$170~~was deferred at December 31,~~000, respectively~~ 2021. No consulting fees and no options were granted to him during these periods. During the three months and ~~six~~nine months ended ~~September~~December 3031, 2020, Mr. Russo received no payroll or consulting fees, however in the three and ~~six~~nine months ended ~~September~~December 3031, 2020, he received a bonus of $50,000 and was granted options to purchase 215,000 shares of Common stock.

The Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of the date of this filing, the Company had approximately $485,000 of cash to cover its operating expenses, and new investment requirements and is continuing to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed interim financial statements have been prepared assuming the Company will continue to operate as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment companies report delays in their programs.13

14The Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of December 31, 2021, the Company had approximately $600,000 of cash to cover its operating expenses, and new investment requirements and is continuing to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed interim financial statements have been prepared assuming the Company will continue to operate as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment companies report delays in their programs.

At March 31, 2020, management determined that the Company was an investment company for purposes of Accounting Standards Codification Topic 946, Financial Services—Investment Companies (ASC Topic 946) disclosure, and adopted the specialized accounting and reporting guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”) was incorporated in Delaware in December 2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021 for review by the Securities and Exchange Commission (the “SEC”). KI is an internally managed, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Immediately upon effectiveness of this N-2 Registration Statement, the Company will merge with KI and the Company will be the surviving entity. As of the completion of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the Securities Act and may continue the current offering by filing post-effective amendments to the Registration Statements. Prior to the merger, the Company had fewer than 100 non -affiliated investors and filed under the 1934 Act relying on exemption Rule 3( c )(1).

As a BDC, the Company will be required to comply with certain regulatory requirements. The Company also intends to elect to be treated for U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company is required to comply with additional regulatory requirements. The Company has prepared and submitted sequentially two N-2 Registration Statements to the SEC for review but has not yet received final approval of its registration as at the filing date of this report.

NOTE 2 - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

(A) BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, these unaudited condensed financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments (consisting only of normal recurring adjustments), which the Company considers necessary, for a fair presentation of those financial statements. The results of operations and cash flows for the three months and ~~six~~nine months ended ~~September~~December 3031, 2021 may not necessarily be indicative of results that may be expected for any succeeding quarter or for the entire fiscal year. The condensed balance sheet as of March 31, 2021 was derived from the audited financial statements at that date, but does not include all the information and footnotes required by U.S. GAAP. The information contained in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements of the Company for the year ended March 31, 2021, included in the Annual Report on Form 10-K as filed with the ~~Securities and Exchange Commission (the “~~SEC”) on August 10, 2021.

The Company’s condensed interim financial statements are prepared in accordance with U.S. GAAP, which requires the use of estimates, assumptions and the exercise of subjective judgment as to future uncertainties. Actual results could differ from those estimates, assumptions, and judgments. Significant items subject to such estimates will include determining the fair value of investments, revenue recognition, income tax uncertainties, stock-based compensation, and other contingencies.

The Company’s financial statements are prepared using the specialized accounting principles of ASC Topic 946. In accordance with this specialized accounting guidance, the Company recognizes and carries all of its investments at fair value with changes in fair value recognized in earnings. Additionally, the Company will not apply consolidation or equity method of accounting to its investments. The carrying amount of the Company’s financial instruments such as cash and payables approximates fair value due to the short maturity of such instruments. Net assets are calculated as the carrying amounts of assets, including the fair value of investments, less the carrying amounts of its liabilities.

(B) RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

The Company’s previously issued financial statements as of and for three and six months ended September 30, 2021 and the three months ended June 30, 2021 have been restated to reflect the dividends attributable for the Class B-1, B-2 and B-3 Preferred Stock. The Class B-1, B-2 and B-3 Preferred Stock have cumulative dividends amounting to $98,968 and $350,694 for three and six months ended September 30, 2021, respectively, and $251,726 for the three months ended June 30, 2021. Previously, the Company did not present the cumulative dividends attributable to Class B-1, B-2 and B-3 Preferred Stock in its calculation of earnings (loss) per common share. To correct this misstatement, the Company has included dividends attributable to Class B-1, B-2 and B-3 Preferred Stock for the three and six months ended September 30, 2021 and three months ended June 30, 2021, in its calculation of earnings (loss) per common share below, resulting in a decrease of net income and increase in net loss attributable to common shareholders. There has been no change in the Company’s total assets, liabilities or operating results.

The correction of the errors is as follows:

SCHEDULE OF CORRECTION OF THE ERRORS


	For the three months ended						For the six months ended
	September 30, 2021			June 30, 2021			September 30, 2021
Net increase (decrease) in net assets resulting from operations	$	996,133		$	(333,792	)	$	662,341
Less: Dividends attributable to Class B-1, B-2 & B-3 stockholders		(98,968	)		(251,726	)		(350,694	)
Net increase (decrease) in net assets resulting from operations attributable to Common Shareholders (as restated)	$	897,165		$	(585,518	)	$	311,647

As restated:
Weighted Average Common Shares		13,273,871			13,268,871			13,270,794
Weighted Average Fully Diluted Shares		27,500,194			13,268,871			22,228,602
Basic Earnings (Loss) per common share	$	0.07		$	(0.04	)	$	0.02
Diluted Earnings (Loss) per common share	$	0.04		$	(0.04	)	$	0.01

As reported:
Weighted Average Common Shares		13,271,996			13,268,871			13,269,764
Weighted Average Fully Diluted Shares		27,338,695			13,268,871			26,263,218
Basic Earnings (Loss) per common share	$	0.08		$	(0.03	)	$	0.05
Diluted Earnings (Loss) per common share	$	0.04		$	(0.03	)	$	0.03

(BC) INVESTMENT TRANSACTIONS AND NET REALIZED AND UNREALIZED GAIN OR LOSS ON INVESTMENTS

The Company generates increases or decreases in its net assets from the sale of complete or partial investments following a merger or acquisition (“M&A”) transaction or restructuring or from the revaluation of portfolio company investments to recognize changes in their fair value, either upwards or downwards. As a minority early-stage investor, the Company does not have the ability to manage the timing or acceptance of liquidity events that will realize its investments, nor the ability to predict when they may happen, although as a general guideline, it would expect such events to occur approximately four to five years after its investments are made. The Company records the realized gains and losses from investment activities upon completion of sale and receipt of net proceeds, after deducting related transaction expenses. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized. The Company is in periodic contact with the management of its portfolio investment companies to provide a basis for valuation changes. The Company does not expect to receive interest and principal repayments on its convertible notes and generally expects these notes to convert into equity securities upon completion of qualified subsequent financings. Accrued interest is recorded as an adjustment to the fair value of the convertible notes.

(CD) INCOME TAXES

The Company accounts for income taxes under the Financial Accounting Standards Accounting Standard Codification Topic 740 “Accounting for Income Taxes” (“Topic 740”). Under Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under Topic 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period, which includes the enactment date.

(DE) USE OF ESTIMATES

In preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period presented. Actual results may differ from these estimates.

Significant estimates during the three months and ~~six~~nine months ended ~~September~~December 3031, 2021 and ~~September~~March 3031, ~~2020~~2021 include the valuation of the investment portfolio, deferred tax assets, tax valuation allowance, stock options and warrants.

(E) CASH AND CASH EQUIVALENTS

The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents at September 30, 2021 and March 31, 2021, respectively.

(F) CONCENTRATIONS

The Company maintains its cash in bank checking and deposit accounts, which, at times, may exceed federally insured limits. As of September 30, 2021, and March 31, 2021, the Company’s bank balance exceeded the federally insured limit by approximately $70,000 and $1.2 million, respectively. The Company has not experienced any losses in such accounts through September 30, 2021.

(GF) ~~STOCK-BASED~~CASH ~~COMPENSATION~~AND CASH EQUIVALENTS

~~Financial~~The ~~Accounting~~Company ~~Standards~~considers ~~Board Accounting Standards Codification Topic 718, “Stock Compensation” requires generally that~~ all ~~equity~~highly ~~awards~~liquid ~~granted~~investments towith ~~employees~~original ~~and~~maturities ~~consultants~~of bethree ~~accounted~~months ~~for~~or atless ~~fair value. This fair value is measured~~ at ~~grant date for stock settled awards, and at subsequent exercise or settlement for cash-settled awards. Under this method,~~ the ~~Company~~time ~~records~~of anpurchase ~~expense equal~~ to ~~the~~be ~~fair~~cash ~~value of the options or warrants issued~~equivalents. ~~The fair value is computed using the Black Scholes options pricing model.~~ ~~The~~There ~~Company~~were ~~granted~~no ~~consultants~~cash ~~and~~equivalents ~~advisors~~at ~~490,000~~December ~~and 510~~31,~~000~~ ~~options during the three months ended September 30,~~ 2021 and ~~September 30,~~March ~~2020~~31, ~~and 740,000 and 510,000 options during the six months ended September 30,~~ 2021 ~~and September 30~~, ~~2020,~~ respectively.

(HG) ~~NET EARNINGS PER COMMON SHARE~~CONCENTRATIONS

InThe ~~accordance~~Company ~~with~~maintains ~~Statement~~its ofcash ~~Financial~~in ~~Accounting~~bank ~~Standards~~checking ~~Accounting~~and ~~Standard~~deposit ~~Codification~~accounts, ~~Topic 260~~which, ~~“Earnings~~at ~~per Share”~~times, ~~basic~~ ~~earnings~~may ~~per~~exceed ~~common~~federally ~~share~~insured islimits. ~~computed~~As byof ~~dividing the net income less preferred dividends for the period by the weighted average~~December ~~number~~31, of2021, ~~common~~and ~~shares~~March ~~outstanding.~~31, ~~Diluted~~2021, ~~earnings per common share is computed by dividing net income less preferred dividends by~~ the ~~weighted~~Company’s ~~average~~bank ~~number~~balance ofexceeded ~~common shares outstanding including~~ the ~~effect~~federally ofinsured ~~common~~limit ~~stock~~by ~~equivalents~~approximately ~~consisting of preferred stock~~$360, ~~stock~~000 ~~options~~ and ~~warrants~~$1.2 million, respectively. The ~~following~~Company ~~table~~has ~~sets~~not ~~out~~experienced ~~the~~any ~~number~~losses ~~of shares used~~ in ~~calculating~~such ~~fully-~~accounts ~~diluted~~through ~~earnings~~December ~~per~~31, ~~common share using the if-converted method~~2021.

~~Weighted~~(H) ~~Average~~STOCK-BASED ~~method~~COMPENSATION

~~Number~~Financial ofAccounting ~~shares~~Standards ~~used~~Board inAccounting ~~calculating~~Standards ~~fully~~Codification Topic 718, “Stock Compensation” requires generally that all equity awards granted to employees and consultants be accounted for at fair value. This fair value is measured at grant date for stock settled awards, and at subsequent exercise or settlement for cash-settled ~~diluted~~awards. ~~earnings~~Under ~~per~~this ~~common~~method, ~~shares~~the Company records an expense equal to the fair value of the options or warrants issued. The fair value is computed using the Black Scholes options pricing model. The Company granted consultants and advisors 1,550,000 and 217,500 options during the three months ended December 31, 2021 and December 31, 2020, and 2,290,000 and 847,500 options during the nine months ended December 31, 2021 and December 31, 2020, respectively.

~~SCHEDULE~~(I) NET OF EARNINGS (LOSS) PER COMMON SHARE

	Three months ended September 30, 2021		Six months ended September 30, 2021
Common Stock		13,271,996		13,269,764
Common stock subscribed not issued		-		-
Series A preferred stock		4,200,000		4,200,000
Series B preferred stock		5,307,240		4,361,525
Options		2,962,792		2,835,262
Warrants		1,596,667		1,596,667
Total shares used in calculating fully-diluted earnings per common share		27,338,695		26,263,218

In accordance with Statement of Financial Accounting Standards Accounting Standard Codification Topic 260, “Earnings per Share”, the Company uses the two-class method to compute net income (loss) per common share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Holders of Class B-1, B-2 and B-3 of the Company’s convertible preferred stock are entitled to participate in distributions, when and if declared by the board of directors, that are made to common stockholders and, as a result, are considered participating securities. As of December 31, 2021, convertible preferred stock dividends totaling $482,693 were accumulated and in arrears. As the Company’s Board of Directors had not declared such dividends payable, the Company has not recognized such dividend payable liability as of December 31, 2021, and will not recognize such dividend liability until they are declared by the Company’s Board of Directors. Notwithstanding, the Company has presented such dividend value as a component of the net increase (decrease) in net assets resulting from operations attributable to common shareholders in the calculation of basic and diluted earnings (loss) per common share.

	Three months ended September 30, 2020		Six months ended September 30, 2020
Common Stock issued		5,836,832		5,836,832
Series A preferred stock		4,200,000		4,200,000
Series B preferred stock		1,830,208		1,250,595
Options		1,920,000		1,571,429
Warrants		4,200,000		4,200,000
Total shares used in calculating fully-diluted earnings per common share		17,987,040		17,058,856

Under the two-class method, for periods with net income, basic net income per share of common stock is computed by dividing the net income attributable to shares of common stock by the weighted average number of shares of common stock outstanding during the period. Net income attributable to shares of common stock is computed by subtracting from net income the portion of current period earnings that participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss as the holders of the participating securities have no contractual obligation to fund losses. Diluted net income per share of common stock is computed under the two-class method by using the weighted average number of shares of common stock outstanding plus the potential dilutive effects of stock options, warrants and non-participating convertible preferred shares (Class A and B). In addition, the Company analyzes the potential dilutive effect of the outstanding convertible securities under the if-converted method when calculating diluted income per share of common stock in which it is assumed that the outstanding convertible securities convert into common stock at the beginning of the period or date of issuance, if the convertible security was issued during the period. The Company reports the more dilutive of the approaches (two-class or if-converted) as its diluted net income per share of common stock during the period.

(IThe )following ~~INVESTMENT~~table ~~AND~~sets ~~VALUATION~~out OFthe ~~INVESTMENT~~number ATof ~~FAIR~~shares ~~VALUE~~used in calculating fully-diluted earnings per common share:

SCHEDULE OF EARNINGS PER SHARE

Weighted average method

Number of shares used in calculating fully diluted earnings per common shares (two-class method)

	Three months to December 31, 2021		Nine months to December 31, 2021
Common stock		13,287,621		13,273,038
Class A Preferred Stock		4,200,000		4,200,000
Class B Preferred Stock		286,250		286,250
Options		4,145,500		3,044,305
Warrants		1,596,667		1,596,667

Total shares used in calculating fully-diluted earnings per common share, two-class method		23,516,038		22,400,260

Weighted average method

Number of shares used in calculating fully diluted earnings per common shares (if-converted method)

	Three months to December 31, 2020		Nine months to December 31, 2020
Common stock		8,528,007		5,836,831
Class A Preferred Stock		4,200,000		4,200,000
Class B Preferred Stock		2,789,954		1,933,912
Options		2,157,500		1,842,873
Warrants		1,596,667		3,329,067

Total shares used in calculating fully-diluted earnings per common share, if-converted method		19,272,128		17,142,683

(J) INVESTMENT AND VALUATION OF INVESTMENT AT FAIR VALUE

The Company reviews the performance of its investments based on available information, including management reports, press releases, web site announcements and progress reports, third party equity updates, management interviews and, where accessible, financial reports, to determine their fair values. In the event that management considers the fair value of an investment to be greater or less than the current book value, the difference will be reflected as unrealized gains or losses in investments in the statements of operations.

The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing U.S. GAAP that require the use of fair value measurements which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is an exchange price notion under which fair value is the price in an orderly transaction between market participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the asset or liability.

The Company has established procedures to estimate the fair value of its investments which the Company’s board of directors has reviewed and approved. The Company uses observable market data to estimate the fair value of investments to the extent that market data is available. In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active, the Company uses the valuation methodologies described below with unobservable data based on the best available information in the circumstances, which incorporates the Company’s assumptions about the factors that a market participant would use to value the asset.

For investments for which quoted market prices are not available, which comprise most of our investment portfolio, fair value is estimated by using the income, market, or back-solve approach. The income approach is based on the assumption that value is created by the expectation of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive those future benefits. The market approach compares recent comparable transactions to the investment. The back solve method involves comparing available data over a period of time and inferring a new valuation based on changes from a known starting point, for example the cost of an investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. These valuation methodologies involve a significant degree of judgment on the part of our management and board.

In determining the appropriate fair value of an investment using these approaches, the most significant information and assumptions may include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral, the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the company does business, comparisons of financial ratios of peer companies that are public, merger and acquisition ~~comparables~~comparable, the principal market and enterprise values, environmental factors, subsequent financings by the portfolio investment, among other factors.

The estimated fair values do not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments, the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments existed.

The authoritative accounting guidance prioritizes the use of market-based inputs over entity-specific inputs and establishes a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation. The three levels of valuation hierarchy are defined as follows:

Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data

Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. Most of the Company’s investments are Level 3.

18Critical accounting policies and practices are the policies that are both most important to the portrayal of the Company’s financial condition and results, and require management’s most difficult, subjective, or complex judgments, often as a result of the need to make estimates about matters that are inherently uncertain. These include estimates of the fair value of Level 3 investments and other estimates that affect the reported amounts of assets and liabilities as of the date of the financial statements and the reported amounts of certain revenues and expenses during the reporting period. It is likely that changes in these estimates will occur in the near term. The Company’s estimates are inherently subjective in nature and actual results could differ materially from such estimates. See “Note 1 – Significant Accounting Policies” to our financial statements as of March 31, 2021, as filed with the SEC on August 10, 2021, for further detail regarding our critical accounting policies and recently issued or adopted accounting pronouncements.

~~Critical~~(K) ~~accounting~~RECENT ~~policies~~ACCOUNTING and practices are the policies that are both most important to the portrayal of the Company’s financial condition and results, and require management’s most difficult, subjective, or complex judgments, often as a result of the need to make estimates about matters that are inherently uncertain. These include estimates of the fair value of Level 3 investments and other estimates that affect the reported amounts of assets and liabilities as of the date of the consolidated financial statements and the reported amounts of certain revenues and expenses during the reporting period. It is likely that changes in these estimates will occur in the near term. The Company’s estimates are inherently subjective in nature and actual results could differ materially from such estimates. See “Note 1 – Significant Accounting Policies” to our financial statements as of March 31, 2021, as filed with the SEC on August 10, 2021, for further detail regarding our critical accounting policies and recently issued or adopted accounting pronouncements.PRONOUNCEMENTS

(J) RECENT ACCOUNTING PRONOUNCEMENTS

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

(KL) OTHER ~~CURRENT~~ ASSETS

Other ~~current~~ assets principally include deferred offering costs. Since April 2019, the Company has conducted a series of sales of common and preferred stock to fund its ongoing investment program and cost of operations. Typically, it expects that raising capital through the sale of any series of securities, from start to finish, may take from six to nine months and in order to match the cost and benefits of this process, the Company adopted a policy of capitalizing direct expenses incurred in the course of raising capital, with the intention of netting accumulated expenses against proceeds from sale of equity, and reporting the net funds raised at the close. Direct expenses include legal fees, investor relations fees, investor roadshows and meeting expenses, and related filing and printing fees. At ~~September~~December 3031, 2021 and March 31, 2021, the Company had deferred $~~230~~293,~~434~~564 and $169,891, respectively, of such expenses, relating to the preparation and filing of an N-2 Registration Statement.

NOTE 3 – COMMITMENTS AND CONTINGENCIES

The Company has no commitments or contingencies as of the date of this filing. The Company may be subject to litigation during the normal course of business but has not received any such claims to date.

NOTE 4 - RELATED PARTY TRANSACTIONS

At ~~September~~December 3031, 2021 and March 31, 2021, the Company had accrued and owed $8783,000 and $51,420, respectively, to officers of the Company for deferred payroll and consulting service fees.

At ~~September~~December 3031, 2021, officers or directors of the Company held board positions at four portfolio companies: Beam Semiconductor Inc., ~~Trellis~~Achelios ~~Bioscience~~Therapeutics Inc., ~~Exodos~~Trellis ~~Life~~Bioscience ~~Sciences~~LLC LPand INBay Technology Inc. At March 31, ~~and~~2021, officers or directors of the Company held board positions at four portfolio companies: Beam Semiconductor Inc., Achelios Therapeutics Inc., Trellis Bioscience LLC and Exodos Life Sciences LP.

NOTE 5 – INVESTMENTS

The following table summarizes the Company’s investment portfolio at ~~September~~December 3031, 2021 and March 31, 2021.

SUMMARY OF INVESTMENT PORTFOLIO

	September 30, 2021				March 31, 2021
	December 31, 2021				March 31, 2021
Number of portfolio companies		6669				51
Fair value	$	1012,~~442~~156,~~813~~511			$	6,821,407
Cost		78,~~904~~926,~~636~~469				5,686,545
% of portfolio at fair value
Convertible notes		34,~~801~~679,~~833~~776	3638.4	%		2,553,954	37.4	%
Preferrred stock		4,538,653	43.5	%		3,129,458	45.9	%
Preferred stock		5,225,498	43.0	%		3,129,458	45.9	%
Common stock		~~956~~955,~~327~~237	97.29	%		391,995	5.7	%
SAFE		~~575~~725,000	56.50	%		325,000	4.8	%
Other ownership units		571,000	54.57	%		421,000	6.2	%
Total	$	1012,~~442~~156,~~813~~511	100.0	%	$	6,821,407	100.0	%

A SAFE is a Simple Agreement for Future Equity in the form of a warrant to purchase equity stock in a future priced round.

Our investment portfolio represents approximately 9694% and 97% of our net assets at ~~September~~December 3031, 2021 and ~~98% at~~ March 31, 2021, respectively. Investments in early-stage start-up private operating entities are valued based on available metrics, such as relevant market multiples and comparable company valuations, company specific-financial data including subsequent financings, actual and projected results, and independent third-party valuation estimates.

Significant Unobservable Inputs for Level 3 Assets and Liabilities

In accordance with FASB ASC 820, Fair Value Management, the tables below provide quantitative information about the Company’s fair value measurements of its Level 3 assets as of ~~September~~December 3031, 2021 and March 31, 2021. In addition to the techniques and inputs noted in the tables above, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not meant to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. To the extent an unobservable input is not reflected in the tables below, such input is deemed insignificant with respect to the Company’s Level 3 fair value measurements. Significant changes in the inputs in isolation would result in a significant change in the fair value measurement, depending on the materiality of the investment.

The following table summarizes the valuation techniques and significant unobservable inputs used for investments that are categorized within Level 3 of the fair value hierarchy as of ~~September~~December 3031, 2021 and March 31, 2021:

SCHEDULE OF INVESTMENTS

As of September 30, 2021

As of December 31, 2021

~~Fair Value~~

Fair Value

~~Valuation Approach/ Technique~~

Valuation Approach/ Technique

~~Unobservable Inputs~~

Unobservable Inputs

~~Range/ Weighted Average~~

Range/ Weighted Average

Convertible notes: Basepaws Inc

~~201,663~~$

394,980

~~Market approach based on indicative term sheet and last round of financing~~

Market approach based on indicative term sheet and last round of financing

~~As if converted note and Series A term sheet of $37.5 million~~

~~50:50~~As ~~weight~~if converted note and Series A term sheet of $37.5 million

Various

Convertible notes: Promaxo Inc

183,876

Market approach based on available comparables and financial performance

Conversion prospects, market yield, remaining maturity

5% yield

Convertible notes: Cyberdontics Inc

190,422

Valuation based on indicative securities transaction using a backsolve calculation to approximate value.

Market cap of $12 million on current SAFE offering applied to cap table

Various

Convertible notes: Other

3,416,294

Market approach based on available comparables and financial performance

Conversion prospects, market yield, remaining maturity

1-12% yield

Convertible notes: Promaxo Inc

185,136

Market approach based on available comparables and financial performance

Conversion prospects, market yield, remaining maturity

5% yield

Preferred stock in private companies” Shyft Moving Inc

269,820

Market approach based on indicative term sheet and last round of financing

50/50 weighting to prior A-3 preferred and indicated pre Series B price. Forecast revenue from investor deck and 75% percentile for public company peer valuation ratios

Based on Series B valuation of $80 million

Convertible notes: Other

3,909,238

Market approach based on available comparables and financial performance

Conversion prospects, market yield, remaining maturity

1-12% yield

Preferred stock in private companies: Seal Rock Therapeutics Inc

199,112

Market approach based on indicative term sheet and last round of financing

50/50 weighting to prior Series seed preferred and indicated Note price. 75% percentile for public company peer valuation ratios

Based on new Note indication of $80 million

Preferred stock in private company: Inhalon Inc

256,198

Valuation based on indicative securities transaction using a backsolve calculation to approximate value.

Market cap of $40 million on current note offering, and cap table

Various

Preferred stock in private companies: Femto DX Inc

290,046

Market approach based on indicative term sheet and last round of financing

50/50 weighting to prior Series B-2 preferred price and public market. 75% percentile for public company peer valuation ratios

Based on Series B valuation of $170 million

Preferred stock in private company: Neuroflow Inc

676,882

Valuation based on indicative securities transaction using a backsolve calculation to approximate value.

Weighting applied to $17 million valuation and 6-7x forecast revenue

Various

Preferred stock in private companies: Promaxo Inc

1,034,984

Market approach based on available comparables and financial performance

a) Last round of financing for series B-2 price, 118% change in enterprise value @75th percentile b) revenue multiples 2021 13.3X 2022 9.3x

0%-168.3% 0.6x - 27.7x 0.5x - 59.4x

Preferred stock in private company: Valfix Inc

105,607

Valuation based on indicative securities transaction using a backsolve calculation to approximate value.

Market value of $29.5 million invested capital applied to cap table

Various

Preferred stock in private companies: Other

2,744,691

Market approach based on available comparables and financial performance

Market approach based on available information from portfolio companies

Various

Preferred stock in private companies Shyft Moving Inc

269,820

Market approach based on indicative term sheet and last round of financing

50/50 weighting to prior A-3 preferred and indicated pre Series B price. Forecast revenue from investor deck and 75% percentile for public company peer valuation ratios

Based on Series B valuation of $80 million

Common stock in private companies

325,000

Market approach based on available comparables and financial performance

Historic or projected revenue and/or EBITDA multiples discounted for lack of marketability

Various

Preferred stock in private companies: Seal Rock Therapeutics Inc

199,375

Market approach based on indicative term sheet and last round of financing

50/50 weighting to prior series seed preferred and indicated note price. 75% percentile for public company peer valuation ratios

Based on new note indication of $80 million

SAFE

575,000

Market approach based on available comparables and financial performance

Precedent and follow-on transactions adjusted for marketability

Various

Preferred stock in private companies: Femto DX Inc

290,046

Market approach based on indicative term sheet and last round of financing

50/50 weighting to prior series B-2 preferred price and public market. 75% percentile for public company peer valuation ratios

Based on Series B valuation of $170 million

Other investments

571,000

Market approach based on available comparables and financial performance

Precedent and follow-on transactions adjusted for marketability

Various

Preferred stock in private companies: Promaxo Inc

1,034,684

Market approach based on available comparables and financial performance

a) Last round of financing for series B-2 price, 118% change in enterprise value at 75th percentile; b) revenue multiples 2021 13.3x 2022 9.3x

0%-168.3% 0.6x - 27.7x 0.5x - 59.4x

Total Investments

9,811,486

Preferred stock in private companies: Other

2,392,886

Market approach based on available comparables and financial performance

Market approach based on available information from portfolio companies

Various

Common stock in private companies

325,000

Market approach based on available comparables and financial performance

Historic or projected revenue and/or EBITDA multiples discounted for lack of marketability

Various

SAFE

725,000

Market approach based on available comparables and financial performance

Precedent and follow-on transactions adjusted for marketability

Various

Total Investments

10,955,274

	As of March 31, 2021
	Fair Value		Valuation Approach/ Technique	Unobservable Inputs	Range/ Weighted Average
Convertible notes: Kitotech Medical Inc	$	326,871	Market approach based on available comparables and financial performance	Market cap of $28.51 million a, Public company 75th percentile As if converted 2020 note	Range : $28.514 million
Convertible notes		2,227,083	Market approach based on available comparables and financial performance	Conversion prospects, market yield, remaining maturity	1-12% yield
Preferred stock in private companies: Femto DX Inc		159,835	Market approach based on available comparables and financial performance	Based on Series B financing and public company peer multiples using 50:50 percentile	Market value of invested capital $58.66 million
Preferred stock in private companies: Neuroflow Inc		437,495	Market approach based on available comparables and financial performance	Based on Series Seed 2 and last round of financing - Series B	Market value of invested capital $57.98 million
Preferred stock in private companies: other		2,532,128	Market approach based on available comparables and financial performance	Market approach based on available information from portfolio companies	Various
Common stock in private companies		300,000	Market approach based on available comparables and financial performance	Historic or projected revenue and/or EBITDA multiples	Various
SAFE		325,000	Market approach based on available comparables and financial performance	Precedent and follow-on transactions adjusted for marketability	Various
Other investments		421,000	Market approach based on available comparables and financial performance	Precedent and follow-on transactions adjusted for marketability	Various
Total Investments	$	6,729,412

The following table presents fair value measurements of investments, by major class, as of September 30, 2021, and March 31, 2021, according to the fair value hierarchy:

	As of March 31, 2021
	Fair Value		Valuation Approach/ Technique	Unobservable Inputs	Range/ Weighted Average

Convertible notes: Kitotech Medical Inc		326,871	Market approach based on available comparables and financial performance	Market cap of $28.51 million a public company 75th percentile as if converted 2020 note	Range : $28.514 million

Convertible notes		2,227,083	Market approach based on available comparables and financial performance	Conversion prospects, market yield, remaining maturity	1-12% yield

Preferred stock in private companies: Femto DX Inc		159,835	Market approach based on available comparables and financial performance	Based on Series B financing and public company peer multiples using 50:50 percentile	Market value of invested capital $58.66 million

Preferred stock in private companies: Neuroflow Inc		437,495	Market approach based on available comparables and financial performance	Based on Series Seed 2 and last round of financing - Series B	Market value of invested capital $57.98 million

Preferred stock in private companies: other		2,532,128	Market approach based on available comparables and financial performance	Market approach based on available information from portfolio companies	Various

Common stock in private companies		300,000	Market approach based on available comparables and financial performance	Historic or projected revenue and/or EBITDA multiples	Various

SAFE		325,000	Market approach based on available comparables and financial performance	Precedent and follow-on transactions adjusted for marketability	Various

Other investments		421,000	Market approach based on available comparables and financial performance	Precedent and follow-on transactions adjusted for marketability	Various
Total Investments		6,729,412

The following table presents fair value measurements of investments, by major class, as of December 31, 2021, and March 31, 2021, according to the fair value hierarchy:

	As of September 30, 2021
Description	(Level 1)		(Level 2)		(Level 3)		Total
	As of December 31, 2021
	Quoted prices in active markets for identical securities		Significant other observable inputs		Significant unobservable inputs
Description	(Level 1)		(Level 2)		(Level 3)		Total
Investments at Fair Value
Private Portfolio Companies
Convertible notes	$	-	$	-	$	34,~~801~~679,~~833~~776	$	34,~~801~~679,~~833~~776
Preferred stock		-		-		45,~~538~~225,~~653~~498		45,~~538~~225,~~653~~498
Common stock		-		-		325,000		325,000
SAFEs		-		-		~~575~~725,000		~~575~~725,000
Other ownership interests		-		-		571,000		571,000
		-		-		10,955,274		10,955,274
		-		-		9,811,486		9,811,486
Public Portfolio Companies
Common stock		~~631~~630,~~327~~237		-		-		~~631~~630,~~327~~237
Total Investments at Fair value	$	~~631~~630,~~327~~237	$	-	$	910,~~811~~955,~~486~~274	$	1011,~~442~~585,~~813~~511

	As of March 31, 2021
Description	Level 1		Level 2		Level 3		Total
March 31, 2021
Investments at Fair Value
Private Portfolio Companies
Convertible notes	$	-	$	-	$	2,553,954	$	2,553,954
Preferred stock		-		-		3,129,458		3,129,458
Common stock		-		-		300,000		300,000
SAFEs		-		-		325,000		325,000
Other ownership interests		-		-		421,000		421,000
		-		-		6,729,412		6,729,412
Public Portfolio Companies
Common stock		91,995		-		-		91,995
Total Investments at Fair value	$	91,995	$	-	$	6,729,412	$	6,821,407

All investments were treated as Level 3 at December 31, 2021 with the exception of four companies, two of which are invested in common stock of the public companies and treated as Level 1 and two of which valued at net asset value (NAV) as practical expedient and valued at $571,000.

As of September 30, 2021, and March 31, 2021, all our investments were treated as Level 3 with the exception of two which are invested in common stock of a public company and treated as Level 1.

We focus on making our investments in the United States, Canada, and Israel. All investments are made and reported in U.S. dollars. Assets that are denominated in foreign currencies are translated into U.S. dollars at closing rates of exchange on the date of valuation. Transactions during the year are translated at the rate of exchange prevailing on the date of the transaction. The Company does not isolate that portion of results of operations resulting from the changes in foreign exchange rates on securities from fluctuations resulting from changes in market prices of such securities. Such foreign currency translation gains and losses are included in the net realized gains or losses from investments and net changes in unrealized gain or losses from investments on the statement of operations.

Description	(Level 1)		(Level 2)		(Level 3)		Total
	As of March 31, 2021
Description	Level 1		Level 2		Level 3		Total
March 31, 2021
Investments at Fair Value
Private Portfolio Companies
Convertible notes	$	-	$	-	$	2,553,954	$	2,553,954
Preferred stock		-		-		3,129,458		3,129,458
Common stock		-		-		300,000		300,000
SAFEs		-		-		325,000		325,000
Other ownership interests		-		-		421,000		421,000
		-		-		6,729,412		6,729,412

Public Portfolio Companies
Common stock		91,995		-		-		91,995

Total Investments at Fair value	$	91,995	$	-	$	6,729,412	$	6,821,407

	America			Canada		Rest of World		Total
Fair value beginning of year March 31, 2021	$	5,486,011		$	907,560	$	427,836	$	6,821,407
New investments		12,~~668~~653,~~091~~478			~~200~~225,000		~~350~~450,000		23,~~218~~328,~~091~~478
Proceeds from sale of investments		-(88,554	)		-		-		-(88,554	)
Realized gains		-			-		-		-
Net change in unrealized gains included in condensed Statements of Operations		1,833,616			117,531		144,033		2,095,180
Net change in unrealized gains included in condensed Statements of Operations		1,360,028			29,556		13,731		1,403,315
Fair value end of nine months December 31, 2021	$	9,884,551		$	1,250,091	$	1,021,869	$	12,156,511
Fair value end of six months September 30, 2021	$	8,514,130		$	1,137,116	$	791,567	$	10,442,813
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.								$	2,095,180
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.								$	1,403,315

	America		Canada		Rest of World		Total
Fair value beginning of year March 31, 2020	$	2,170,499	$	245,000	$	250,000	$	2,665,499
New investments		~~540~~1,935,000		~~150~~425,000		50,000		~~740~~2,410,000
Proceeds from sale of investments		-		-		-		-
Net change in unrealized gains included in condensed Statements of Operations		656,188		129,374		21,381		806,943
Realized gains		-		-		-		-
Fair value end of nine months December 31, 2020	$	4,761,687	$	799,374	$	321,381	$	5,882,442
Net change in unrealized gains included in condensed Statements of Operations		438,953		21,947		17,348		478,248
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.							$	806,943
Fair value end of six months September 30, 2020	$	3,149,452	$	416,947	$	317,348	$	3,883,747
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.							$	478,248

Working on the experience of our technical advisors, we limit our investments to fintech, technology, and life sciences.

	Fintech		Technology		Life science		Total
Fair value beginning of year March 31, 2021	$	126,030	$	1,394,318	$	5,301,059	$	6,821,407
New investments		-		590,600		1,627,491		2,218,091
Proceeds from sale of investments		-		-		-		-
Realized gains		-		-		-		-
Net change in unrealized gains included in condensed Statements of Operations		-		45,531		1,357,784		1,403,315
Fair value end of six months September 30, 2021	$	126,030	$	2,030,449	$	8,286,334	$	10,442,813
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.							$	1,403,315

	Fintech		Technology		Life science		Total
Fair value beginning of year March 31, 2020	$	101,500	$	685,002	$	1,878,997	$	2,665,499
New investments		-		-		740,000		740,000
Proceeds from sale of investments		-		-		-		-
Realized gains		-		-		-		-
Net change in unrealized gains included in condensed Statements of Operations		24,530		37,769		415,949		478,248
Fair value end of six months September 30, 2020	$	126,030	$	722,771	$	3,034,946	$	3,883,747
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.							$	478,248

WeWorking ~~invest~~on ~~in early-stage private companies developing products or solutions in~~ the ~~fields~~experience of fintech, technology and life sciences. Typically, we are investing in interest bearing notes that may be convertible into equity securities upon the completion of qualified subsequent financings, preferred stock, SAFEs or other forms of ownership. Typically notes carry a two-year term and are then rolled over for additional periods if no other maturity triggers have been achieved. If a convertible note investment were, in our ~~judgment,~~technical ~~to become impaired~~advisors, we ~~would reverse the accrued interest and adjust the valuation to reflect management’s assessment of fair value. If a convertible note investment exceeds its maturity date~~ we ~~would~~limit ~~request~~our ~~the~~investments ~~portfolio company~~ to ~~document an extension~~fintech, ~~as well as consider whether the overdue note~~technology, ~~along with all other available performance data~~ and ~~management~~life ~~reviews lead us to consider whether there should be an adjustment in fair value of the investment~~sciences. ~~There were no transfers into or out of Level 3 during the three and six months ended September 30, 2021 and September 30, 2020.~~

	Fintech		Technology		Life science			Total
Fair value beginning of year March 31, 2021	$	126,030	$	1,394,318	$	5,301,059		$	6,821,407
New investments		-		815,600		2,512,878			3,328,478
Proceeds from sale of investments		-		-		(88,554	)		(88,554	)
Net change in unrealized gains included in condensed Statements of Operations		-		61,179		2,034,001			2,095,180
Fair value end of nine months December 31, 2021	$	126,030	$	2,271,097	$	9,759,384		$	12,156,511
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.								$	2,095,180

	Fintech		Technology		Life science		Total
Fair value beginning of year March 31, 2020	$	101,500	$	685,002	$	1,878,997	$	2,665,499
Fair value beginning	$	101,500	$	685,002	$	1,878,997	$	2,665,499
New investments		-		325,000		2,085,000		2,410,000
Net change in unrealized gains included in condensed Statements of Operations		24,530		74,158		708,255		806,943
Fair value end of nine months December 31, 2020	$	126,030	$	1,084,160	$	4,672,252	$	5,882,442
Fair value ending	$	126,030	$	1,084,160	$	4,672,252	$	5,882,442
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period.							$	806,943

We invest in early-stage private companies developing products or solutions in the fields of fintech, technology and life sciences. Typically, we are investing in interest bearing notes that may be convertible into equity securities upon the completion of qualified subsequent financings, preferred stock, SAFEs or other forms of ownership. Typically notes carry a two-year term and are then rolled over for additional periods if no other maturity triggers have been achieved. If a convertible note investment were, in our judgment, to become impaired, we would reverse the accrued interest and adjust the valuation to reflect management’s assessment of fair value. If a convertible note investment exceeds its maturity date we would request the portfolio company to document an extension, as well as consider whether the overdue note, along with all other available performance data and management reviews lead us to consider whether there should be an adjustment in fair value of the investment. There were no transfers into or out of Level 3 during the three and nine months ended December 31, 2021 and December 31, 2020.

	Convertible notes			Preferred stock		Common stock		SAFEs		Other ownership interests		Total
Fair value March 31, 2021	$	2,553,954		$	3,129,458	$	391,995	$	325,000	$	421,000	$	6,821,407
Conversions into preferred stock		-			-		-		-		-		-
New investments		1,~~027~~752,491			~~600~~835,~~000~~387		190,600		~~250~~400,000		150,000		23,~~218~~328,~~091~~478
Proceeds from sale of investments		-(88,554	)		-		-		-		-		-(88,554	)
Realized gains		-			-		-		-		-		-
Unrealized gains included in condensed Statements of Operations		461,885			1,260,653		372,642		-		-		2,095,180
Unrealized gains included in condensed Statements of Operations		220,388			809,195		373,732		-		-		1,403,315
Fair value December 31, 2021	$	4,679,776		$	5,225,498	$	955,237	$	725,000	$	571,000	$	12,156,511
Fair value September 30, 2021	$	3,801,833		$	4,538,653	$	956,327	$	575,000	$	571,000	$	10,442,813

	Convertible notes			Preferred stock		Common stock			SAFEs			Other ownership interests		Total
Fair value March 31, 2020	$	1,528,002		$	701,497	$	126,500		$	73,500		$	236,000	$	2,665,499
Fair value, beginning	$	1,528,002		$	701,497	$	126,500		$	73,500		$	236,000	$	2,665,499
Conversions into preferred stock		(597,984	)		678,313		-			(80,329	)		-		-
New investments		~~100~~935,000			~~440~~1,025,000		~~100~~200,000			-150,000			100,000		~~740~~2,410,000
Proceeds from sale of investments		-			-		-			-			-		-
Unrealized gains included in condensed Statements of Operations		556,954			67,665		65,495			81,829			35,000		806,943
Realized gains		-			-		-			-			-		-
Fair value December 31, 2020	$	2,421,972		$	2,472,475	$	391,995		$	225,000		$	371,000	$	5,882,442
Unrealized gains included in condensed Statements of Operations		178,986			279,433		(62,000	)		81,829			-		478,248
Fair value, ending	$	2,421,972		$	2,472,475	$	391,995		$	225,000		$	371,000	$	5,882,442
Fair value September 30, 2020	$	1,209,004		$	2,099,243	$	164,500		$	75,000		$	336,000	$	3,883,747

NOTE 6– EQUITY

(A) PREFERRED STOCK

Series A

The Company has sold 4,200,000 Series A Stock Units (“Units”) consisting of one share of Series A Preferred Stock and one warrant to purchase a share of Common Stock at $0.80 per share. The Units were sold in a private placement to accredited investors. The Series A Preferred Stock will be converted into shares of Common Stock upon listing of the Company on Nasdaq or NYSE. In the event of any liquidation or winding up of the Company, the holders of the Series A shall be entitled to receive in preference to the holders of shares of Common Stock a per share amount equal to two times (2 X) their original purchase price plus any declared but unpaid dividends (the Liquidation Preference). All share issuances and obligations are recognized on the books and stock register.

On March 2, 2021, in preparation for an intended IPO, the Company made an offer to all its preferred shareholders to protect them against the possibility that the IPO price might be less than their preferred stock price. Accordingly, Series A-1 and Series A-2 Preferred Stock were created, and the holders of Series A Preferred Stock were granted an opportunity to purchase shares of Common Stock at $0.40 per share. If shareholders purchased at least $6,000 of Common Stock, their shares of Series A Preferred Stock were exchanged for Series A-1 which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and if shareholders purchased a pro-rated amount of Common Stock their Series A Preferred Stock were exchanged for Series A-2 Preferred Stock which in turn is convertible into shares of Common Stock at a discount of 10% to the IPO price. In all other respects the Series A-1 and Series A-2 Preferred Stock has the same rights and obligations as the Series A Preferred Stock. As of September 30, 2021, 1,437,500 shares of Series A Preferred Stock had been exchanged for Series A-1 Preferred Stock, and 2,212,500 shares of Series A Preferred Stock had been exchanged for Series A-2 Preferred Stock, respectively, leaving outstanding 550,000 shares of Series A Preferred Stock (“Series A”) designated at a par value of $0.01 per share.

~~Series~~NOTE B6 – EQUITY

There were also 6,000,000 shares of Series B Preferred Stock (“Series B”) authorized designated at a par value of $0.01 per share. The Series B can be converted into shares of Common Stock upon listing of the Company on Nasdaq. In the event of any liquidation or winding up of the Company, the holders of the Series B shall be entitled to receive in preference to the holders of Common Shares and Series A ~~Preferred Stock, a per share amount equal to two times (2 X~~) ~~their original purchase price plus any declared but unpaid dividends (the~~ ~~Liquidation~~PREFERRED Preference). The holders of Series B shall be entitled to receive out of any funds of the Corporation at a time legally available for the declaration of dividends, dividends at a cumulative rate of 10% under such terms and conditions as the Board shall prescribe, provided, however, that in the event dividends shall be declared, dividends on issued and outstanding Series B shall be payable before any dividends shall be declared or paid upon or set apart for the Common Stock.STOCK

OnClass ~~March~~A 2, 2021, in preparation for an intended future IPO, the Company made an offer to all its preferred shareholders to protect them against the possibility that the IPO price might be less than their preferred stock price. Accordingly, Series B-1 and Series B-2 Preferred Stock (“Series B-1” and “Series B-2”, respectively) were created, and the holders of the Series B were granted an opportunity to purchase shares of Common Stock at $0.40 per share. If shareholders purchased at least $6,000 of Common Stock, their Series B were exchanged for Series B-1 which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and if shareholders purchased a pro-rated amount of Common Stock their Series B were exchanged for Series B-2 which converts into shares of Common Stock at a discount of 10% to the IPO price. In all other respects, the Series B-1 and Series B-2 have the same rights and obligations as the Series B. At September 30, 2021, 1,166,406 shares of Series B had been exchanged for Series B-1, and 2,176,250 shares of Series B had been exchanged for Series B-2, respectively, leaving outstanding 286,250 shares of Series B. During the three and six months ended September 30, 2021, the Company sold 1,591,250 and 2,282,500 shares of Series B-1 Preferred Stock for $1,273,000 and $1,826,001, respectively.

AsThe ~~of September 30, 2021, the~~ Company ~~authorized~~has ansold ~~additional 3~~4,~~000~~200,000 Class ~~shares~~A ofStock ~~Series~~Units B(“Units”) ~~stock~~consisting ~~designated~~of asone ~~Series~~share ~~B-3~~of Class A Preferred Stock (“~~Series B-3~~Class A”) ~~bringing~~designated ~~Series~~at ~~B to~~ a par ~~total~~value of ~~9,000,000~~$0.01 per ~~authorized~~share ~~shares~~and ~~with~~one awarrant ~~par~~to ~~value~~purchase a share of Common Stock at $0.01 80 per share. The ~~Certificate~~Units ofwere ~~Designation of~~sold ~~the~~in ~~Series~~a ~~B-3~~private ~~shares~~placement ~~was~~to ~~filed~~accredited ~~with~~investors. ~~the~~The ~~Delaware~~Class ~~Secretary~~A will be converted into shares of ~~State~~Common Stock upon listing of the Company on ~~October~~Nasdaq 5,or ~~2021~~NYSE. ~~The~~In ~~Series~~the ~~B-3~~event ~~will~~of beany ~~offered~~liquidation ~~for~~or ~~$0.80 per~~winding ~~share~~up ~~and~~of ~~accrue~~the aCompany, ~~cumulative~~the ~~dividend~~holders of the ~~10%~~Class ~~per~~A ~~annum.~~shall ~~The~~be ~~remaining~~entitled ~~terms~~to ~~and~~receive ~~conditions~~in ~~are~~preference ~~substantially~~to the ~~same~~holders asof ~~for~~shares ~~all other~~of ~~Series~~Common BStock ~~shares,~~a ~~including~~per ~~mandatory~~share ~~conversion~~amount ~~upon~~equal ato ~~majority~~two times ~~vote~~(2x) oftheir ~~the~~original ~~Series~~purchase ~~B-3~~price ~~shareholders,~~plus ~~closing~~any ofdeclared abut ~~qualified~~unpaid ~~financing of~~dividends. atAll ~~least~~share ~~$10~~issuances ~~million,~~and orobligations ~~listing~~are recognized on athe ~~public~~books and stock ~~exchange~~register.

B)On ~~COMMON~~March ~~STOCK~~2, 2021, in preparation for an intended IPO, the Company made an offer to all its preferred stockholders to protect them against the possibility that the IPO price might be less than their preferred stock price. Accordingly, Class A-1 Preferred Stock and Class A-2 Preferred Stock were created, and the holders of Class A were granted an opportunity to purchase shares of Common Stock at $0.40 per share. If Class A stockholders purchased at least $6,000 of Common Stock, their shares of Class A Preferred Stock were exchanged for shares of Class A-1 Preferred Stock which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and if stockholders purchased a pro-rated amount of Common Stock, their shares of Class A Preferred Stock were exchanged for Class A-2 Preferred Stock which in turn is convertible into shares of Common Stock at a discount of 10% to the IPO price. In all other respects the Class A-1 Preferred Stock and Class A-2 Preferred Stock have the same rights and obligations as the Class A Preferred Stock. As of December 31, 2021, 1,437,500 shares of Class A Preferred Stock had been exchanged for Class A-1 Preferred Stock, and 2,212,500 shares of Class A Preferred Stock had been exchanged for Class A-2 Preferred Stock, respectively, leaving outstanding 550,000 shares of Class A.

~~The~~Class Company has authorized 40,000,000 shares of common stock at a par value of $0.01 per share. As of September 30, 2021, and March 31, 2021 a total of 13,287,621 and 9,983,082 shares of the Company’s common stock were issued and outstanding, respectively.B

~~During~~There ~~the~~are ~~three~~9,000,000 shares ~~and~~of ~~six~~Class ~~months~~B ~~ended~~Preferred ~~September~~Stock 30(“Class B”) authorized designated at a par value of $0.01 per share. This designation includes Classes B, ~~2021~~B-1, B-2, inand ~~connection~~B-3. ~~with~~The ~~the~~Class ~~amendment~~B will be converted into shares of ~~Preferred~~Common Stock ~~rights~~upon ~~described~~listing inof Athe ~~above,~~Company on Nasdaq or NYSE. In the event ~~Company~~of ~~sold~~any 3liquidation or winding up of the Company,~~285,789~~ ~~shares~~the holders of the Class B shall be entitled to receive in preference to the holders of Common ~~Stock~~Shares ~~for~~and $1Class A Preferred Stock,~~314,317~~ a per share amount equal to one times (1x) their original purchase price plus any declared but unpaid dividends. The holders of ~~which~~Class ~~$1,191,442~~B ~~was~~shall ~~received~~be ~~and~~entitled ~~accrued~~to asreceive ~~subscription~~dividends ~~liability~~either atfirst or simultaneously with dividends declared, ~~March~~set 31apart or paid, ~~2021~~on Junior Stock.

~~During~~On ~~each~~March of2, 2021, in preparation for an intended future IPO, the ~~three~~Company made an offer to all its preferred stockholders to protect them against the possibility that the IPO price might be less than their preferred stock price. Accordingly, Class B-1 and ~~six~~Class ~~months~~B-2 ~~ended~~Preferred Stock ~~September~~(“Class 30B-1” and “Class B-2”, ~~2021~~respectively) were created, and the ~~Company~~holders ~~issued~~of 18the Class B were granted an opportunity to purchase shares of Common Stock at $0.40 per share. If stockholders purchased at least $6,~~750~~000 of Common Stock, their Class B were exchanged for Class B-1 which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and if stockholders purchased a pro-rated amount of Common Stock their Class B were exchanged for ~~$618~~Class B-2 which converts into shares of Common Stock at a discount of 10% to the IPO price. The Class B-1 and B-2 accrue a dividend of 10% per annum payable only in the event of an IPO or liquidation event in common stock assuming it was first converted into B-1 or B-2 as the case may be at the Original Issue Price. In all other respects, the Class B-1 and Class B-2 have the same rights and obligations as the Class B. At December 31, 2021, 1,166,406 shares of Class B had been exchanged for Class B-1, and 2,176,250 shares of Class B had been exchanged for Class B-2, respectively, inleaving ~~connection~~outstanding ~~with~~286,250 shares of Class B. During the ~~exercise~~three and nine month periods ended December 31, 2021, the Company sold 2,176,250 and 4,458,750 shares of ~~stock~~Class ~~options~~B-1 Preferred Stock for $1,741,000 and $3,567,001, respectively.

As of December 31, 2021, the Company authorized 3,000,000 shares of Class B-3 Preferred (“Class B-3”). The Certificate of Designation of the Class B-3 shares was filed with the Delaware Secretary of State on October 5, 2021. The Class B-3 will be offered for $0.80 per share and have a cumulative dividend of 10% per annum payable only when as and if declared by the Board. The remaining terms and conditions are substantially the same as for all other Class B shares, including mandatory conversion upon a majority vote of the Class B-3 stockholders, closing of a qualified financing of at least $10 million, or listing on NYSE or NASDAQ. As of the date of this filing, the board of directors has not declared any dividends.

B) COMMON STOCK

The Company has authorized 40,000,000 shares of common stock at a par value of $0.01 per share. As of December 31, 2021, and March 31, 2021 a total of 13,287,621 and 9,983,082 shares of the Company’s common stock were issued and outstanding, respectively.

During the three and nine month periods ended December 31, 2021, in connection with the amendment of Preferred Stock rights described in A) Preferred Stock above, the Company had sold zero and 3,285,789 shares of Common Stock for $0 and $1,314,317, of which $1,191,442 was received and accrued as subscription liability at March 31, 2021.

During each of the three and nine month periods ended December 31, 2021, the Company issued zero and 18,750 shares of Common Stock for $0 and $618, respectively, in connection with the exercise of stock options.

C) STOCK OPTIONS

In April 2018, the Board approved the introduction of the Kyto Technology and Life Science, Inc. Incentive Stock Option Plan (“the 2018 Plan”) reserving 2,697,085 shares for issuance to employees, consultants and directors, with the objective of securing the benefit of services for stock options rather than cash salaries.

In July 2019, the Board approved the introduction of the Kyto Technology and Life Science 2019 Stock Option and Incentive Plan (“2019 Plan”), and reserved 2 million shares for issuance to directors, officers, consultants, and advisors. Options granted under the 2019 Plan expire May 21, 2029.

In December 2020, the Board approved the ~~introduction of the~~ Kyto Technology and Life Science 2020 Non Qualified Stock Option Plan (“2020 Plan”), and reserved 2 million shares for issuance to directors, officers, consultants and advisors. Options granted under the 2020 Plan expire December 16, 2030. On December 20, 2021, the Board approved the creation of the 2021 Stock and Incentive Plan and reserved 2,000,000 shares of common stock as a pool for the grant of stock options.

During the three months ended ~~September~~December 3031, 2021, and ~~September~~December 3031, 2020, the Company issued a total of ~~490~~750,000 and ~~510~~217,~~000~~ 500 non-qualified stock options, respectively, to consultants and advisors vesting over terms of two years. During the corresponding ~~six~~nine months ended ~~September 30~~December 31, 2021, and ~~September 30~~December 31, 2020, the Company issued a total of ~~740~~2,290,000 and ~~630~~847,~~000~~ 500 non-qualified stock options, respectively.

SCHEDULE OF OPTIONS VESTED

	Number of options granted			Weighted average exercise price			Weighted average remaining life years
Outstanding March 31, 2021		2,634,250		$	0.05			8.13
Granted		~~740~~2,290,000			0.07			9.4267
Exercised		(18,750	)		(0.03	)		-
Cancelled		-			-			-
Outstanding September 30, 2021		3,355,500		$	0.06			8.63
Outstanding December 31, 2021		4,905,500		$	0.06			8.71
Exercisable September 30, 2021		2,085,041		$	0.04			8.90
Exercisable December 31, 2021		2,791,705		$	0.05			8.90

In connection with the grant of stock options the Company recognizes the value of the related option expense using the Black Scholes model, with appropriate assumptions for option life, stock value, risk free interest rate, volatility, and cancellations.

	September 30, 2021			March 31, 2021
	December 31, 2021			March 31, 2021
Stock Price at grant date	$	0.07		$	$0.033 - $ 0.078
Exercise Price	$	0.07		$	$0.033 - $ 0.078
Term in Years		0 - 2.00			0 - 2.00
Volatility assumed		196	%		71% - 196%	%
Annual dividend rate		0.0	%		0.0	%
Risk free discount rate		0.12	%		0.12% - 2.0%	%

The compensation expense calculated at time of grant is recognized over the vesting period for the options granted. During the three and ~~six~~nine months ended ~~September~~December 3031, 2021, the Company recognized $1032,~~897~~ 579 and $2154,~~454,~~ 033 respectively, as stock-based compensation expense. For the corresponding three and ~~six~~nine months ended ~~September~~December 3031, 2020, the Company recognized $123,~~805~~474 and $1317,~~851~~326, respectively.

The intrinsic value of outstanding options at ~~September~~December 3031, 2021 was $62,580, and $56,987 of the option expense upon grant remained ~~unrecognized~~ unrecognized at ~~September~~December 3031, 2021 with a remaining vesting period of 1.44 13 years.

D) WARRANTS

In conjunction with the sale of ~~Series~~Class A Stock Units, the Company issued 4,200,000 warrants to purchase common stock at a price of $1.20 per share for a period of three years. The Company did not bifurcate the value of the warrants as the fair value of the warrant was determined to be de minimis. The Company has not issued any warrants since September, 2019. At ~~September~~December 3031, 2021 and March 31, 2021 the fair value of the warrants was de minimis.

SCHEDULE OF WARRANTS

	Number of warrants			Weighted average exercise price		Weighted average remaining life in years
Outstanding March 31, 2020		4,200,000		$	1.20		2.9
Granted		-			-		-
Exercised		(2,603,333	)	$	10.2060		-
Cancelled		-			-		-
Outstanding September 30, 2020		1,596,667		$	1.20		1.4
Outstanding December 31, 2020		1,596,667		$	1.20		2.2
Exercisable March 31, 2020		4,200,000		$	1.20		2.9
Exercisable September 30, 2020		1,596,667		$	1.20		1.4
Exercisable December 31, 2020		1,596,667		$	1.20		1.4

	Number of warrants		Weighted average exercise price		Weighted average remaining life in years
Outstanding March 31, 2021		1,596,667	$	1.20		1.4
Granted		-				-
Exercised		-				-
Cancelled		-				-
Outstanding September 30, 2021		1,596,667	$	1.20		1.1
Exercisable March 31, 2021		1,596,667	$	1.20		1.4
Exercisable September 30, 2021		1,596,667	$	1.20		1.1

	Number of warrants		Weighted average exercise price		Weighted average remaining life in years
Outstanding March 31, 2021		1,596,667	$	1.20		1.4
Granted		-		-		-
Exercised		-		-		-
Cancelled		-		-		-
Outstanding December 31, 2021		1,596,667	$	1.20		0.6

Exercisable March 31, 2021		1,596,667	$	1.20		1.4
Exercisable December 31, 2021		1,596,667	$	1.20		0.6

The Company values the warrants using the Black Scholes model, with appropriate assumptions for warrant life, stock value, risk free interest rate, and volatility. The assumptions used for warrant valuation were as follows:

	December 31, 2021
Stock Price at grant date	$	0.006
Exercise Price	$	1.200
Term in Years		3~~.00~~
Volatility assumed		73	%
Annual dividend rate		0.0	%
Risk free discount rate		1.79	%

NOTE 7 – FINANCIAL HIGHLIGHTS

SCHEDULE OF FINANCIAL HIGHLIGHTS

Per share data ( a)	Three months ended			Three months ended			Six months ended			Six months ended
Per share data (a)	Three months ended December 31, 2021			Three months ended December 31, 2020			Nine months ended December 31, 2021			Nine months ended December 31, 2020
	September 30, 2021			September 30, 2020			September 30, 2021			September 30, 2020
Net asset value	$	0.97		$	0.75		$	0.97		$	0.95
Net asset value	$	0.82		$	0.72		$	0.82		$	0.72
Net investment loss	$	(0.03	)	$	(0.04	)	$	(0.08	)	$	(0.08	)
Net investment loss	$	(0.03	)	$	(0.03	)	$	(0.06	)	$	(0.03	)
Net unrealized gain on investments	$	0.05		$	0.04		$	0.16		$	0.12
Net unrealized gain on investments	$	0.10		$	0.05		$	0.11		$	0.08
Net increase in net assets	$	0.02		$	-		$	0.07		$	0.04
Net increase in net assets	$	0.08		$	0.05		$	0.05		$	0.05
Ratios and Supplemental Data
Net assets, end of period	$	1012,~~817~~911,~~894~~623		$	46,~~230~~399,~~731~~543		$	1012,~~817~~911,~~894~~623		$	46,~~230~~399,~~731~~543
Weighted average common shares outstanding, end of period		13,~~271~~287,~~996~~621			58,~~836~~528,~~832~~007			13,~~269~~273,~~764~~038			56,~~836~~737,~~832~~152
Total operating expenses/net assets		32.39	%		35.82	%		6.8.6	%		48.73	%
Net investment loss/net assets		3(2.39	)%		3(5.82	)%		6.(8.6	)%		4(8.73	)%
Total return		9.2.5	%		7(0.51	)%		67.16	%		64.63	%

(a)

Per share data is based on the weighted average number of common shares outstanding at the end of the period.

NOTE 8 - SUBSEQUENT EVENTS

OnSubsequent ~~October~~to 5February 21, 2021, the Company ~~filed~~has acollected ~~Form~~more ~~8-K~~than ~~announcing the Designation of 3~~$800,000~~,000~~ from ~~million~~the ~~shares~~sale of ~~B-3~~stock ~~Preferred~~since ~~Stock.~~December ~~As of November 13~~31, 2021, ~~the Company has sold $546,000 of shares of Series B-3 Preferred Stock~~ and ~~invested~~spent $~~300~~400,000 ~~in three follow-~~ on new investments.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

PLAN OF OPERATIONS

The Company was originally formed to acquire and develop proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases and had been evaluating a number of strategies. ~~As of March 31, 2018, the Company had accumulated a deficit of $32,380,746 from all prior operations.~~ In April 2018, the Board adopted a new business plan focused on the development of early-stage technology and life science businesses through early stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, sophisticated early stage investors and successful entrepreneurs with experience across a number of technology and life science products and markets, and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment groups and other sophisticated investors and participates only after these groups have completed due diligence and committed to invest, in effect becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors. ~~The~~ The Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally, it is expected that investments will be realized from an exit within a period of four to five years following initial investment. Such exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions or an initial public offering (“IPO”) which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. Other than making its initial and, potentially, follow-on investments in its portfolio companies, the Company does not provide any financial support to any of its investees.

28The Company has one regular employee – the CEO, Mr, Paul Russo. Prior to December 31, 2020, he was acting as a consultant to the Company and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged as an employee of the Company at a salary of $400,000 per annum of which $100,000 and $300,000 was earned in the three months and nine months ended December 31, 2021, respectively, of which a balance of $80,000 was deferred at December 31, 2021. No consulting fees and no options were granted to him during these periods. During the three months and nine months ended December 31, 2020, Mr. Russo received no payroll or consulting fees, however in the three and nine months ended December 31, 2020, he received a bonus of $50,000 and was granted options to purchase 215,000 shares of Common stock.

The Company has one regular employee – the CEO, Mr, Paul Russo. Prior to December 31, 2020, was acting as a consultant to the Company and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged as an employee of the Company at a salary of $400,000 per annum of which 60% was paid monthly from January through April 2021, and 75% was paid in subsequent months, with the balance deferred to be paid once the Company lists and starts trading on the Nasdaq exchange. The full terms of Mr. Russo’s employment are described in a Form 8-K on February 1, 2021, incorporated by reference herein, which was approved by the Compensation committee of the Board of Directors on that date. During the three months ended September 30, 2021, Mr. Russo received $80,000 gross pay, no consulting fees and no options were granted. During the three months ended September 30, 2020, Mr. Russo received no payroll or consulting fees, and no options were granted to him.29

The Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of ~~the~~December ~~date~~31, ~~of this filing~~2021, the Company had approximately $~~485~~600,000 of cash to cover its operating expenses, and new investment requirements, and is continuing to to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ~~ongoing~~ ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on ~~attractive~~ attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment companies report delays in their programs.

At March 31, 2020, management determined that the Company was an investment company for purposes of ASC 946 disclosure, and committed to follow the specialized accounting and reporting guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”) was incorporated in Delaware in December 2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021 for review by the SEC. KI is an internally managed, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Immediately upon effectiveness of this N-2 Registration Statement, the Company will merge with KI and the Company will be the surviving entity. As of the completion of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the Securities Act and may continue the current offering by filing post-effective amendments to the Registration Statements. Prior to the merger, the Company had fewer than 100 non-affiliated investors and filed under the 1934 Act relying on exemption Rule 3( c )(1).

Results of Operations

Revenue: In the three months and ~~six~~nine months ended ~~September~~December 3031, 2021 the Company reported no realized investment income as there were no liquidity events related to its investment portfolio. The Company reported $1691,~~350,449~~864 and $12,~~403~~095,~~415~~180 of net change in unrealized gains from investments respectively, in these periods. In the three months and ~~six~~nine months ended ~~September~~December 3031, 2020 the Company reported no realized investment income as there were no liquidity events related to its investment portfolio. The Company reported $~~478~~328,~~248~~694 and $806,942 of net change in unrealized gains from investments respectively, in these same periods.

Professional fees: In the three months and nine months ended December 31, 2021, the Company reported $98,241 and $371,600, respectively, of professional fees, mainly for legal and accounting services. In the corresponding three months and nine months ended December 31, 2020 the Company reported $91,669 and $168,212, respectively.

~~Professional~~Other ~~fees~~operating expenses: Other operating expenses include payroll, consulting, and travel and conference fees associated with raising capital and review of investment deal-flow. In the three months and ~~six~~nine months ended ~~September~~December 3031, 2021, the Company ~~reported~~incurred other operating expenses of $~~107~~273,~~201~~473 and $~~273~~741,~~359~~089, respectively~~, of professional fees, mainly for legal and accounting services~~. In the corresponding three months and ~~six~~nine months ended ~~September~~December 3031, 2020, the Company ~~reported~~incurred other operating expenses of $63241,~~605~~047 and $76363,~~543~~983, respectively.

29For the three months and nine months ended December 31, 2021, the Company’s net increase in net assets resulting from operations was $188,151 and $499,798, respectively. For the corresponding three months and nine months ended December 31, 2020, the Company’s net increase (decrease) in net assets resulting from operations was ($4,017) and $275,252, respectively.

Other Operating expenses: Other operating expenses include payroll, consulting, and travel and conference fees associated with raising capital and review of investment deal-flow. In the three months and six months ended September 30, 2021, the Company incurred other operating expenses of $245,519 and $466,127, respectively. In the corresponding three months and six months ended September 30, 2020, the Company incurred other operating expenses of $96,506 and $122,936, respectively.

~~For~~During the three ~~months~~ and ~~six~~nine months ended ~~September~~December 3031, 2021, the Company’s ~~net~~was ~~increase~~subject to shelter in ~~net~~place ~~assets~~regulations ~~resulting~~imposed ~~from~~by ~~operations~~the ~~was~~State of California ~~$996,133~~in mitigation of the spread of the Corona 19 virus. Since the Company does not have any dedicated office space and ~~$662~~works virtually from the homes of its officers,~~341,~~ ~~respectively~~there was no major disruption in working routines which continued by video and teleconference. ~~For~~Uncertainty arising from Covid 19 created a slow-down in the ~~corresponding~~rate ~~three~~at ~~months~~which ~~and~~the ~~six~~Company ~~months~~was ~~ended~~able ~~September~~to 30raise Class B funding, ~~2020~~and thereby continue to make investments, however the Company’s did see a reduction in travel and investor relations expenses during the period. The Company has ~~net~~more ~~increase~~than 60 discrete investments in ~~net~~a ~~assets~~range ~~resulting~~of ~~from~~different ~~operations~~industry ~~was~~and ~~$318~~geographic segments,~~137~~ many of which are in the life science and medical ~~$279~~space. While there is clearly a risk that our portfolio companies may be adversely affected in their ability to raise future funding or do business,~~269,~~ ~~respectively~~there have been no management reports revealing major problems and some of our portfolio companies may actually benefit from new opportunities created. We believe that our policy of spreading our investments in relatively small amounts over a large number of portfolio companies helps mitigate some of the risk that might be suffered by any of our investments.

~~During the three months ended September 30~~Liquidity, ~~2021, the Company was subject to shelter in place regulations imposed by the State of California~~ inCapital ~~mitigation~~Resources ~~of the spread of the Corona 19 virus. Since the Company does not have any dedicated office space~~ and ~~works~~Going virtually from the homes of its officers, there was no major disruption in working routines which continued by video and teleconference. Uncertainty arising from Covid 19 created a slow-down in the rate at which the Company was able to raise Series B funding, and thereby continue to make investments, however the Company did see a reduction in travel and investor relations expenses during the period. The Company has more than 60 discrete investments in a range of different industry and geographic segments, many of which are in the life science and medical space. While there is clearly a risk that our portfolio companies may be adversely affected in their ability to raise future funding or do business, there have been no management reports revealing major problems and some of our portfolio companies may actually benefit from new opportunities created. We believe that our policy of spreading our investments in relatively small amounts over a large number of portfolio companies helps mitigate some of the risk that might be suffered by any of our investments.Concern

~~Liquidity~~The Company had net assets of $12,911,623 and ~~Capital~~$6,993,163 ~~Resources~~at December 31, 2021 and March 31, 2021, respectively. Cash was $608,223 and $1,437,868 at December 31, 2021 and March 31, 2021, respectively.

The Company’s ~~had~~condensed ~~net~~interim ~~assets~~financial ofstatements ~~$10,817,894~~are ~~and~~prepared $6in accordance with U.S. GAAP,~~993,163~~ atwhich ~~September~~requires 30the use of estimates, ~~2021~~assumptions and ~~March~~the ~~31,~~exercise ~~2021,~~of ~~respectively~~subjective judgment as to future uncertainties. ~~Cash~~Actual ~~was~~results ~~$316,124~~could ~~and~~differ $1from those estimates,~~437~~ assumptions,~~868 at~~ ~~September~~and 30judgments. Significant items subject to such estimates will include determining the fair value of investments, ~~2021~~revenue ~~and~~recognition, ~~March~~income 31tax uncertainties, ~~2021~~stock-based compensation, ~~respectively~~and other contingencies.

The Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of December 31, 2021, the Company had approximately $600,000 of cash to cover its operating expenses, and new investment requirements and is continuing to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed interim financial statements have been prepared assuming the Company will continue to operate as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment companies report delays in their programs.

Cash from operating activities

The Company used net cash of $34,~~071~~520,~~238~~139 in operating activities during the ~~six~~nine months ended ~~September~~December 3031, 2021 compared to $~~909~~2,~~564~~876,156 used for the ~~six~~nine months ended ~~September~~December 3031, 2020. ~~Main~~The main reasons for the higher level in 2021 were an increase in investments in portfolio ~~companies~~ companies and increased professional fees and operating expenses.

Cash from investing activities

No cash was used in investing activities.

Cash from financing activities

The Company had a net cash inflow from financing activities of $13,~~949~~690,494 in the ~~six~~nine months ended ~~September~~December 3031, 2021 compared to $13,~~273~~406,~~250~~195 in the ~~three~~nine months ended ~~September~~December 3031, 2020. This inflow included $13,~~826~~567,001 proceeds from the sale of ~~Series~~Class B preferred stock (including B-1 and B-3), and $122,875 proceeds from the sale of common stock, respectively, in the ~~six~~nine months ended ~~September~~December 3031, 2021, compared to $1,~~270~~873,~~000~~125 from the sale of ~~Series~~Class B preferred stock, and $1,566,229 proceeds from the sale of common stock, respectively, in the corresponding nine ~~six~~ month prior period ended ~~September~~December 3031, 2020.

The Company’s plan of operations for the next twelve months is to continue to focus its efforts on finding new sources of capital by means of private placements, and to use this capital to fund additional investments as they become available, and to cover operating expenses. The Company is planning to uplift from OTC to the NASDAQ market, and raise additional funding from an initial public offering (“IPO)” for which as an initial step it has submitted an N-2 filing to the SEC for review.

CRITICAL ACCOUNTING POLICIES

USE OF ESTIMATES

Significant estimates at ~~September~~December 3031, 2021 and March 31, 2021 include the valuation of investments, deferred tax assets, tax allowance, stock options and warrants.

INVESTMENT AND VALUATION OF INVESTMENT AT FAIR VALUE

The Company reviews the performance of its investments based on available information, including management reports, press releases, web site announcements and progress reports, third party equity updates, management interviews and, where accessible, financial reports, to determine their fair values. In the event that Management considers the fair value of an investment to be greater or less than the current book value, the difference will be reflected as unrealized gains or losses in investments in the statements of operations.

The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing GAAP that require the use of fair value measurements which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.

In determining the appropriate fair value of an investment using these approaches, the most significant information and assumptions may include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral, the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the company does business, comparisons of financial ratios of peer companies that are public, merger and acquisition comparables, the principal market and enterprise values, environmental factors, subsequent financings by the portfolio investment, among other factors.

RECENT ACCOUNTING PRONOUNCEMENTS

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

OFF-BALANCE SHEET ARRANGEMENTS

As of the date of this Quarterly Report on Form 10-Q, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

IMPACT OF INFLATION

The Company does not foresee any implications being created by the current rate of inflation.

CONTRACTUAL OBLIGATION

The Company has no contractual obligations outside the normal course of business with its vendors, advisors, and consultants.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting company.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer/chief financial officer (principal financial officer) as appropriate, to allow timely decisions regarding required disclosure. During the three months ended ~~September~~December 3031, 2021 we carried out an evaluation, under ~~the~~ the supervision and with the participation of our management, including the principal executive officer and the principal financial officer (principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13(a)-15(e) under the 1934 Act. Based on this evaluation, because of the Company’s limited resources and limited number of employees, management concluded that our disclosure controls and procedures were ineffective as of ~~September~~December 3031, 2021. Notwithstanding this conclusion, we believe that our unaudited condensed financial statements contained in this Quarterly Report fairly present our financial position, results of operations and cash flows for the periods covered thereby in all material respects.

Management’s Report on Internal Control over Financial Reporting

With the participation of our Chief Executive Officer and Chief Financial Officer (principal financial officer), our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of ~~September~~December 3031, 2021 based on the framework in Internal Controls—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on our evaluation and the material weaknesses described below, management concluded that the Company did not maintain effective internal control over financial reporting as of ~~September~~December 3031, 2021 based on the COSO framework criteria. Management has identified control deficiencies regarding the lack of segregation of duties and the need for a stronger internal control environment. Management of the Company believes that these material weaknesses are due to the small size of the Company’s accounting staff. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of such remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the internal control framework. In addition, we have identified the following material weaknesses: (i) the Company utilizes accounting software that does not prevent erroneous or unauthorized changes to previous reporting periods and/or can be adjusted so as not to provide an adequate audit trail of entries made in the accounting software, and (ii) we have identified a material weakness in our internal controls relating to the accounting of transactions that are either highly complex and/or unusual in nature. ~~In such instances, we seek to augment our internal accounting capabilities by obtaining assistance from third-parties who have greater expertise in such areas.~~

~~These~~ During the quarter ended December 31, 2021, we discovered our internal control ~~deficiencies~~over ~~could~~financial reporting did not result in athe ~~misstatement~~proper ofaccounting ~~account~~for ~~balances~~earnings ~~that~~per ~~would~~share ~~result~~for the inthree amonths ~~reasonable~~ended ~~possibility~~June ~~that~~30, a2021 ~~material misstatement~~and tothe ~~our~~three ~~financial~~and ~~statements~~six ~~may~~months ~~not~~ended beSeptember ~~prevented~~30, or2021, ~~detected~~which onwe determined to be a ~~timely~~material ~~basis~~weakness. Accordingly, we have determined that these control deficiencies as described above together constitute a material weakness. However, management believes that despite our material weaknesses, our financial statements for the three and ~~six~~nine month periods ended ~~September 30~~December 31, 2021 are fairly stated, in all material respects, in accordance with USU.S. GAAP.

Limitations on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer (principal financial officer), does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

3234

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None

ITEM 1A. RISK FACTORS.

Not required for smaller reporting company.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

The ~~Corporation~~Company ~~filed~~has aissued ~~certificate~~certificates of ~~Designation~~designation ~~in April 2021~~ for ~~the issue of~~ up to ~~3,200,000~~9 million shares of Series B-1, ~~Preferred stock to accredited investors under Section 4(~~B-2), orand ~~Rule~~B-3 ~~506~~ of ~~Regulation~~which ~~D of the Securities Act 1933. As of the filing date~~8,087,656 ~~the~~were ~~Corporation~~subscribed ~~had~~through ~~sold~~December ~~a total of 5~~31,~~911,416~~ ~~shares of Series B Preferred stock to accredited investors~~2021. ~~The Company will use the net proceeds for investment purposes and operating expenses.~~

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

Index to Exhibits on page 13

3335

INDEX TO EXHIBITS

EXHIBIT NUMBER		DESCRIPTION

3 (i) (a)		Articles of Incorporation of Kyto BioPharma Inc.

3(i) (b)		Articles of Amendment changing name to Kyto Technology and Life Science Inc *

3(ii)		Bylaws of Kyto Technology and Life Science Inc. **

3.4		Delaware incorporation and revised articles of incorporation **

18.1		Auditors preferability letter re adoption of ASC 946***

31.1		Section 302 certification of principal executive officer and principal financial & accounting officer

32.1		Certification pursuant to 18 USC Section 1350 adopted pursuant to section 906 of the Sarbanes Oxley Act of 2002 of the principal executive officer and principal financial accounting officer

*	Filed as Exhibit to Company’s Form 10-SB on September 12, 2003 with the Securities and Exchange Commission.
**	Previously filed with Form 8-K on July 17, 2019.
***	Filed as Exhibit with Form 10-K on July 2, 2020.

3436

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kyto Technology and Life Science, Inc. By: /s/ Paul Russo Paul Russo Chief Executive Officer, principal executive officer,

	Kyto Technology and Life Science, Inc.

	By:	/s/ Paul Russo
		Paul Russo
		Chief Executive Officer, principal executive officer,

Date: February 22, 2022

Date: November 18, 2021

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kyto Technology and Life Science, Inc. By: /s/ Simon Westbrook Simon Westbrook Principal financial and accounting officer

	Kyto Technology and Life Science, Inc.

	By:	/s/ Simon Westbrook
		Simon Westbrook
		Principal financial and accounting officer

Date: February 22, 2022

~~Date: November 18, 2021~~37

Filing Compare · Kyto Technology & Life Science, Inc.